Document:

Exhibit 10.1

 

SECURITIES
PURCHASE AGREEMENT

 

This SECURITIES
PURCHASE AGREEMENT (the “Agreement”), dated as of April 29, 2013, is by and among Crumbs Bake Shop, Inc.,
a Delaware corporation with offices located at 110 West 40th Street, Suite 2100, New York, New York 10018 (the “Company”),
and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively,
the “Buyers”).

 

RECITALS

 

A.          The
Company and each Buyer is executing and delivering this Agreement in reliance upon the exemption from securities registration afforded
by Section 4(2) of the Securities Act of 1933, as amended (the “1933 Act”), and Rule 506 of Regulation D (“Regulation
D”) as promulgated by the United States Securities and Exchange Commission (the “SEC”) under the 1933
Act.

 

B.           The
Company has authorized the issuance of senior convertible notes, in the aggregate amount of up to $10,000,000, in the form attached
hereto as Exhibit A (the “Notes”), which Notes shall be convertible into shares of the Company’s
common stock, $0.0001 par value per share (the “Common Stock”) (as converted, collectively, the “Conversion
Shares”), in accordance with the terms of the Notes.

 

C.           Each
Buyer wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, a Note in the
aggregate original principal amount set forth opposite such Buyer’s name on the Schedule of Buyers.

 

D.           The
Notes are entitled to interest, and certain other amounts, which, at the option of the Company and subject to certain conditions,
may be paid in shares of Common Stock (the “Interest Shares”) or in cash.

 

E.           At
the First Closing, the parties hereto shall execute and deliver a Registration Rights Agreement, in the form attached hereto as
Exhibit B (the “Registration Rights Agreement”), pursuant to which the Company has agreed to provide
certain registration rights with respect to the Registrable Securities (as defined in the Registration Rights Agreement), under
the 1933 Act and the rules and regulations promulgated thereunder, and applicable state securities laws.

 

F.           The
Notes, the Conversion Shares and the Interest Shares are collectively referred to herein as the “Securities.”

 

G.           Each
of the Company’s Subsidiaries (as defined below) will execute a guaranty, in the form set forth in Exhibit C,
in favor of each Buyer (each, a “Guaranty” and collectively, the “Guaranties”) pursuant to
which each of such Subsidiaries will guarantee the obligations of the Company under the Notes.

 

AGREEMENT

 

NOW, THEREFORE, in
consideration of the premises and the mutual covenants contained herein and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Company and each Buyer hereby agree as follows:

 

1.     
     PURCHASE AND SALE OF NOTES.

 

(a)          Notes.
Subject to the satisfaction (or waiver) of the conditions set forth in Sections 6 and 7 below, the Company shall issue and sell
to each Buyer, and each Buyer severally, but not jointly, shall purchase from the Company on each Closing Date (as defined below),
a Note in the original principal amount as is set forth opposite such Buyer’s name on Exhibit A hereto.

 

    	 

    	 

    

 

(b)          Closing.
The first closing (the “First Closing”) and each subsequent closing (a “Subsequent Closing”)
of the purchase of the Notes by the Buyers (each, a “Closing” and together, the “Closings”)
shall occur at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (“Mintz Levin”), 666 Third
Avenue, New York, NY 10017 or remotely via the exchange of documents and signatures by facsimile or e-mail. The date and time of
the First Closing (the “First Closing Date”) shall be 10:00 a.m., New York time, on the first (1st)
Business Day on which the conditions to the Closing set forth in Sections 6 and 7 below are satisfied or waived, but in no event
prior to May 10, 2013 (or such other date mutually agreed to by the Company and each participating Buyer) and shall require, at
minimum, a purchase of Notes by the participating Buyers in the aggregate principal amount of $2,000,000, in accordance with their
Note purchase allocation as set forth on the Schedule of Buyers. The date and time of any Subsequent Closing (a “Subsequent
Closing Date”, and together with the First Closing Date, the “Closing Dates”), shall be 10:00 a.m.,
New York time, on such later date as is mutually agreed to by the Company and each participating Buyer, but in no event later than
30 days following the First Closing Date. As used herein “Business Day” means any day other than a Saturday,
Sunday or other day on which commercial banks in New York, New York are authorized or required by law to remain closed.

 

(c)          Purchase
Price. The aggregate purchase price for the Notes to be purchased by each Buyer (the “Purchase Price”) shall
be the amount set forth opposite such Buyer’s name on the Schedule of Buyers.

 

(d)          Form
of Payment. On each Closing Date, (i) each participating Buyer shall pay its respective Purchase Price (less, in the case of
any Buyer, the amounts withheld pursuant to Section 4(g)) to the Company for the Notes to be issued and sold to such Buyer at such
Closing, by wire transfer of immediately available funds in accordance with the Flow of Funds Letter (as defined below) and (ii)
the Company shall deliver to each participating Buyer (A) a Note in the aggregate original principal amount as is set forth opposite
such Buyer’s name on the First Closing or a Subsequent Closing Date, as applicable, found on the Schedule of Buyers, duly
executed on behalf of the Company and registered in the name of such Buyer or its designee.

 

(e)          Buyer
Assignees. Each Buyer shall have the option to appoint one or more assignees (each a “Buyer Assignee”)
as listed on the Schedule of Buyer Assignees, which may be amended from time to time without the consent of the Company, to purchase
all or a portion of its aggregate original principal amount of Notes (as set forth on column (3) of the Schedule of Buyers) to
satisfy such Buyer’s obligation to purchase Notes hereunder; provided, however, that each Buyer Assignee who purchases Notes
at a Closing shall be deemed a Buyer for purposes of this Agreement with respect to such Notes and the representations and warranties
contained in Section 2 of this Agreement shall be true and correct in all material respects with respect to such Buyer Assignee
as of the applicable Closing Date.

 

2.     
     BUYER’S REPRESENTATIONS AND WARRANTIES.

 

Each Buyer, severally
and not jointly, represents and warrants to the Company with respect to only itself that, as of the date hereof and as of each
Closing Date:

 

(a)          Organization;
Authority. If an entity, such Buyer is an entity duly organized, validly existing and in good standing under the laws of the
jurisdiction of its organization with the requisite power and authority to enter into and to consummate the transactions contemplated
by the Transaction Documents (as defined below) to which it is a party and otherwise to carry out its obligations hereunder and
thereunder.

 

(b)          No
Public Sale or Distribution. Such Buyer (i) is acquiring its Note, (ii) may acquire the Interest Shares in accordance with
the terms of the Notes and, (iii) upon conversion of its Note will acquire the Conversion Shares issuable upon conversion thereof,
in each case, for its own account and not with a view towards, or for resale in connection with, the public sale or distribution
thereof in violation of applicable securities laws, except pursuant to sales registered or exempted under the 1933 Act; provided,
however, by making the representations herein, such Buyer does not agree, or make any representation or warranty, to hold any of
the Securities for any minimum or other specific term and reserves the right to dispose of the Securities at any time in accordance
with or pursuant to a registration statement or an exemption under the 1933 Act. Such Buyer is acquiring the Securities hereunder
in the ordinary course of its business. Such Buyer does not presently have any agreement or understanding, directly or indirectly,
with any Person, and has no present intention of having any such agreement or understanding, to distribute any of the Securities
in violation of applicable securities laws. Such Buyer is neither (x) a broker-dealer registered under the Securities Exchange
Act of 1934, as amended (the “1934 Act”), or an entity engaged in a business that would require it to be so
registered nor (y) in the business of underwriting securities.

 

(c)          Accredited
Investor Status. Such Buyer is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D,
as amended, under the 1933 Act.

 

    	2

    	 

    

 

(d)          Reliance
on Exemptions. Such Buyer understands that the Securities are being offered and sold to it in reliance on specific exemptions
from the registration requirements of United States federal and state securities laws and that the Company is relying in part upon
the truth and accuracy of, and such Buyer’s compliance with, the representations, warranties, agreements, acknowledgments
and understandings of such Buyer set forth herein in order to determine the availability of such exemptions and the eligibility
of such Buyer to acquire the Securities.

 

(e)          Information.
Such Buyer and its advisors, if any, have been furnished with all materials relating to the business, finances and operations of
the Company and materials relating to the offer and sale of the Securities which have been requested by such Buyer. Such Buyer
and its advisors, if any, have been afforded the opportunity to ask questions of the Company. Such Buyer understands that its investment
in the Securities involves a high degree of risk. Such Buyer has sought such accounting, legal and tax advice as it has considered
necessary to make an informed investment decision with respect to its acquisition of the Securities.

 

(f)          No
Governmental Review. Such Buyer understands that no United States federal or state agency or any other government or governmental
agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment
in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

(g)          Transfer
or Resale. Such Buyer understands that except as provided in the Registration Rights Agreement and Section 4(h) hereof: (i)
the Securities have not been and are not being registered under the 1933 Act or any state securities laws and, accordingly, are
characterized as “restricted securities” under the U.S. federal securities laws inasmuch as they are being acquired
from the Company in a transaction not involving a public offering and may not be offered for sale, sold, assigned or transferred
unless (A) subsequently registered thereunder, (B) such Buyer shall have delivered to the Company (if requested by the Company)
an opinion of counsel to such Buyer, in a form reasonably acceptable to the Company, to the effect that such Securities to be sold,
assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such registration, or (C) such Buyer
provides the Company with reasonable assurance that such Securities can be sold, assigned or transferred pursuant to Rule 144 or
Rule 144A promulgated under the 1933 Act (or a successor rule thereto) (collectively, “Rule 144”); (ii) any
sale of the Securities made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144, and further, if
Rule 144 is not applicable, any resale of the Securities under circumstances in which the seller (or the Person (as defined below)
through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the 1933 Act) may require compliance
with some other exemption under the 1933 Act or the rules and regulations of the SEC promulgated thereunder; and (iii) neither
the Company nor any other Person is under any obligation to register the Securities under the 1933 Act or any state securities
laws or to comply with the terms and conditions of any exemption thereunder.

 

(h)          Validity;
Enforcement. This Agreement and the Registration Rights Agreement have been duly and validly authorized, executed and delivered
on behalf of such Buyer and constitutes the legal, valid and binding obligations of such Buyer enforceable against such Buyer in
accordance with their respective terms, except as such enforceability may be limited by general principles of equity or applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the
enforcement of applicable creditors’ rights and remedies.

 

(i)          No
Conflicts. The execution, delivery and performance by such Buyer of this Agreement and the Registration Rights Agreement and
the consummation by such Buyer of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational
documents of such Buyer, if applicable, (ii) conflict with, or constitute a default (or an event which with notice or lapse of
time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation
of, any agreement, indenture or instrument to which such Buyer is a party, or (iii) result in a violation of any law, rule, regulation,
order, judgment or decree (including federal and state securities laws) applicable to such Buyer, except in the case of clauses
(ii) and (iii) above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably
be expected to have a material adverse effect on the ability of such Buyer to perform its obligations hereunder.

 

(j)          Residency.
If an individual, such Buyer is a resident of the jurisdiction specified below his or her address on the Schedule of Buyers. If
an entity, such Buyer maintains its principal place of business in the jurisdiction specified below its address on the Schedule
of Buyers.

 

    	3

    	 

    

 

(k)          Certain
Trading Activities. Such Buyer has not directly or indirectly, nor has any Person acting on behalf of or pursuant to any understanding
with such Buyer, engaged in any transactions in the securities of the Company (including, without limitation, any Short Sales (as
defined below) involving the Company’s securities) during the period commencing as of the time that such Buyer was first
contacted regarding the specific investment in the Company contemplated by this Agreement and ending immediately prior to the execution
of this Agreement by such Buyer (it being understood and agreed that for all purposes of this Agreement, and, without implication
that the contrary would otherwise be true, that neither transactions nor purchases nor sales shall include
the location and/or reservation of borrowable shares of Common Stock). “Short Sales” means all “short
sales” as defined in Rule 200 promulgated under Regulation SHO under the 1934 Act.

 

(l)        
  Experience of Such Buyer. Such Buyer, either alone or together with its representatives, has such
knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and
risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment. Such
Buyer is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a
complete loss of such investment.

 

(m)          Not
a 10% Owner. Such Buyer is not a “beneficial owner” of more than 10% of the shares of Common Stock (as defined
for purposes of Rule 13d-3 of the 1934 Act).

 

(n)          No
General Solicitation. Such Buyer did not learn of the investment in the Securities as a result of any general solicitation
or general advertising (within the meaning of Regulation D).

 

(o)          Brokers
and Finders. Except as set forth in this Agreement, no Person will have, as a result of the transactions contemplated by the
Transaction Documents, any valid right, interest or claim against or upon the Company, any Subsidiary (as defined below) or such
Buyer for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or
on behalf of such Buyer.

 

3.       
   REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

 

The Company represents
and warrants to each of the Buyers that, as of the date hereof and as of each Closing Date:

 

(a)          Organization
and Qualification. Each of the Company and each of its Subsidiaries are entities duly organized and validly existing and in
good standing under the laws of the jurisdiction in which they are formed, and have the requisite power and authorization to own
their properties and to carry on their business as now being conducted and as presently proposed to be conducted. Each of the Company
and each of its Subsidiaries is duly qualified as a foreign entity to do business and is in good standing in every jurisdiction
in which its ownership of property or the nature of the business conducted by it makes such qualification necessary, except to
the extent that the failure to be so qualified or be in good standing would not have a Material Adverse Effect. As used in this
Agreement, “Material Adverse Effect” means any material adverse effect on (i) the business, properties, assets,
liabilities, operations (including results thereof), condition (financial or otherwise) or prospects of the Company and its Subsidiaries,
taken as a whole, (ii) the transactions contemplated hereby or in any of the other Transaction Documents or (iii) the authority
or ability of the Company or any of its Subsidiaries to perform any of their respective obligations under any of the Transaction
Documents (as defined below). For the avoidance of doubt, the term “Material Adverse Effect” shall not include
any change in the market prices for the Company’s securities. Other than the Persons (as defined below) set forth on Schedule
3(a), the Company has no Subsidiaries. “Subsidiaries” means any Person in which the Company, directly or
indirectly, (I) owns a majority of the outstanding capital stock or holds a majority of equity or similar interest of such Person
or (II) controls or operates all or any part of the business, operations or administration of such Person, and each of the foregoing,
is individually referred to herein as a “Subsidiary.”

 

    	4

    	 

    

 

(b)          Authorization;
Enforcement; Validity. The Company has the requisite power and authority to enter into and perform its obligations under this
Agreement and the other Transaction Documents and to issue the Securities in accordance with the terms hereof and thereof. Each
Subsidiary has the requisite power and authority to enter into and perform its obligations under its Guaranty. The execution and
delivery of this Agreement and the other Transaction Documents by the Company and the consummation by the Company of the transactions
contemplated hereby and thereby (including, without limitation, the issuance of the Notes and the reservation for issuance and
issuance of the Conversion Shares issuable upon conversion of the Notes and the reservation for issuance and issuance any Interest
Shares issuable pursuant to the terms of the Notes) have been duly authorized by the Company’s board of directors or a duly
appointed committee thereof (collectively, the “Board”). The execution and delivery by each Subsidiary of its
Guaranty and the performance by such Subsidiary of its obligations contained therein have been duly authorized by the board of
directors or other governing body of such Subsidiary. Other than the filing with the SEC of one or more Registration Statements
in accordance with the requirements of the Registration Rights Agreement, the 8-K Filing (as defined below), a Form D with the
SEC, any other filings as may be required by any state securities agencies and any listing application and related notices and
filings to be made with the Principal Market (as defined in Section 3(d) (collectively, the “Required Approvals”),
no further filing, consent or authorization is required by the Company or its Subsidiaries, their respective boards of directors
or their stockholders (other than the Stockholder Approval (as defined in Section 4(v), if required) or other governing bodies
in connection with the transactions contemplated by this Agreement. This Agreement has been, and the other Transaction Documents
to which it is a party will be prior to the Closing, duly executed and delivered by the Company, and each constitutes the legal,
valid and binding obligations of the Company, enforceable against the Company in accordance with its respective terms, except as
such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation or similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies
and except as rights to indemnification and to contribution may be limited by federal or state securities law and public policy,
and the remedy of specific performance and injunctive and other forms of equitable relief may be subject to equitable defenses
and to the discretion of the court before which any proceeding therefor may be brought. Each Guaranty, when executed and delivered
by a Subsidiary, will be duly executed and delivered by such Subsidiary and shall constitute the legal, valid and binding obligation
of such Subsidiary, enforceable against such Subsidiary in accordance with its terms, except as such enforceability may be limited
by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating
to, or affecting generally, the enforcement of applicable creditors’ rights and remedies and except as rights to indemnification
and to contribution may be limited by federal or state securities law and public policy, and the remedy of specific performance
and injunctive and other forms of equitable relief may be subject to equitable defenses and to the discretion of the court before
which any proceeding therefor may be brought. “Transaction Documents” means, collectively, this Agreement, the
Notes, the Guaranties, the Registration Rights Agreement, the Irrevocable Transfer Agent Instructions (as defined below) and each
of the other agreements and instruments entered into or delivered by any of the parties hereto in connection with the transactions
contemplated hereby and thereby, as may be amended from time to time.

 

(c)          Issuance
of Securities. The issuance of the Notes has been duly authorized and upon issuance in accordance with the terms of this Agreement
shall be validly issued and free from all preemptive or similar rights, taxes, liens, charges and other encumbrances with respect
to the issue thereof. As of the Closing, the Company shall have reserved from its duly authorized capital stock not less than (i)
125% of the maximum number of Conversion Shares initially issuable upon conversion of the Notes (assuming for purposes hereof that
the Notes are convertible at the initial Conversion Price (as defined in the Notes) of $1.55 and without taking into account any
limitations on the conversion of the Notes set forth in the Notes) and (ii) 100% of the maximum number of Interest Shares initially
issuable pursuant to the terms of the Notes from the Closing Date through the five year anniversary of the Closing Date (determined
as if issued on the Trading Day (as defined in the Notes) immediately preceding the Closing Date without taking into account any
limitations on the issuance of securities set forth in the Notes). Upon issuance or conversion in accordance with the Notes, the
Conversion Shares and the Interest Shares, respectively, when issued, will be validly issued, fully paid and nonassessable and
free from all preemptive or similar rights, taxes, liens, charges and other encumbrances with respect to the issue thereof, with
the holders being entitled to all rights accorded to a holder of Common Stock. Subject to the accuracy of the representations and
warranties of the Buyers in this Agreement, the offer and issuance by the Company of the Securities is exempt from registration
under the 1933 Act.

 

    	5

    	 

    

 

(d)          No
Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and its Subsidiaries and the
consummation by the Company and its Subsidiaries of the transactions contemplated hereby and thereby (including, without limitation,
the issuance of the Notes, the Conversion Shares and the Interest Shares and the reservation for issuance of the Conversion Shares
and the Interest Shares) will not (i) result in a violation of the Charter (as defined below) or other organizational documents
of the Company or any of its Subsidiaries, any capital stock of the Company or any of its Subsidiaries or Bylaws (as defined below)
of the Company or any of its Subsidiaries, (ii) conflict with, or constitute a default (or an event which with notice or lapse
of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation
of, any agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party, or (iii) subject to the
Required Approvals, result in a violation of any law, rule, regulation, order, judgment or decree (including foreign, federal and
state securities laws and regulations and the rules and regulations of the Nasdaq Capital Market (the “Principal Market”)
and including all applicable federal laws, rules and regulations) applicable to the Company or any of its Subsidiaries or by which
any property or asset of the Company or any of its Subsidiaries is bound or affected except, in the case of clause (ii) or (iii)
above, to the extent such violations that would not reasonably be expected to have a Material Adverse Effect.

 

(e)          Consents.
Except for the Required Approvals, neither the Company nor any Subsidiary is required to obtain any consent from, authorization
or order of, or make any filing or registration with (other than the Required Approvals), any Governmental Entity (as defined below)
or any regulatory or self-regulatory agency or any other Person in order for it to execute, deliver or perform any of its respective
obligations under or contemplated by the Transaction Documents, in each case, in accordance with the terms hereof or thereof. All
consents, authorizations, orders, filings and registrations which the Company or any Subsidiary is required to obtain at or prior
to the Closing have been or will be obtained or effected on or prior to the Closing Date, and neither the Company nor any of its
Subsidiaries are aware of any facts or circumstances which might prevent the Company or any of its Subsidiaries from obtaining
or effecting any of the registration, application or filings contemplated by the Transaction Documents. The Company is not in violation
of the requirements of the Principal Market and has no knowledge of any facts or circumstances which could reasonably lead to delisting
or suspension of the Common Stock in the foreseeable future. “Governmental Entity” means any nation, state,
county, city, town, village, district, or other political jurisdiction of any nature, federal, state, local, municipal, foreign,
or other government, governmental or quasi-governmental authority of any nature (including any governmental agency, branch, department,
official, or entity and any court or other tribunal), multi-national organization or body; or body exercising, or entitled to exercise,
any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature.

 

(f)          Acknowledgment
Regarding Buyer’s Purchase of Securities. The Company acknowledges and agrees that each Buyer is acting solely in the
capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated hereby
and thereby and that no Buyer is (i) an officer or director of the Company or any of its Subsidiaries, (ii) an “affiliate”
(as defined in Rule 144) of the Company or any of its Subsidiaries or (iii) to its knowledge, a “beneficial owner”
of more than 10% of the shares of Common Stock (as defined for purposes of Rule 13d-3 of the 1934 Act. The Company further acknowledges
that no Buyer is acting as a financial advisor or fiduciary of the Company or any of its Subsidiaries (or in any similar capacity)
with respect to the Transaction Documents and the transactions contemplated hereby and thereby, and any advice given by a Buyer
or any of its representatives or agents in connection with the Transaction Documents and the transactions contemplated hereby and
thereby is merely incidental to such Buyer’s purchase of the Securities. The Company further represents to each Buyer that
the Company’s and each Subsidiary’s decision to enter into the Transaction Documents to which it is a party has been
based solely on the independent evaluation by the Company, each Subsidiary and their respective representatives.

 

(g)          No
General Solicitation; Placement Agent’s Fees. Neither the Company, nor any of its Subsidiaries or affiliates, nor any
Person acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning
of Regulation D) in connection with the offer or sale of the Securities. The Company shall be responsible for the payment of any
placement agent’s fees, financial advisory fees, or brokers’ commissions (other than for Persons engaged by any Buyer
or its investment advisor except as set forth in this Agreement) relating to or arising out of the transactions contemplated hereby.
Except as set forth in Schedule 3(g) and except with respect to Threadstone Advisors LLC (the “Placement Agent”),
neither the Company nor any of its Subsidiaries has engaged any placement agent or other agent in connection with the offer or
sale of the Securities.

 

    	6

    	 

    

 

(h)          No
Integrated Offering. None of the Company, its Subsidiaries or any of their affiliates, nor, to the knowledge of the Company,
any Person acting on their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers
to buy any security under circumstances that would require registration of the issuance of any of the Securities under the 1933
Act, whether through integration with prior offerings or otherwise, or cause this offering of the Securities to require approval
of stockholders of the Company under any applicable stockholder approval provisions, including, without limitation, under the rules
and regulations of any exchange or automated quotation system on which any of the securities of the Company are listed or designated
for quotation. None of the Company, its Subsidiaries, their affiliates nor, to the knowledge of the Company, any Person acting
on their behalf will take any action or steps that would require registration of the issuance of any of the Securities under the
1933 Act or cause the offering of any of the Securities to be integrated with other offerings of securities of the Company.

 

(i)           Dilutive
Effect. The Company understands and acknowledges that the number of Conversion Shares and Interest Shares may increase in certain
circumstances. The Company further acknowledges that its obligation to issue the Conversion Shares upon conversion of the Notes
in accordance with this Agreement and the Notes and the Interest Shares in accordance with this Agreement and the Notes is absolute
and unconditional (subject to any limitations on conversion as set forth in the Notes) regardless of the dilutive effect that such
issuance may have on the ownership interests of other stockholders of the Company.

 

(j)          Application
of Takeover Protections; Rights Agreement. At or prior to Closing, the Company and its Board shall have taken all necessary
action, if any, in order to render inapplicable any control share acquisition, interested stockholder, business combination, poison
pill (including, without limitation, any distribution under a rights agreement) or other similar anti-takeover provision under
the Charter, Bylaws or other organizational documents or the laws of the jurisdiction of its incorporation or otherwise which is
or could become applicable to any Buyer as a result of the transactions contemplated by this Agreement, including, without limitation,
the Company’s issuance of the Securities and any Buyer’s ownership of the Securities. At or prior to Closing, the Company
and its Board shall have taken all necessary action, if any, in order to render inapplicable any stockholder rights plan or similar
arrangement relating to accumulations of beneficial ownership of shares of Common Stock or a change in control of the Company or
any of its Subsidiaries.

 

(k)          SEC
Documents; Financial Statements. Except as set forth on Schedule 3(k), during the two (2) years prior to the date hereof,
the Company has timely filed all reports, schedules, forms, statements and other documents required to be filed by it with the
SEC pursuant to the reporting requirements of the 1934 Act (all of the foregoing filed prior to the date hereof and all exhibits
included therein and financial statements, notes and schedules thereto and documents incorporated by reference therein being hereinafter
referred to as the “SEC Documents”). The Company has delivered to the Buyers or their respective representatives
true, correct and complete copies of each of the SEC Documents not available on the EDGAR system. Except as set forth on Schedule
3(k), as of their respective dates, the SEC Documents complied in all material respects with the requirements of the 1934 Act
and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none of the SEC Documents,
at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. Except as set forth on Schedule 3(k), as of their respective dates, the financial statements
of the Company included in the SEC Documents complied as to form in all material respects with applicable accounting requirements
and the published rules and regulations of the SEC with respect thereto as in effect as of the time of filing. Such financial statements
have been prepared in accordance with generally accepted accounting principles, consistently applied, during the periods involved
(except (i) as may be otherwise indicated in such financial statements or the notes thereto, or (ii) in the case of unaudited interim
statements, to the extent they may exclude footnotes or may be condensed or summary statements) and, except as set forth on Schedule
3(k), fairly present in all material respects the financial position of the Company as of the dates thereof and the results
of its operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit
adjustments which will not be material, either individually or in the aggregate). No other information provided by or on behalf
of the Company to any of the Buyers which is not included in the SEC Documents (including, without limitation, information referred
to in Section 2(e) of this Agreement) contains any untrue statement of a material fact or omits to state any material fact necessary
in order to make the statements therein not misleading, in the light of the circumstance under which they are or were made.

 

    	7

    	 

    

 

(l)          Absence
of Certain Changes. Since the date of the Company’s most recent audited financial statements contained in a Form 10-K,
there has been no material adverse change and no material adverse development in the business, assets, liabilities, properties,
operations (including results thereof), condition (financial or otherwise) or prospects of the Company and its Subsidiaries taken
as a whole. Since the date of the Company’s most recent audited financial statements contained in a Form 10-K, neither the
Company nor any of its Subsidiaries has (i) declared or paid any dividends, (ii) sold any assets, individually or in the aggregate,
outside of the ordinary course of business or (iii) made any material capital expenditures, individually or in the aggregate, outside
the ordinary course of business. Neither the Company nor any of its Subsidiaries has taken any steps to seek protection pursuant
to any law or statute relating to bankruptcy, insolvency, reorganization, receivership, liquidation or winding up, nor does the
Company or any Subsidiary have any knowledge or reason to believe that any of their respective creditors intend to initiate involuntary
bankruptcy proceedings or any actual knowledge of any fact which would reasonably lead a creditor to do so. The Company and its
Subsidiaries, on a consolidated basis, are not as of the date hereof, and after giving effect to the transactions contemplated
hereby to occur at the Closing, will not be Insolvent (as defined below). For purposes of this Section 3(l), “Insolvent”
means, with respect to the Company and its Subsidiaries, on a consolidated basis, (i) the present fair saleable value of the Company’s
and its Subsidiaries’ assets is less than the amount required to pay the Company’s and its Subsidiaries’ total
Indebtedness (as defined below), (ii) the Company and its Subsidiaries are unable to pay their debts and liabilities, subordinated,
contingent or otherwise, as such debts and liabilities become absolute and matured or (iii) the Company and its Subsidiaries intend
to incur or believe that they will incur debts that would be beyond their ability to pay as such debts mature. Neither the Company
nor any of its Subsidiaries has engaged in any business or in any transaction, and is not about to engage in any business or in
any transaction, for which the Company’s or such Subsidiary’s remaining assets constitute unreasonably small capital.

 

(m)          No
Undisclosed Events, Liabilities, Developments or Circumstances. Except as disclosed in the SEC Documents, no event, liability,
development or circumstance has occurred or exists, or is reasonably expected to exist or occur with respect to the Company, any
of its Subsidiaries or any of their respective businesses, properties, liabilities, prospects, operations (including results thereof)
or condition (financial or otherwise), that (i) would be required to be disclosed by the Company under applicable securities laws
on a registration statement on Form S-1 filed with the SEC relating to an issuance and sale by the Company of its Common Stock
and which has not been publicly announced, (ii) could have a material adverse effect on any Buyer’s investment hereunder
or (iii) could have a Material Adverse Effect.

 

(n)          Conduct
of Business; Regulatory Permits. Neither the Company nor any of its Subsidiaries is in violation of any term of or in default
under its Charter, any certificate of designation, preferences or rights of any other outstanding series of preferred stock of
the Company or any of its Subsidiaries or Bylaws or their organizational charter, certificate of formation or certificate of incorporation
or bylaws, respectively. Except as disclosed in the SEC Documents, neither the Company nor any of its Subsidiaries is in violation
of any judgment, decree or order or any statute, ordinance, rule or regulation applicable to the Company or any of its Subsidiaries,
and neither the Company nor any of its Subsidiaries will conduct its business in violation of any of the foregoing, except in all
cases for possible violations which could not, individually or in the aggregate, have a Material Adverse Effect. Except as set
forth on Schedule 3(n), without limiting the generality of the foregoing, the Company is not in violation of any of the
rules, regulations or requirements of the Principal Market and has no knowledge of any facts or circumstances that could reasonably
lead to delisting or suspension of the Common Stock by the Principal Market in the foreseeable future. Since June 30, 2011, (i)
the Common Stock has been listed or designated for quotation on the Principal Market or the Nasdaq Global Market, (ii) trading
in the Common Stock has not been suspended by the SEC or the Principal Market and (iii) except as disclosed in the SEC Documents,
the Company has received no communication, written or oral, from the SEC or the Principal Market regarding the suspension or delisting
of the Common Stock from the Principal Market. The Company and each of its Subsidiaries possess all certificates, authorizations
and permits issued by the appropriate regulatory authorities necessary to conduct their respective businesses, except where the
failure to possess such certificates, authorizations or permits would not have, individually or in the aggregate, a Material Adverse
Effect, and neither the Company nor any such Subsidiary has received any notice of proceedings relating to the revocation or modification
of any such certificate, authorization or permit.

 

    	8

    	 

    

 

(o)          Foreign
Corrupt Practices. Neither the Company nor any of its Subsidiaries nor, to the knowledge of the Company, any director, officer,
agent, employee or other Person acting on behalf of the Company or any of its Subsidiaries has, in the course of its actions for,
or on behalf of, the Company or any of its Subsidiaries (i) used any corporate funds for any unlawful contribution, gift, entertainment
or other unlawful expenses relating to political activity, (ii) made any direct or indirect unlawful payment to any foreign or
domestic government official or employee from corporate funds, (iii) violated or is in violation of any provision of the U.S. Foreign
Corrupt Practices Act of 1977, as amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other
unlawful payment to any foreign or domestic government official or employee.

 

(p)          Sarbanes-Oxley
Act. The Company and each Subsidiary is in material compliance with all applicable requirements of the Sarbanes-Oxley Act of
2002 that are effective as of the date hereof, and all applicable rules and regulations promulgated by the SEC thereunder that
are effective as of the date hereof.

 

(q)          Transactions
With Affiliates. Except as disclosed in the SEC Documents, none of the officers, directors or employees of the Company or any
of its Subsidiaries is presently a party to any transaction with the Company or any of its Subsidiaries (other than for ordinary
course services as employees, officers or directors), including any contract, agreement or other arrangement providing for the
furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments
to or from any such officer, director or employee or, to the knowledge of the Company or any of its Subsidiaries, any corporation,
partnership, trust or other Person in which any such officer, director, or employee has a substantial interest or is an employee,
officer, director, trustee or partner.

 

(r)          Equity
Capitalization. As of the date hereof, the authorized capital stock of the Company consists of (i) 100,000,000 shares of Common
Stock, of which 13,577,437 are issued, 11,982,853 are issued and outstanding, and 12,774,095 shares are reserved for issuance pursuant
to securities (other than the Notes) exercisable or exchangeable for, or convertible into, shares of Common Stock and (ii) 1,000,000
shares of preferred stock, 234,000 of which are issued and outstanding and 440,000 of which are reserved for future issuance pursuant
to contractual obligations applicable to the Company. Of the issued shares of Common Stock, 1,594,584 are held in treasury. All
of such outstanding shares are duly authorized and have been, or upon issuance will be, validly issued and are fully paid and nonassessable.
To the Company’s knowledge, 4,716,153 shares of the Company’s issued and outstanding Common Stock on the date hereof
are owned by Persons who are “affiliates” (as defined in Rule 405 of the 1933 Act and calculated based on the assumption
that only executive officers, directors and holders of at least 10% of the Company’s issued and outstanding Common Stock
are “affiliates” without conceding that any such Persons are “affiliates” for purposes of federal securities
laws) of the Company or any of its Subsidiaries. Except as disclosed in the SEC Documents or in a Schedule 13G or Schedule 13D,
as the same may be amended, that has been filed with the SEC via EDGAR, to the Company’s knowledge, no Person owns 10% or
more of the Company’s issued and outstanding shares of Common Stock (calculated based on the assumption that all Convertible
Securities (as defined below), whether or not presently exercisable or convertible, have been fully exercised or converted (as
the case may be) taking account of any limitations on exercise or conversion (including “blockers”) contained therein
without conceding that such identified Person is a 10% stockholder for purposes of federal securities laws). (i) None of the Company’s
or any Subsidiary’s capital stock is subject to preemptive rights or any other similar rights or any liens or encumbrances
suffered or permitted by the Company or any Subsidiary; (ii) except as set forth in the capitalization table included in Schedule
3(r), there are no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever
relating to, or securities or rights convertible into, or exercisable or exchangeable for, any capital stock of the Company or
any of its Subsidiaries, or contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries
is or may become bound to issue additional capital stock of the Company or any of its Subsidiaries or options, warrants, scrip,
rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into,
or exercisable or exchangeable for, any capital stock of the Company or any of its Subsidiaries; (iii) except as set forth in the
capitalization table included in Schedule 3(r), there are no outstanding debt securities, notes, credit agreements, credit
facilities or other agreements, documents or instruments evidencing Indebtedness of the Company or any of its Subsidiaries or by
which the Company or any of its Subsidiaries is or may become bound; (iv) there are no financing statements securing obligations
in any amounts filed in connection with the Company or any of its Subsidiaries; (v) except as disclosed in Schedule 3(r),
there are no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale of
any of their securities under the 1933 Act (except pursuant to the Registration Rights Agreement); (vi) except as set forth in
the capitalization table included in Schedule 3(r), there are no outstanding securities or instruments of the Company or
any of its Subsidiaries which contain any redemption or similar provisions, and there are no contracts, commitments, understandings
or arrangements by which the Company or any of its Subsidiaries is or may become bound to redeem a security of the Company or any
of its Subsidiaries; (vii) except as provided under the Company’s Equity Incentive Plan, there are no securities or instruments
containing anti-dilution or similar provisions that will be triggered by the issuance of the Securities; (viii) except for the
Company’s Equity Incentive Plan, neither the Company nor any Subsidiary has any stock appreciation rights or “phantom
stock” plans or agreements or any similar plan or agreement; and (ix) neither the Company nor any of its Subsidiaries have
any liabilities or obligations required to be disclosed in the SEC Documents which are not so disclosed in the SEC Documents, other
than those incurred in the ordinary course of the Company’s or its Subsidiaries’ respective businesses and which, individually
or in the aggregate, do not or could not have a Material Adverse Effect. The Company has furnished to the Buyers true, correct
and complete copies of the Company’s Certificate of Incorporation, as amended and supplemented and as in effect on the date
hereof (the “Charter”), and the Company’s bylaws, as amended and as in effect on the date hereof (the
“Bylaws”), and the terms of all securities convertible into, or exercisable or exchangeable for, shares of Common
Stock and the material rights of the holders thereof in respect thereto.

 

    	9

    	 

    

 

(s)          Indebtedness
and Other Contracts. Except as disclosed on Schedule 3(s), neither the the Company nor any of its Subsidiaries (i) has
any outstanding Indebtedness (as defined below), (ii) is a party to any contract, agreement or instrument, the violation of which,
or default under which, by the other party(ies) to such contract, agreement or instrument could reasonably be expected to result
in a Material Adverse Effect, (iii) is in violation of any term of, or in default under, any contract, agreement or instrument
relating to any Indebtedness, except where such violations and defaults would not result, individually or in the aggregate, in
a Material Adverse Effect, or (iv) is a party to any contract, agreement or instrument relating to any Indebtedness, the performance
of which, in the judgment of the Company’s officers, has or is expected to have a Material Adverse Effect. For purposes of
this Agreement: (x) “Indebtedness” of any Person means, without duplication (A) all indebtedness for borrowed
money, (B) all obligations issued, undertaken or assumed as the deferred purchase price of property or services (including, without
limitation, “capital leases” in accordance with generally accepted accounting principles) (other than trade payables
entered into in the ordinary course of business), (C) all reimbursement or payment obligations with respect to letters of credit,
surety bonds and other similar instruments, (D) all obligations evidenced by notes, bonds, debentures or similar instruments, including
obligations so evidenced incurred in connection with the acquisition of property, assets or businesses, (E) all indebtedness created
or arising under any conditional sale or other title retention agreement, or incurred as financing, in either case with respect
to any property or assets acquired with the proceeds of such indebtedness (even though the rights and remedies of the seller or
bank under such agreement in the event of default are limited to repossession or sale of such property), (F) all monetary obligations
under any leasing or similar arrangement which, in connection with generally accepted accounting principles, consistently applied
for the periods covered thereby, is classified as a capital lease, (G) all indebtedness referred to in clauses (A) through (F)
above secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by)
any mortgage, lien, pledge, charge, security interest or other encumbrance upon or in any property or assets (including accounts
and contract rights) owned by any Person, even though the Person which owns such assets or property has not assumed or become liable
for the payment of such indebtedness, and (H) all Contingent Obligations in respect of indebtedness or obligations of others of
the kinds referred to in clauses (A) through (G) above; provided, however, that the term “Indebtedness” shall not include
any obligation of the Company or any Subsidiary to pay unsecured amounts due under or with respect to real estate operating leases;
(y) “Contingent Obligation” means, as to any Person, any direct or indirect liability, contingent or otherwise,
of that Person with respect to any Indebtedness, lease, dividend or other obligation of another Person if the primary purpose or
intent of the Person incurring such liability, or the primary effect thereof, is to provide assurance to the obligee of such liability
that such liability will be paid or discharged, or that any agreements relating thereto will be complied with, or that the holders
of such liability will be protected (in whole or in part) against loss with respect thereto; and (z) “Person”
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization,
any other entity and any Governmental Entity or any department or agency thereof.

 

(t)          Absence
of Litigation. Except as disclosed in the SEC Documents and as disclosed in Schedule 3(t), there is no action, suit,
proceeding, inquiry or investigation before or by the Principal Market, any court, public board, other Governmental Entity, self-regulatory
organization or body pending or, to the knowledge of the Company, threatened against or affecting the Company or any of its Subsidiaries,
the Common Stock or any of the Company’s or its Subsidiaries’ officers or directors which is outside of the ordinary
course of business or individually or in the aggregate material to the Company or any of its Subsidiaries. Without limitation of
the foregoing, there has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation
by the SEC involving the Company, any of its Subsidiaries or any current or former director or executive officer of the Company
or any of its Subsidiaries. The SEC has not issued any stop order or other order suspending the effectiveness of any registration
statement filed by the Company under the 1933 Act or the 1934 Act.

 

    	10

    	 

    

 

(u)          Insurance.
The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility against such losses and
risks and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company
and its Subsidiaries are engaged. Neither the Company nor any such Subsidiary has been refused any insurance coverage sought or
applied for, and neither the Company nor any such Subsidiary has any reason to believe that it will be unable to renew its existing
insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to
continue its business at a cost that would not have a Material Adverse Effect.

 

(v)         Employee
Relations. Except as disclosed in the SEC Documents, neither the Company nor any of its Subsidiaries is a party to any collective
bargaining agreement or employs any member of a union. The Company believes that its and its Subsidiaries’ relations with
their respective employees are good. No executive officer (as defined in Rule 501(f) promulgated under the 1933 Act) or other key
employee of the Company or any of its Subsidiaries has notified the Company or any such Subsidiary that such officer intends to
leave the Company or any such Subsidiary or otherwise terminate such officer’s employment with the Company or any such Subsidiary.
To the knowledge of the Company, no executive officer or other key employee of the Company or any of its Subsidiaries is, or is
now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information
agreement, non-competition agreement, or any other contract or agreement or any restrictive covenant, and the continued employment
of each such executive officer or other key employee (as the case may be) does not subject the Company or any of its Subsidiaries
to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all federal,
state, local and foreign laws and regulations respecting labor, employment and employment practices and benefits, terms and conditions
of employment and wages and hours, except where failure to be in compliance would not, either individually or in the aggregate,
reasonably be expected to result in a Material Adverse Effect.

 

(w)          Title.
The Company and its Subsidiaries have good and marketable title in fee simple to all real property and have good and marketable
title to all personal property owned by them which is material to the business of the Company and its Subsidiaries, in each case,
free and clear of all liens, encumbrances and defects except such as do not materially affect the value of such property and do
not interfere with the use made and proposed to be made of such property by the Company and any of its Subsidiaries. Any real property
and facilities held under lease by the Company or any of its Subsidiaries are held by them under valid, subsisting and enforceable
leases with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property
and buildings by the Company or any of its Subsidiaries.

 

(x)          Intellectual
Property Rights. The Company and its Subsidiaries own or possess adequate rights or licenses to use all trademarks, trade names,
service marks, service mark registrations, service names, patents, patent rights, copyrights, original works, inventions, licenses,
approvals, governmental authorizations, trade secrets and other intellectual property rights and all applications and registrations
therefor (“Intellectual Property Rights”) necessary to conduct their respective businesses as now conducted
and as presently proposed to be conducted. Except as disclosed on Schedule 3(x), none of the Company’s or its Subsidiaries’
Intellectual Property Rights have expired, terminated or been abandoned, or are expected to expire, terminate or be abandoned,
within two years from the date of this Agreement. The Company has no knowledge of any infringement by the Company or any of its
Subsidiaries of Intellectual Property Rights of others. There is no claim, action or proceeding being made or brought, or to the
knowledge of the Company or any of its Subsidiaries, being threatened, against the Company or any of its Subsidiaries regarding
their Intellectual Property Rights. The Company is not aware of any facts or circumstances which might give rise to any of the
foregoing infringements or claims, actions or proceedings. The Company and each of its Subsidiaries have taken reasonable security
measures to protect the secrecy, confidentiality and value of all of their Intellectual Property Rights, except where failure to
take such measures would not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.

 

    	11

    	 

    

 

(y)          Environmental
Laws. The Company and its Subsidiaries (i) are in compliance with all Environmental Laws (as defined below) in all material
respects, (ii) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct
their respective businesses and (iii) are in material compliance with all terms and conditions of any such permit, license or approval
where, in each of the foregoing clauses (i), (ii) and (iii), the failure to so comply could be reasonably expected to have, individually
or in the aggregate, a Material Adverse Effect. The term “Environmental Laws” means all federal, state, local
or foreign laws relating to pollution or protection of human health or the environment (including, without limitation, ambient
air, surface water, groundwater, land surface or subsurface strata), including, without limitation, laws relating to emissions,
discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes
(collectively, “Hazardous Materials”) into the environment, or otherwise relating to the manufacture, processing,
distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes,
decrees, demands or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations
issued, entered, promulgated or approved thereunder.

 

(z)          Subsidiary
Rights. Except as set forth on Schedule 3(z), the Company or one of its Subsidiaries has the unrestricted right to vote,
and (subject to limitations imposed by applicable law) to receive dividends and distributions on, all capital securities of its
Subsidiaries as owned by the Company or such Subsidiary.

 

(aa)        Tax
Status. Except as set forth on Schedule 3(aa), the Company and each of its Subsidiaries (i) has made or filed all foreign,
federal and state income and all other tax returns, reports and declarations required by any jurisdiction to which it is subject,
(ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due
on such returns, reports and declarations, except those being contested in good faith and (iii) has set aside on its books provision
reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations
apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the
officers of the Company and its Subsidiaries know of no basis for any such claim. The Company is not operated in such a manner
as to qualify as a passive foreign investment company, as defined in Section 1297 of the U.S. Internal Revenue Code of 1986, as
amended.

 

(bb)        Internal
Accounting and Disclosure Controls. The Company and each of its Subsidiaries maintains internal control over financial reporting
(as such term is defined in Rule 13a-15(f) under the 1934 Act) that is effective to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles, including that (i) transactions are executed in accordance with management’s general or specific
authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally
accepted accounting principles and to maintain asset and liability accountability, (iii) access to assets or incurrence of liabilities
is permitted only in accordance with management’s general or specific authorization and (iv) the recorded accountability
for assets and liabilities is compared with the existing assets and liabilities at reasonable intervals and appropriate action
is taken with respect to any difference. The Company maintains disclosure controls and procedures (as such term is defined in Rule
13a-15(e) under the 1934 Act) that are effective in ensuring that information required to be disclosed by the Company in the reports
that it files or submits under the 1934 Act is recorded, processed, summarized and reported, within the time periods specified
in the rules and forms of the SEC, including, without limitation, controls and procedures designed to ensure that information required
to be disclosed by the Company in the reports that it files or submits under the 1934 Act is accumulated and communicated to the
Company’s management, including its principal executive officer or officers and its principal financial officer or officers,
as appropriate, to allow timely decisions regarding required disclosure. Except as disclosed in the SEC Documents, neither the
Company nor any of its Subsidiaries has received any notice or correspondence from any accountant or other Person relating to any
potential material weakness or significant deficiency in any part of the internal controls over financial reporting of the Company
or any of its Subsidiaries, that has not been cured or otherwise resolved prior to the date hereof.

 

(cc)        Off
Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company or any of its Subsidiaries
and an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company in its 1934 Act filings
and is not so disclosed or that otherwise could be reasonably likely to have a Material Adverse Effect.

 

(dd)        Investment
Company Status. The Company is not, and upon consummation of the sale of the Securities will not be, an “investment company,”
an affiliate of an “investment company,” a company controlled by an “investment company” or an “affiliated
person” of, or “promoter” or “principal underwriter” for, an “investment company” as
such terms are defined in the Investment Company Act of 1940, as amended.

 

    	12

    	 

    

 

(ee)        Acknowledgement
Regarding Buyers’ Trading Activity. It is understood and acknowledged by the Company that (i) following the public disclosure
of the transactions contemplated by the Transaction Documents in accordance with the terms thereof and except for the restrictions
on transfer contemplated by Section 2(g), none of the Buyers have been asked by the Company or any of its Subsidiaries to agree,
nor has any Buyer agreed with the Company or any of its Subsidiaries, to desist from effecting any transactions in or with respect
to (including, without limitation, purchasing or selling, long and/or short) any securities of the Company, or “derivative”
securities based on securities issued by the Company or to hold the Securities for any specified term; (ii) any Buyer, and counterparties
in “derivative” transactions to which any such Buyer is a party, directly or indirectly, presently may have a “short”
position in the Common Stock which was established prior to such Buyer’s knowledge of the transactions contemplated by the
Transaction Documents; and (iii) each Buyer shall not be deemed to have any affiliation with or control over any arm’s length
counterparty in any “derivative” transaction. The Company further understands and acknowledges that following the public
disclosure of the transactions contemplated by the Transaction Documents pursuant to the Press Release (as defined below) one or
more Buyers may engage in hedging and/or trading activities at various times during the period that the Securities are outstanding,
including, without limitation, during the periods that the value and/or number of the Interest Shares or Conversion Shares, as
applicable, deliverable with respect to the Securities are being determined and such hedging and/or trading activities, if any,
can reduce the value of the existing stockholders’ equity interest in the Company both at and after the time the hedging
and/or trading activities are being conducted. The Company acknowledges that such aforementioned hedging and/or trading activities
do not constitute a breach of this Agreement, the Notes, or any other Transaction Document or any of the documents executed in
connection herewith or therewith.

 

(ff)         Manipulation
of Price. Neither the Company nor any of its Subsidiaries has, and, to the knowledge of the Company, no Person acting on their
behalf has, directly or indirectly, (i) taken any action designed to cause or to result in the stabilization or manipulation of
the price of any security of the Company or any of its Subsidiaries to facilitate the sale or resale of any of the Securities,
(ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed
to pay to any Person any compensation for soliciting another to purchase any other securities of the Company or any of its Subsidiaries.

 

(gg)       U.S.
Real Property Holding Corporation. Neither the Company nor any of its Subsidiaries is, or has ever been, and so long as any
of the Securities are held by any of the Buyers, shall become, a U.S. real property holding corporation within the meaning of Section
897 of the Internal Revenue Code of 1986, as amended, and the Company and each Subsidiary shall so certify upon any Buyer’s
request.

 

(hh)       Registration
Eligibility. Subject to the Company’s compliance with paragraphs (b) and (c) of General Instruction I.B.4 to Form S-3,
the Company believes that is eligible to register the Registrable Securities for resale by the Buyers using Form S-3 promulgated
under the 1933 Act.

 

(ii)         Transfer
Taxes. On the Closing Date, all stock transfer or other taxes (other than income or similar taxes) which are required to be
paid in connection with the issuance, sale and transfer of the Securities to be sold to each Buyer hereunder will be, or will have
been, fully paid or provided for by the Company, and all laws imposing such taxes will be or will have been complied with.

 

(jj)          Shell
Company Status. The Company is not currently, and has not been within the last 12 months, an issuer identified in, or subject
to, Rule 144(i).

 

(kk)        Illegal
or Unauthorized Payments; Political Contributions. Neither the Company nor any of its Subsidiaries nor, to the Company’s
knowledge (after reasonable inquiry of its executive officers and directors), any of the officers, directors, employees, agents
or other representatives of the Company or any of its Subsidiaries or any other business entity or enterprise with which the Company
or any Subsidiary is or has been affiliated or associated, has, directly or indirectly, made or authorized any payment, contribution
or gift of money, property, or services, whether or not in contravention of applicable law, (a) as a kickback or bribe to any Person
or (b) to any political organization, or the holder of or any aspirant to any elective or appointive public office except for personal
political contributions not involving the direct or indirect use of funds of the Company or any of its Subsidiaries.

 

(ll)         Money
Laundering. The Company and its Subsidiaries are in compliance with, and have not previously violated, the USA Patriot Act
of 2001 and all other applicable U.S. and non-U.S. anti-money laundering laws and regulations, including, but not limited to, the
laws, regulations and Executive Orders and sanctions programs administered by the U.S. Office of Foreign Assets Control, including,
but not limited, to (i) Executive Order 13224 of September 23, 2001 entitled, “Blocking Property and Prohibiting Transactions
With Persons Who Commit, Threaten to Commit, or Support Terrorism” (66 Fed. Reg. 49079 (2001)); and (ii) any regulations
contained in 31 CFR, Subtitle B, Chapter V.

 

    	13

    	 

    

  

(mm)      Management.
Except as set forth in Schedule 3(mm) hereto, since the Company’s incorporation on October 29, 2009, no current officer
or director or, to the knowledge of the Company, former officer or director of the Company or any of its Subsidiaries has been
the subject of:

 

(i)            a
petition under bankruptcy laws or any other insolvency or moratorium law or the appointment by a court of a receiver, fiscal agent
or similar officer for such Person, or any partnership in which such person was a general partner at or within two years before
the filing of such petition or such appointment, or any corporation or business association of which such person was an executive
officer at or within two years before the time of the filing of such petition or such appointment;

 

(ii)           a
conviction in a criminal proceeding or a named subject of a pending criminal proceeding (excluding traffic violations, including
those relating to driving while intoxicated or driving under the influence);

 

(iii)          any
order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently
or temporarily enjoining any such person from, or otherwise limiting, the following activities:

 

(1)         Acting
as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage
transaction merchant, any other person regulated by the United States Commodity Futures Trading Commission or an associated person
of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated person,
director or employee of any investment company, bank, savings and loan association or insurance company, or engaging in or continuing
any conduct or practice in connection with such activity;

 

(2)         Engaging
in any type of business practice; or

 

(3)         Engaging
in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of securities
laws or commodities laws;

 

(iv)        any
order, judgment or decree, not subsequently reversed, suspended or vacated, of any authority barring, suspending or otherwise limiting
for more than 60 days the right of any such person to engage in any activity described in the preceding sub paragraph, or to be
associated with persons engaged in any such activity;

 

(v)         a
finding by a court of competent jurisdiction in a civil action or by the SEC or other authority to have violated any securities
law, regulation or decree and the judgment in such civil action or finding by the SEC or any other authority has not been subsequently
reversed, suspended or vacated; or

 

(vi)        a
finding by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated
any federal commodities law, and the judgment in such civil action or finding has not been subsequently reversed, suspended or
vacated.

 

(nn)         No
Additional Agreements. The Company does not have any agreement or understanding with any Buyer with respect to the transactions
contemplated by the Transaction Documents other than as specified in the Transaction Documents.

 

(oo)         Public
Utility Holding Act. None of the Company nor any of its Subsidiaries is a “holding company,” or an “affiliate”
of a “holding company,” as such terms are defined in the Public Utility Holding Act of 2005.

 

(pp)         Federal
Power Act. None of the Company nor any of its Subsidiaries is subject to regulation as a “public utility” under
the Federal Power Act, as amended.

 

    	14

    	 

    

 

(qq)         Ranking
of Notes. No Indebtedness of the Company, at the Closing, will be senior to, or pari passu with, the Notes in right
of payment, whether with respect to payment or redemptions, interest, damages, upon liquidation or dissolution or otherwise.

 

(rr)           Disclosure.
The Company confirms that neither it nor any other Person acting on its behalf has provided any of the Buyers or their agents or
counsel with any information that constitutes or could reasonably be expected to constitute material, non-public information concerning
the Company or any of its Subsidiaries, other than (i) the existence of the transactions contemplated by this Agreement and the
other Transaction Documents and (ii) certain information provided to the Buyers as part of their due diligence review of the Company
and its Subsidiaries (the “Other Data”). From and after the filing of the 8-K Filing, no Buyer will be deemed
by the Company to be in possession of any material non-public information. The Company acknowledges that the Buyers will be entitled
to rely on the representation and warranty contained in the foregoing sentence in effecting transactions in the Company’s
securities and that such reliance is reasonable. All disclosure provided to the Buyers regarding the Company and its Subsidiaries,
their businesses and the transactions contemplated hereby, including the schedules to this Agreement, furnished by or on behalf
of the Company or any of its Subsidiaries is true and correct in all material respects and does not contain any untrue statement
of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the
circumstances under which they were made, not misleading. Each press release issued by the Company or any of its Subsidiaries during
the twelve (12) months preceding the date of this Agreement did not at the time of release contain any untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the
light of the circumstances under which they are made, not misleading. No event or circumstance has occurred or information exists
with respect to the Company or any of its Subsidiaries or its or their business, properties, liabilities, prospects, operations
(including results thereof) or conditions (financial or otherwise), which, under applicable law, rule or regulation, requires public
disclosure at or before the date hereof or announcement by the Company but which has not been so publicly disclosed. The Company
acknowledges and agrees that no Buyer makes or has made any representations or warranties with respect to the transactions contemplated
hereby other than those specifically set forth in Section 2.

 

4.           COVENANTS.

 

(a)          Reasonable
Best Efforts. Each Buyer shall use its reasonable best efforts to timely satisfy each of the conditions to be satisfied by
it as provided in Section 6 of this Agreement. The Company shall use its reasonable best efforts to timely satisfy each of the
conditions to be satisfied by it as provided in Section 7 of this Agreement.

 

(b)          Form
D and Blue Sky. The Company agrees to file a Form D with respect to the Securities as required under Regulation D and to provide
a copy thereof to each Buyer promptly after such filing. The Company shall, on or immediately after the Closing Date, take such
action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to, qualify the Securities
for sale to the Buyers at the Closing pursuant to this Agreement under applicable securities or “Blue Sky” laws of
the states of the United States (or to obtain an exemption from such qualification), and shall provide evidence of any such action
so taken to the Buyers on or immediately after the Closing Date. Without limiting any other obligation of the Company under this
Agreement, the Company shall timely make all filings and reports relating to the offer and sale of the Securities required under
all applicable securities laws (including, without limitation, all applicable federal securities laws and all applicable “Blue
Sky” laws), and the Company shall comply in all material respects with all applicable federal, state and local laws, statutes,
rules, regulations and the like relating to the offering and sale of the Securities to the Buyers.

 

(c)          Reporting
Status. Until the fifth anniversary of the date of this Agreement (the “Reporting Period”), the Company
shall timely file all reports required to be filed with the SEC pursuant to the 1934 Act, and the Company shall not terminate its
status as an issuer required to file reports under the 1934 Act even if the 1934 Act or the rules and regulations thereunder would
no longer require or otherwise permit such termination.

 

(d)          Use
of Proceeds. The Company will use the proceeds from the sale of the Securities for general corporate purposes, but not for
(i) except as set forth on Schedule 4(d), the repayment of any outstanding Indebtedness of the Company or any of its Subsidiaries,
(ii) the redemption or repurchase of any securities of the Company or any of its Subsidiaries, or (iii) the settlement of any outstanding
litigation.

 

    	15

    	 

    

 

(e)          Financial
Information. The Company agrees to send the following to each Buyer (as defined in the Registration Rights Agreement) during
the Reporting Period (i) unless the following are filed with the SEC through EDGAR and are available to the public through the
EDGAR system, within one (1) Business Day after the filing thereof with the SEC, a copy of its Annual Reports on Form 10-K and
Quarterly Reports on Form 10-Q, any interim reports or any consolidated balance sheets, income statements, stockholders’
equity statements and/or cash flow statements for any period other than annual, any Current Reports on Form 8-K and any registration
statements (other than on Form S-8) or amendments filed pursuant to the 1933 Act, and (ii) copies of any notices and other information
made available or given to the stockholders of the Company generally, contemporaneously with the making available or giving thereof
to the stockholders.

 

(f)          Listing.
The Common Stock is currently traded only on the Principal Market and the Company shall take all necessary actions to maintain
the trading of the Common Stock on the Principal Market. If the Common Stock becomes listed or designated for quotation on any
other Eligible Market (as defined below), then the Company shall promptly secure the listing or designation for quotation (as the
case may be) of all of the Registrable Securities upon each national securities exchange and automated quotation system, if any,
upon which the Common Stock is then listed or designated for quotation (as the case may be) (subject to official notice of issuance)
and shall maintain such listing or designation for quotation (as the case may be) of all Registrable Securities from time to time
issuable under the terms of the Transaction Documents on such then applicable national securities exchange or automated quotation
system. The Company shall take all necessary actions to maintain the Common Stock’s trading on the Principal Market. If in
the future, the Common Stock becomes listed or designated for quotation on any of The New York Stock Exchange, the NYSE Amex, the
Nasdaq Global Select Market, the Nasdaq Global Market or the Nasdaq Capital Market (each, together with the Principal Market, an
“Eligible Market”), the Company shall maintain the Common Stock’s listing or designation for quotation
(as the case may be) on such market. Neither the Company nor any of its Subsidiaries shall take any action which could be reasonably
expected to result in the delisting or suspension of the Common Stock on an Eligible Market on which the Common Stock is then traded,
listed or designated for quotation. The Company shall pay all fees and expenses in connection with satisfying its obligations under
this Section 4(f). The Company’s obligations under this Section 4(f) shall terminate and be of no further force or effect
at the expiration of the Reporting Period.

 

(g)          Fees.
The Company shall reimburse Michael Serruya for (i) all reasonable costs and expenses incurred by him or his affiliates in connection
with the transactions contemplated by the Transaction Documents (including, without limitation, as applicable, all reasonable legal
fees and disbursements of Mintz Levin, counsel to Michael Serruya, any other reasonable fees and expenses in connection with the
structuring, documentation and implementation of the transactions contemplated by the Transaction Documents and due diligence and
regulatory filings in connection therewith), which amount shall not exceed, in the aggregate, $87,500 (the “Expense Amount”);
and (ii) a corporate finance fee of $200,000 to be paid to Delavaco Capital (the “Corporate Finance Fee”) in
cash, without prior written notice to the Company. The Expense Amount and Corporate Finance Fee shall be withheld by Michael Serruya
from his Purchase Price at the Closing or paid by the Company upon termination of this Agreement on demand by Michael Serruya and/or
Mintz Levin. Subject to the limitation set forth in the immediately preceding sentence, if the amount so withheld at the Closing
by Michael Serruya was less than the Expense Amount actually incurred by Michael Serruya, in connection with the transactions contemplated
by the Transaction Documents and entitled to reimbursement from the Company in accordance herewith or any other Transaction Document,
the Company shall promptly reimburse Michael Serruya, on demand for such Expense Amount not so reimbursed by the Company on the
date hereof or through such withholding at the Closing. The Company shall be responsible for the payment of any placement agent’s
fees, financial advisory fees, transfer agent fees, the fees and expenses of DTC (as defined below) fees or broker’s commissions
(other than for Persons engaged by any Buyer) relating to or arising out of the transactions contemplated hereby (including, without
limitation, any fees payable to the Placement Agent in connection with the transactions contemplated by this Agreement). The Company
shall pay, and hold each Buyer harmless against, any liability, loss or expense (including, without limitation, reasonable attorneys’
fees and out-of-pocket expenses) arising in connection with any claim relating to any such payment. Except as otherwise set forth
in the Transaction Documents, each party to this Agreement shall bear its own expenses in connection with the sale of the Securities
to the Buyers.

 

    	16

    	 

    

 

(h)          Pledge
of Securities. Notwithstanding anything to the contrary contained in this Agreement, but subject to any requirements imposed
by applicable securities laws and rules, the Company acknowledges and agrees that the Securities may be pledged by a Buyer in connection
with a bona fide margin agreement or other loan or financing arrangement that is secured by the Securities. The pledge of Securities
shall not be deemed to be a transfer, sale or assignment of the Securities hereunder, and no Buyer effecting a pledge of Securities
shall be required to provide the Company with any notice thereof or otherwise make any delivery to the Company pursuant to this
Agreement or any other Transaction Document. The Company hereby agrees to execute and deliver such documentation as a pledgee of
the Securities may reasonably request in connection with a pledge of the Securities to such pledgee by a Buyer.

 

(i)          Disclosure
of Transactions and Other Material Information. The Company shall, on or before 8:30 a.m., New York time, on the first (1st)
Business Day after the date of this Agreement, issue a press release (the “Press Release”) reasonably acceptable
to the Buyers disclosing all the material terms of the transactions contemplated by the Transaction Documents. On or before 8:30
a.m., New York time, on the first (1st) Business Day after the date of this Agreement, the Company shall file a Current
Report on Form 8-K that (i) describes all the material terms of the transactions contemplated by the Transaction Documents in the
form required by the 1934 Act and attaching all the material Transaction Documents (including, without limitation, this Agreement
(and all schedules to this Agreement), the form of Notes and the form of the Registration Rights Agreement) and (ii) discloses
the Other Data (such Form 8-K, including all attachments, the “8-K Filing”). From and after the filing of the
8-K Filing, the Company shall have disclosed all material, non-public information (if any) provided to any of the Buyers by the
Company or any of its Subsidiaries or any of their respective officers, directors, employees or agents in connection with the transactions
contemplated by the Transaction Documents. The Company shall not, and the Company shall cause each of its Subsidiaries and each
of its and their respective officers, directors, employees and agents not to, provide any Buyer with any material, non-public information
regarding the Company or any of its Subsidiaries from and after the issuance of the Press Release without the express prior written
consent of such Buyer. In the event of a breach of any of the foregoing covenants or any of the covenants or agreements contained
in any other Transaction Document, by the Company, any of its Subsidiaries, or any of its or their respective officers, directors,
employees and agents (as determined in the reasonable good faith judgment of such Buyer), in addition to any other remedy provided
herein or in the Transaction Documents, such Buyer shall have the right to make a public disclosure, in the form of a press release,
public advertisement or otherwise, of such breach or such material, non-public information, as applicable, without the prior approval
by the Company, any of its Subsidiaries, or any of its or their respective officers, directors, employees or agents. No Buyer shall
have any liability to the Company, any of its Subsidiaries, or any of its or their respective officers, directors, employees, stockholders
or agents, for any such disclosure provided that such disclosure is true, accurate and complete in all material respects. Subject
to the foregoing, neither the Company, its Subsidiaries nor any Buyer shall issue any press releases or any other public statements
with respect to the transactions contemplated hereby; provided, however, the Company shall be entitled, without the prior approval
of any Buyer, to make the Press Release and any press release or other public disclosure with respect to such transactions (A)
in substantial conformity with the 8-K Filing and contemporaneously therewith and (B) as is required by applicable law and regulations
(provided that in the case of clause (A) each Buyer shall be consulted by the Company in connection with any such press release
or other public disclosure prior to its release). Without the prior written consent of the applicable Buyer, the Company shall
not (and shall cause each of its Subsidiaries and affiliates to not) disclose the name of such Buyer in any filing, announcement,
release or otherwise (other than the 8-K Filing or as required by applicable law). Notwithstanding anything contained in this Agreement
to the contrary and without implication that the contrary would otherwise be true, except with respect to confidentiality obligations
of a Designated Nominee (as defined herein) in respect of such Designated Nominee’s position as a director of the Company,
the Company expressly acknowledges and agrees that upon filing of the Form 8-K, no Buyer shall have (unless expressly agreed to
by a particular Buyer in a written definitive and binding agreement executed by the Company and such particular Buyer (it being
understood and agreed that no Buyer may bind any other Buyer with respect thereto)), any duty of confidentiality with respect to,
or a duty not to trade on the basis of, any material, non-public information regarding the Company or any of it Subsidiaries.

 

(j)          Additional
Registration Statements. Until the Applicable Date (as defined below) and at any time thereafter while any Registration Statement
is not effective or the prospectus contained therein is not available for use, the Company shall not file a registration statement
under the 1933 Act relating to securities that are not the Registrable Securities (other than pursuant to a registration statement
on Form S-4 or Form S-8 (or a similar or successor form)). “Applicable Date” means the first date on which the
resale by the Buyers of all Registrable Securities is covered by one or more effective Registration Statements (as defined in the
Registration Rights Agreement) (and each prospectus contained therein is available for use on such date).

 

    	17

    	 

    

 

(k)          Additional
Issuance of Securities. For so long as any Notes are outstanding, the Company will not, without the prior written consent of
Buyers holding a majority in aggregate principal amount of the Notes then outstanding, issue any Notes (other than to the Buyers
as contemplated hereby) and the Company shall not issue any other securities that would cause a breach or default under the Notes.
The Company agrees that for the period commencing on the date hereof and ending on the date immediately following the one hundred
twentieth (120th) Trading Day following the Applicable Date (provided that such period shall be extended by the number
of Trading Days during such period and any extension thereof contemplated by this proviso on which any Registration Statement is
not effective or any prospectus contained therein is not available for use) (the “Restricted Period”),
neither the Company nor any of its Subsidiaries shall directly or indirectly issue, offer, sell, grant any option or right to purchase,
or otherwise dispose of (or announce any issuance, offer, sale, grant of any option or right to purchase or other disposition of)
any equity security of the Company or any equity-linked or related security of the Company (including, without limitation, any
“equity security” (as that term is defined under Rule 405 promulgated under the 1933 Act), any Convertible Securities
(as defined below), any debt, any preferred stock or any purchase rights) (any such issuance, offer, sale, grant, disposition or
announcement (whether occurring during the Restricted Period or at any time thereafter) is referred to as a “Subsequent
Placement”). Notwithstanding the foregoing, this Section 4(k) shall not apply in respect of, and the term “Subsequent
Placment” shall not include, the issuance of (A) shares of Common Stock or other equity-based awards, including, without
limitation, standard options to purchase shares of Common Stock (“Equity Awards”), to directors, officers,
employees or consultants of the Company in their capacity as such pursuant to an Approved Stock Plan (as defined below), provided
that (1) all such issuances (taking into account the shares of Common Stock issuable pursuant to Equity Awards) after the date
hereof pursuant to this clause (A) do not, in the aggregate, exceed more than 10% of the Common Stock issued and outstanding immediately
prior to the date hereof and (2) the terms of such Equity Awards are not amended or changed after the date of issuance to decrease
the exercise, conversion, or exchange price at which shares of Common Stock may be issued thereunder, to increase the securities
receivable upon the exercise, conversion or exchange thereof, or to otherwise materially and adversely affect any of the Buyers;
(B) shares of Common Stock issued upon the conversion or exercise of Convertible Securities (other than Equity Awards that are
covered by clause (A) above) issued prior to the date hereof or for which rights to require such issuance were outstanding prior
to the date hereof and disclosed in Schedule 3(r), provided that the conversion, exercise or other method of issuance (as the case
may be) of any such Convertible Security is made solely pursuant to the conversion, exercise or other method of issuance (as the
case may be) provisions of such Convertible Security that were in effect on the date immediately prior to the date of this Agreement
or, if not yet issued, on the date of issuance, the conversion, exercise or issuance price of any such Convertible Securities (other
than Equity Awards that are covered by clause (A) above) is not lowered, none of such Convertible Securities (other than Equity
Awards that are covered by clause (A) above) are amended after issuance to increase the number of shares issuable thereunder and
none of the terms or conditions of any such Convertible Securities (other than Equity Awards that are covered by clause (A) above)
are otherwise materially changed in any manner that adversely affects any of the Buyers; (C) the Conversion Shares, (D) the Interest
Shares, and (E) shares of Common Stock issued in connection with strategic mergers and acquisitions, provided that (I) the primary
purpose of such issuance is not to raise capital, (II) the acquirer of such shares of Common Stock in such issuance solely consists
of either (1) the actual owners of such assets or securities acquired in such merger or acquisition or (2) the stockholders, partners
or members of the foregoing Persons, (III) the number or amount (as the case may be) of such shares of Common Stock issued to each
such Person by the Company shall not be disproportionate to such Person’s actual ownership of such assets or securities to
be acquired by the Company (as applicable) and (IV) all such issuances of shares of Common Stock after the date hereof pursuant
to this clause (E) do not, in the aggregate, exceed more than 10% of the Common Stock issued and outstanding immediately prior
to the date hereof. “Approved Stock Plan” means any compensatory benefit plan (within the meaning of Rule 701
under the Securities Act but without regard to whether the Company is eligible to rely on Rule 701) which has been approved by
the Board prior to or subsequent to the date hereof pursuant to which awards or grants of securities or other plan interests may
be issued to any employee, officer or director for services provided to the Company in their capacity as such. “Convertible
Securities” means any capital stock or other security of the Company or any of its Subsidiaries that is at any time and
under any circumstances directly or indirectly convertible into, exercisable or exchangeable for, or which otherwise entitles the
holder thereof to acquire, any capital stock or other security of the Company (including, without limitation, Common Stock) or
any of its Subsidiaries.

 

    	18

    	 

    

 

(l)          Reservation
of Shares. So long as any Notes remain outstanding, the Company shall take all action necessary to at all times have authorized,
and reserved for the purpose of issuance of no less than (i) 125% of the maximum number of Conversion Shares initially issuable
upon conversion of the Notes (assuming for purposes hereof that the Notes are convertible at the initial Conversion Price (as defined
in the Notes) and without taking into account any limitations on the conversion of the Notes set forth in the Notes) and (ii) 100%
of the maximum number of Interest Shares initially issuable pursuant to the terms of the Notes from the Closing Date through the
five year anniversary of the Closing Date (determined as if issued on the Trading Day (as defined in the Notes) immediately preceding
the Closing Date without taking into account any limitations on the issuance of securities set forth in the Notes).

 

(m)          Conduct
of Business. The business of the Company and its Subsidiaries shall not be conducted in violation of any law, ordinance or
regulation of any Governmental Entity, except where such violations would not reasonably be expected to result, either individually
or in the aggregate, in a Material Adverse Effect.

 

(n)          Other
Notes; Variable Securities. For so long as any Notes remain outstanding, (i) the Company will not issue any Notes (other than
to the Buyers as contemplated hereby) and the Company shall not issue any other securities that would cause a breach or default
under the Notes and (ii) the Company and each Subsidiary shall be prohibited from effecting or entering into an agreement to effect
any Subsequent Placement involving a Variable Rate Transaction. “Variable Rate Transaction” means a transaction
in which the Company or any Subsidiary (x) issues or sells any Convertible Securities either (1) at a conversion, exercise or exchange
rate or other price that is based upon and/or varies with the trading prices of or quotations for the shares of Common Stock at
any time after the initial issuance of such Convertible Securities, or (2) with a conversion, exercise or exchange price that is
subject to being reset at some future date after the initial issuance of such Convertible Securities or upon the occurrence of
specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock,
other than pursuant to a customary “weighted average” anti-dilution provision or (y) enters into any agreement (including,
without limitation, an equity line of credit or an “at-the-market” offering) whereby the Company or any Subsidiary
may sell securities at a future determined price (other than standard and customary “preemptive” or “participation”
rights). Each Buyer shall be entitled to obtain injunctive relief against the Company and its Subsidiaries to preclude any such
issuance, which remedy shall be in addition to any right to collect damages. For the avoidance of doubt, the issuance of a security
which is subject to customary anti-dilution protections, including where the conversion, exercise or exchange price is subject
to adjustment as a result of stock splits, reverse stock splits and other similar recapitalization or reclassification events,
shall not be deemed to be a Variable Rate Transaction.

 

(o)          [Intentionally
Omitted].

 

(p)          Dilutive
Issuances . For so long as any Notes remain outstanding, the Company shall not, in any manner, enter into or affect any Dilutive
Issuance (as defined in the Notes) if the effect of such Dilutive Issuance is to cause the Company to be required to issue upon
conversion of any Notes any shares of Common Stock in excess of that number of shares of Common Stock which the Company may issue
upon conversion of the Notes and without breaching the Company’s obligations under the rules or regulations of the Principal
Market or any such exchange or market that the Company’s Common Stock is then listed or available for quotation on. As of
any date, unless either (i) the Company has obtained the written approval of its stockholders providing for the Company’s
issuance of all of the Securities as described in the Transaction Documents in accordance with applicable law and the rules and
regulations of the Principal Market prior to such date and the Equity Conditions (as defined in the Notes) are satisfied as of
such date or (ii) no Notes remain outstanding, the Company shall not, in any manner, enter into or affect any Dilutive Issuance.

 

(q)          Passive
Foreign Investment Company. The Company shall conduct its business in such a manner as will ensure that the Company will not
be deemed to constitute a passive foreign investment company within the meaning of Section 1297 of the U.S. Internal Revenue Code
of 1986, as amended.

 

    	19

    	 

    

 

(r)          Restriction
on Redemption and Cash Dividends. So long as any Notes are outstanding, the Company shall not, directly or indirectly, redeem,
or declare or pay any cash dividend or distribution on, any securities of the Company without the prior express written consent
of the holders of a majority in aggregate principal amount of the Notes then outstanding (“Majority of Note Holders”);
provided, however, that the foregoing restrictions shall not apply to or impair the Company’s rights or obligations with
respect to (i) redemptions, dividends or distributions made under or pursuant to any Approved Stock Plan, (ii) the Company’s
redemption, at par value, of up to 674,000 shares (subject to the anti-dilution and other adjustment provisions thereof) of its
Series A Voting Preferred Stock, par value $.0001 per share, upon the exchange of New Crumbs Class B Exchangeable Units of Holdings
for shares of Common Stock pursuant to Holdings’ Third Amended and Restated Limited Liability Agreement, dated as of May
5, 2011 (the “LLC Agreement”), the Amended and Restated Certificate of Designation in respect of the Company’s
Series A Voting Preferred Stock (the “Certificate of Designation”), and the Exchange and Support Agreement described
in Schedule 3(r) hereto, or (iii) to the extent such distribution thereunder is deemed to constitute a direct or indirect redemption,
dividend or distribution of or with respect to any capital stock, a distribution under the Tax Receivable Agreement described in
Schedule 3(z) hereto; and provided further that the foregoing restrictions shall apply to any and all amendments or modifications
of any Approved Stock Plan, the LLC Agreement, the Certificate of Designation, the Exchange and Support Agreement and/or the Tax
Receivable Agreement made after the date hereof.

 

(s)          Corporate
Existence. So long as any Buyer beneficially owns any Notes, the Company shall not be party to any Fundamental Transaction
(as defined in the Notes) unless the Company is in compliance with the applicable provisions governing Fundamental Transactions
set forth in the Notes.

 

(t)          Board
Representation. For so long as Michael Serruya is a holder of a Note issued hereunder (the “Representation Period”),
the Nominating and Corporate Governance Committee (the “Nominating Committee”) of the Company’s Board
shall nominate a Designated Nominee (as defined below) for election to the Board at each meeting of the Company’s stockholders
held during the Representation Period at which directors are to be elected, commencing with the Company’s annual meeting
of stockholders currently scheduled to be held in June 2013 (the “2013 Annual Meeting”), and the Board shall
recommend to the stockholders that such Designated Nominee be so elected at such meeting (collectively, the “Nomination
Obligations”).  The Board shall take all such actions necessary during the Representation Period to ensure that
the size of the Board is large enough to accommodate the Designated Nominee’s election to the Board as a director of the
Company.  The Nomination Obligations are subject to the following conditions: (i) the Designated Nominee’s satisfaction
of all legal and governance requirements regarding the Designated Nominee’s service as a director of the Company and (ii)
the fiduciary duties imposed on the directors of the Company by the Nomination Obligations. “Designated Nominee”
means a person designated by Michael Serruya (x) who is able to satisfy all such legal and governance requirements and (y) the
nomination and recommendation of whom would not cause the Nominating Committee or the Board, respectively, to breach such fiduciary
duty (collectively, the “Director Qualifications”). Notwithstanding the foregoing, if (1) the timing of the
Closing at which Michael Serruya first purchases a Note makes it impracticable for the Company to prepare and file with the SEC,
on or before April 30, 2013, a definitive proxy statement containing the information regarding the Designated Nominee that is required
to be disclosed therein pursuant to the SEC’s Schedule 14A or (2) the Designated Nominee fails to timely provide the Company
with all information needed to prepare and file such definitive proxy statement by April 30, 2013 that it may reasonably request
from the Designated Nominee, then, subject to Director Nominee’s satisfaction of the Director Qualifications, (A) the Nominating
Committee shall recommend for election, and the Board shall elect, the Designated Nominee to the Board as soon as is reasonably
practicable following the 2013 Annual Meeting to serve until the next annual meeting of stockholders at which directors are elected
and until his or her successor is duly elected and qualifies and (B) the Nomination Obligations shall commence with such next annual
meeting.

 

(u)          Stock
Splits. Until the Notes are no longer outstanding, the Company shall not effect any stock combination, reverse stock split
or other similar transaction (or make any public announcement or disclosure with respect to any of the foregoing) without the prior
written consent of the Majority of Note Holders; provided, however, that no consent of the Majority of Note Holders shall be required
for a reverse stock split of the Common Stock that the Board, in the good faith exercise of its business judgment, determines to
be necessary or advisable to list or continue listing the Common Stock on the Principal Market or another trading market.

 

    	20

    	 

    

 

(v)         Stockholder
Approval. If, as determined at the time this Agreement is executed and delivered by the Company and the Buyers (the “Execution
Time”), the Conversion Price is less than the greater of (i) the Closing Bid Price immediately prior to the Execution
Time and (ii) the book value of a share of the Common Stock (determined in accordance with the rules and regulations of the Principal
Market) at the Execution Time, or if otherwise required by the Principal Market, then the Company shall provide each stockholder
entitled to vote at a special or annual meeting of stockholders of the Company (each, a “Stockholder Meeting”),
which shall be held no later than sixty (60) days after the First Closing Date (the “Stockholder Meeting Deadline”),
a proxy statement (the “Proxy Statement”) soliciting each such stockholder's affirmative vote at the Stockholder
Meeting for adoption of resolutions (the “Resolutions”) approving the issuance of all of the Conversion Shares
and the Interest Shares as described in the Transaction Documents in accordance with applicable law, the provisions of the Bylaws
and the rules and regulations of the Principal Market (the “Stockholder Approval” and the date such approval
is obtained, the “Stockholder Approval Date”), and the Company shall use its reasonable best efforts to solicit
its stockholders’ adoption of the Resolutions and to cause the Board of Directors of the Company to recommend to the stockholders
that they adopt the Resolutions. “Closing Bid Price” means the last closing bid price for a share of the Common
Stock on the Principal Market as reported by Bloomberg, L.P. The Proxy Statement shall contain such disclosures relating to the
Resolutions and the issuance of the Conversion Shares and the Interest Shares as are required by the SEC’s Schedule 14A and
reasonably acceptable to the Buyers after review by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. at the expense of the Company.
If Stockholder Approval is required pursuant to this Section 4(v) and, despite the Company's reasonable best efforts, the Stockholder
Approval is not obtained at a Stockholder Meeting, then the Company shall cause an additional Stockholder Meeting to be held each
calendar quarter thereafter until Stockholder Approval is obtained. If Stockholder Approval is required pursuant to this Section
4(v), then, pursuant to the Principal Market rules, each of the Buyers acknowledges that the Interest Shares and/or Conversion
Shares acquired prior to the Stockholder Approval may not be voted for the Resolutions at the Stockholder Meeting.

 

(w)          Voting
Agreement. If Stockholder Approval is required pursuant to Section 4(v), then (i) the Company will execute, and will use its
reasonable best efforts to cause each of Stephen Fass, Julian Geiger, John Ireland, Edwin Lewis, EHL Holdings LLC, Mark Klein,
Frederick Kraegel, Leonard Potter, Alan Rose, Jeffrey Roseman and Eric Wesolowski (collectively, the “Principal Stockholders”)
to execute, a voting agreement, in form and substance satisfactory to the Required Buyers (the “Voting Agreement”),
pursuant to which, among other things, each Principal Stockholder will agree, from and after the date of this Agreement and until
the Stockholder Approval is obtained, to vote or cause to be voted (including by written consent, if applicable) at the Stockholder
Meeting all of the voting securities of the Company that are beneficially owned by such Principal Stockholder and entitled to vote
thereon (A) in favor of the adoption of the Resolutions and (B) against any resolution that, if adopted, would be inconsistent
with the Resolutions, and (ii) the Company (A) shall use its reasonable best efforts to effectuate the transactions contemplated
by the Voting Agreement, (B) shall not amend, waive or terminate any provision of the Voting Agreement, (C) and shall enforce the
provisions of the Voting Agreement in accordance with its terms, including, without limitatoin, by promptly using its best efforts
to seek specific performance of the terms of the Voting Agreement in accordance with the terms thereof upon the breach by any of
the Principal Stockholders of any provisions thereof. The Principal Stockholders hold approximately 20.0% of the issued and outstanding
shares of Common Stock of the Company.

 

(x)          Closing
Documents. On or prior to fourteen (14) calendar days after the Closing Date, the Company agrees to deliver, or cause to be
delivered, to each Buyer and Mintz Levin executed copies of the Transaction Documents, Securities and other document required to
be delivered to any party pursuant to Section 7 hereof.

 

(y)          Additional
Agreements. If a Buyer assigns its rights to purchase Notes hereunder to a Buyer Assignee, then the Company and the Buyer Assignee
shall execute and deliver to each other an accession agreement and/or such other documents (the “Assignment Documents”)
as are reasonably necessary to reflect the Buyer’s assignment of such right to such Buyer Assignee and in which the Company
and such Buyer Assignee (i) each confirm that the representations and warranties contained in Section 2 of this Agreement with
respect to such Buyer Assignee and Section 3 of this Agreement with respect to the Company are true and correct in all material
respects as of the date of such Assignment Documents and as of the applicable Closing Date, (ii) agree to be bound by all of the
terms and conditions of this Agreement and (iii) release, upon the Closing of the sale of such assigned Notes, such assigning Buyer
from any and all obligations hereunder, including but not limited to that portion of its commitment to purchase Notes from the
Company, with respect to such assigned Notes; provided, however, that such release of assigning Buyer shall apply if such Closing
of the sale of assigned Notes under this clause (iii) does not occur due to a material breach of the Company’s obligations
under this Agreement.

 

    	21

    	 

    

 

5. 
         REGISTER; TRANSFER AGENT INSTRUCTIONS; LEGEND.

 

(a)          Register.
The Company shall maintain at its principal executive offices (or such other office or agency of the Company as it may designate
by notice to each holder of Securities), a register for the Notes in which the Company shall record the name and address of the
Person in whose name the Notes have been issued (including the name and address of each transferee), the principal amount of the
Notes held by such Person, the number of Conversion Shares issuable upon conversion of the Notes and the number of Interest Shares
issuable with respect to the Notes held by such Person. The Company shall keep the register open and available at all times during
business hours for inspection of any Buyer or its legal representatives.

 

(b)          Transfer
Agent Instructions. The Company shall issue irrevocable instructions to its transfer agent and any subsequent transfer agent,
in a form acceptable to such transfer agent and reasonably acceptable to each of the Buyers (the “Irrevocable Transfer
Agent Instructions”), to issue certificates or credit shares to the applicable balance accounts at The Depository Trust
Company (“DTC”), registered in the name of each Buyer or its respective nominee(s), for the Conversion Shares
and the Interest Shares in such amounts as specified from time to time by each Buyer to the Company upon conversion of the Notes.
The Company represents and warrants that no instruction other than the Irrevocable Transfer Agent Instructions referred to in this
Section 5(b), and stop transfer instructions to give effect to Section 2(g) hereof, will be given by the Company to its transfer
agent with respect to the Securities, and that the Securities shall otherwise be freely transferable on the books and records of
the Company, as applicable, to the extent provided in this Agreement and the other Transaction Documents. If a Buyer effects a
sale, assignment or transfer of the Securities in accordance with Section 2(g), the Company shall permit the transfer and shall
promptly instruct its transfer agent to issue one or more certificates or credit shares to the applicable balance accounts at DTC
in such name and in such denominations as specified by such Buyer to effect such sale, transfer or assignment. In the event that
such sale, assignment or transfer involves Conversion Shares or Interest Shares sold, assigned or transferred pursuant to an effective
registration statement or in compliance with Rule 144, the transfer agent shall issue such shares to such Buyer, assignee or transferee
(as the case may be) without any restrictive legend in accordance with Section 5(d) below. The Company acknowledges that a breach
by it of its obligations hereunder will cause irreparable harm to a Buyer. Accordingly, the Company acknowledges that the remedy
at law for a breach of its obligations under this Section 5(b) will be inadequate and agrees, in the event of a breach or threatened
breach by the Company of the provisions of this Section 5(b), that a Buyer shall be entitled, in addition to all other available
remedies, to an order and/or injunction restraining any breach and requiring immediate issuance and transfer, without the necessity
of showing economic loss and without any bond or other security being required. The Company shall cause its counsel to issue the
legal opinion referred to in the Irrevocable Transfer Agent Instructions to the Company’s transfer agent on each Effective
Date (as defined in the Registration Rights Agreement). Any fees (with respect to the transfer agent, counsel to the Company or
otherwise) associated with the issuance of such opinion or the removal of any legends on any of the Securities shall be borne by
the Company.

 

(c)          Legends.
Each Buyer understands that the Securities have been issued (or will be issued in the case of the Conversion Shares and Interest
Shares) pursuant to an exemption from registration or qualification under the 1933 Act and applicable state securities laws, and
except as set forth below, the Securities shall bear any legend as required by the “blue sky” laws of any state and
a restrictive legend in substantially the following form (and a stop-transfer order may be placed against transfer of such stock
certificates):

 

[NEITHER THE ISSUANCE AND SALE
OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE [CONVERTIBLE] HAVE BEEN][THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN] REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE
STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE
REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER
(IF REQUESTED BY THE COMPANY), IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT
OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE
SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

    	22

    	 

    

 

(d)          Removal
of Legends. Certificates evidencing Securities shall not be required to contain the legend set forth in Section 5(c) above
or any other legend (i) while a registration statement (including a Registration Statement) covering the resale of such Securities
is effective under the 1933 Act, (ii) following any sale of such Securities pursuant to Rule 144 (assuming the transferor is not
an affiliate of the Company), (iii) if such Securities are eligible to be sold, assigned or transferred under Rule 144 (provided
that a Buyer provides the Company with reasonable assurances that such Securities are eligible for sale, assignment or transfer
under Rule 144 which shall not include an opinion of counsel), (iv) in connection with a sale, assignment or other transfer (other
than under Rule 144), provided that such Buyer provides the Company with an opinion of counsel to such Buyer, in a generally acceptable
form, to the effect that such sale, assignment or transfer of the Securities may be made without registration under the applicable
requirements of the 1933 Act or (v) if such legend is not required under applicable requirements of the 1933 Act (including, without
limitation, controlling judicial interpretations and pronouncements issued by the SEC). If a legend is not required pursuant to
the foregoing, the Company shall no later than three (3) Trading Days following the delivery by a Buyer to the Company or the transfer
agent (with notice to the Company) of a legended certificate representing such Securities (endorsed or with stock powers attached,
signatures guaranteed, and otherwise in form necessary to affect the reissuance and/or transfer, if applicable), together with
any other deliveries from such Buyer as may be required above in this Section 5(d), as directed by such Buyer, either: (A) provided
that the Company’s transfer agent is participating in the DTC Fast Automated Securities Transfer Program and such Securities
are Conversion Shares or Interest Shares, credit the aggregate number of shares of Common Stock to which such Buyer shall be entitled
to such Buyer’s or its designee’s balance account with through its Deposit/Withdrawal at Custodian system or (B) if
the Company’s transfer agent is not participating in the Fast Automated Securities Transfer Program, issue and deliver (via
reputable overnight courier) to such Buyer, a certificate representing such Securities that is free from all restrictive and other
legends, registered in the name of such Buyer or its designee (the date by which such credit is so required to be made to the balance
account of such Buyer’s or such Buyer’s nominee with DTC or such certificate is required to be delivered to such Buyer
pursuant to the foregoing is referred to herein as the “Required Delivery Date”). The Company shall be responsible
for any transfer agent fees or DTC fees with respect to any issuance of Securities or the removal of any legends with respect to
any Securities in accordance herewith.

 

(e)          Failure
to Timely Deliver; Buy-In. If the Company fails to (i) issue and deliver (or cause to be delivered) to a Buyer by the Required
Delivery Date a certificate representing the Securities so delivered to the Company by such Buyer that is free from all restrictive
and other legends or (ii) credit the balance account of such Buyer’s or such Buyer’s nominee with DTC for such number
of Conversion Shares or Interest Shares so delivered to the Company, then, in addition to all other remedies available to such
Buyer, the Company shall pay in cash to such Buyer on each day after the Required Delivery Date that the issuance or credit of
such shares is not timely effected an amount in cash equal to 1.5% of the product of (A) the number of shares of Common Stock not
so delivered or credited (as the case may be) to such Buyer or such Buyer’s nominee multiplied by (B) the Closing Sale Price
(as defined in the applicable Note) of the Common Stock on the Trading Day (as defined in the applicable Note) immediately preceding
the Required Delivery Date. In addition to the foregoing, if the Company fails to so properly deliver such unlegended certificates
or so properly credit the balance account of such Buyer’s or such Buyer’s nominee with DTC by the Required Delivery
Date, and if on or after the Required Delivery Date such Buyer purchases (in an open market transaction or otherwise) shares of
Common Stock to deliver in satisfaction of a sale by such Buyer of shares of Common Stock that such Buyer anticipated receiving
from the Company without any restrictive legend, then, in addition to all other remedies available to such Buyer, the Company shall,
within three (3) Trading Days after such Buyer’s request and in such Buyer’s sole discretion, either (i) pay cash to
such Buyer in an amount equal to such Buyer’s total purchase price (including brokerage commissions, if any) for the shares
of Common Stock so purchased (the “Buy-In Price”), at which point the Company’s obligation to deliver
such certificate or credit such Buyer’s balance account shall terminate and such shares shall be cancelled, or (ii) promptly
honor its obligation to deliver to such Buyer a certificate or certificates or credit such Buyer’s DTC account representing
such number of shares of Common Stock that would have been issued if the Company timely complied with its obligations hereunder
and pay cash to such Buyer in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of
shares of Conversion Shares or Interest Shares (as the case may be) that the Company was required to deliver to such Buyer by the
Required Delivery Date times (B) the Closing Sale Price (as defined in the Note) of the Common Stock on the Trading Day immediately
preceding the Required Delivery Date.

 

    	23

    	 

    

 

6.      
    CONDITIONS TO THE COMPANY’S OBLIGATION TO SELL.

 

(a)          The
obligation of the Company hereunder to issue and sell the Notes to each Buyer at each Closing is subject to the satisfaction,
at or before the applicable Closing Date, of each of the following conditions, provided that these conditions are for the Company’s
sole benefit and may be waived by the Company at any time in its sole discretion by providing each Buyer with prior written notice
thereof:

 

(i)            Such
Buyer shall have executed each of the other Transaction Documents to which it is a party and delivered the same to the Company.

 

(ii)           Such
Buyer and each other Buyer shall have delivered to the Company the applicable Purchase Price (less, in the case of any Buyer, the
amounts withheld pursuant to Section 4(g)) for the Note being purchased by such Buyer at the applicable Closing by wire transfer
of immediately available funds in accordance with the Flow of Funds Letter.

 

(iii)          The
representations and warranties of such Buyer shall be true and correct in all material respects as of the date when made and as
of the applicable Closing Date as though originally made at that time (except for representations and warranties that speak as
of a specific date, which shall be true and correct as of such specific date), and such Buyer shall have performed, satisfied and
complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied
or complied with by such Buyer at or prior to such Closing Date.

 

(iv)          The
Company shall have obtained approval of the Principal Market to list or designate for quotation (as the case may be) the Conversion
Shares and the Interest Shares, which the Company shall use its best efforts to obtain.

 

(v)           Prior
to the Closing at which such Buyer will purchase Notes, such Buyer shall have delivered to the Company a true and correct letter
in the form attached hereto as Exhibit D identifying the specific basis for its accredited investor status.

 

7.     
     CONDITIONS TO EACH BUYER’S OBLIGATION TO PURCHASE.

 

(a)          The
obligation of each Buyer to purchase a Note at each Closing such Buyer participates in hereunder is subject to the satisfaction,
at or before the First Closing Date, of each of the following conditions, provided that these conditions are for each Buyer’s
sole benefit and may be waived by such Buyer at any time in its sole discretion by providing the Company with prior written notice
thereof:

 

(i)            Each
of the Company and its Subsidiaries shall have duly executed and delivered to such Buyer each of the Transaction Documents to which
it is a party, and the Company shall have duly executed and delivered to such Buyer, or its Buyer Assignee at such Buyer’s
request, a Note (in such original principal amount as is set forth across from such Buyer’s name in column (3) of the Schedule
of Buyers) being purchased by such Buyer at the First Closing pursuant to this Agreement.

 

(ii)           Such
Buyer shall have received the opinion of Gordon Feinblatt LLC, the Company’s counsel, dated as of the First Closing Date
and each Subsequent Closing Date, in the form reasonably acceptable to such Buyer.

 

(iii)          The
Company shall have delivered to such Buyer a copy of the Irrevocable Transfer Agent Instructions, in the form reasonably acceptable
to such Buyer, which instructions shall have been delivered to and acknowledged in writing by the Company’s transfer agent.

 

(iv)          The
Company shall have delivered to Mintz Levin, for the benefit of such Buyer, a certificate evidencing the formation and good standing
of each of the Company and Holdings issued by the Secretary of State of Delaware as of a date within ten (10) days of the First
Closing Date.

 

    	24

    	 

    

 

(v)          The
Company shall have delivered to Mintz Levin, for the benefit of such Buyer, a certificate evidencing the Company’s and Holdings’
qualification as a foreign corporation or limited liability company, respectively, and good standing issued by the Secretary of
State (or comparable office) of each jurisdiction in which the Company and Holdings conducts business and is required to so qualify,
as of a date within ten (10) days of the First Closing Date.

 

(vi)         The
Company shall have delivered to Mintz Levin, for the benefit of such Buyer, a certified copy of the Charter as certified by the
Delaware Secretary of State within ten (10) days of the First Closing Date.

 

(vii)         Holdings
shall have delivered to Mintz Levin, for the benefit of such Buyer, a certified copy of its certificate of organization as certified
by the Secretary of State of Delaware within ten (10) days of the First Closing Date.

 

(viii)        The
Company and Holdings shall have delivered to Mintz Levin, for the benefit of such Buyer, a certificate, in the form reasonably
acceptable to Mintz Levin, executed by the Secretary of the Company and Holdings and dated as of the First Closing Date, as to
(A) the resolutions consistent with Section 3(b) as adopted by the Company’s Board and Holdings’ Board of Managers
in a form reasonably acceptable to such Buyer, (B) the Certificate of Incorporation of the Company and the certificate of organization
of Holdings and (C) the Bylaws of the Company and the limited liabiilty company agreement of Holdings, each as in effect at the
First Closing.

 

(ix)          Each
of the Subsidiaries other than Holdings shall have delivered to Mintz Levin, on behalf of such Buyer, a certificate, in the form
reasonably acceptable to Mintz Levin, executed by the Secretary of such Subsidiary and dated as of the First Closing Date, as to
the resolutions consistent with Section 3(b) as adopted by such Subsidiary’s board of directors or other governing body.

 

(x)           The
representations and warranties of the Company made in this Agreement shall be true and correct as of the date when made and as
of the First Closing Date as though originally made at that time (except for representations and warranties that speak as of a
specific date, which shall be true and correct as of such specific date) and the Company shall have performed, satisfied and complied
in all respects with the covenants, agreements and conditions required to be performed, satisfied or complied with by the Company
at or prior to the First Closing Date. Such Buyer shall have received a certificate, duly executed by the Chief Executive Officer
of the Company, dated as of the First Closing Date, to the foregoing effect and as to such other matters as may be reasonably requested
by such Buyer in the form acceptable to such Buyer.

 

(xi)          The
Company shall have delivered to such Buyer a report from the Company’s transfer agent identifying the number of shares of
Common Stock outstanding on the First Closing Date immediately prior to the First Closing.

 

(xii)        The
Common Stock (A) shall be designated for quotation or listed (as applicable) on the Principal Market and (B) shall not have been
suspended, as of each Closing Date, by the SEC or the Principal Market from trading on the Principal Market nor shall suspension
by the SEC or the Principal Market have been threatened (except as already disclosed in the SEC Documents), as of the First Closing
Date, either (1) in writing by the SEC or the Principal Market or (2) by falling below the minimum maintenance requirements of
the Principal Market.

 

(xiii)        The
Company shall have obtained all governmental, regulatory or third party consents and approvals, if any, necessary for the sale
of the Securities, including without limitation, those required by the Principal Market.

 

(xiv)        No
statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed
by any court or governmental authority or other Governmental Entity of competent jurisdiction that prohibits the consummation of
any of the transactions contemplated by the Transaction Documents.

 

    	25

    	 

    

 

(xv)       Since
the date of execution of this Agreement, no event or series of events shall have occurred that reasonably would have or result
in a Material Adverse Effect.

 

(xvi)      The
Company shall have obtained approval of the Principal Market to list or designate for quotation (as the case may be) the Conversion
Shares and the Interest Shares.

 

(xvii)     The
Voting Agreement shall have been executed and delivered to such Buyer by the Company and each of the Principal Stockholders.

 

(xviii)    The
Company shall have duly executed and delivered to such Buyer, a flow of funds letter in form and substance reasonably satisfactory
to such Buyer (the “Flow of Funds Letter”).

 

(xix)       The
Company and its Subsidiaries shall have delivered to such Buyer such other documents relating to the transactions contemplated
by this Agreement as such Buyer or its counsel may reasonably request.

 

    	26

    	 

    

 

8.      
    TERMINATION.

 

In the event that the
First Closing shall not have occurred with respect to a Buyer within thirty (30) days of the date hereof, then each of the Company
(with respect to such Buyer) and such Buyer shall have the right to terminate its obligations under this Agreement with respect
to itself at any time on or after the close of business on such date without liability of the Company or such Buyer, as the case
may be, to any other party by providing written notice thereof to such Buyer or the Company, respectively; provided, however, (i)
the right to terminate its obligations under this Agreement pursuant to this Section 8 shall not be available to the Company or
such Buyer if the failure of the transactions contemplated by this Agreement to have been consummated by such date is the result
of the Company’s or such Buyer’s, respectively, breach of this Agreement and (ii) the abandonment of the sale and purchase
of the Notes shall be applicable only to such Buyer, provided further that no such termination shall affect any obligation of the
Company under this Agreement to reimburse such Buyer for the expenses described in Section 4(g) above. Nothing contained in this
Section 8 shall be deemed to release any party from any liability for any breach by such party of the terms and provisions of this
Agreement or the other Transaction Documents or to impair the right of any party to compel specific performance by any other party
of its obligations under this Agreement or the other Transaction Documents.

 

9. 
         MISCELLANEOUS.

 

(a)          Governing
Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement and interpretation of this
Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict
of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the
laws of any jurisdictions other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder
or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees
not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court,
that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is
improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit,
action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees
that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be
deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY
RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH
OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

(b)          Counterparts.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party. In the event that
any signature is delivered by facsimile transmission or by an e-mail which contains a portable document format (.pdf) file of an
executed signature page, such signature page shall create a valid and binding obligation of the party executing (or on whose behalf
such signature is executed) with the same force and effect as if such signature page were an original thereof.

 

(c)          Headings;
Gender. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation
of, this Agreement. Unless the context clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine,
feminine, neuter, singular and plural forms thereof. The terms “including,” “includes,” “include”
and words of like import shall be construed broadly as if followed by the words “without limitation.” The terms “herein,”
“hereunder,” “hereof” and words of like import refer to this entire Agreement instead of just the provision
in which they are found.

 

    	27

    	 

    

 

(d)          Severability;
Maximum Payment Amounts. If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable
by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed
amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such
provision shall not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so modified
continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited
nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations
or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the
parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s)
with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).
Notwithstanding anything to the contrary contained in this Agreement or any other Transaction Document (and without implication
that the following is required or applicable), it is the intention of the parties that in no event shall amounts and value paid
by the Company and/or its Subsidiaries (as the case may be), or payable to or received by any of the Buyers, under the Transaction
Documents (including without limitation, any amounts that would be characterized as “interest” under applicable law)
exceed amounts permitted under any applicable law. Accordingly, if any obligation to pay, payment made to any Buyer, or collection
by any Buyer pursuant the Transaction Documents is finally judicially determined to be contrary to any such applicable law, such
obligation to pay, payment or collection shall be deemed to have been made by mutual mistake of such Buyer, the Company and its
Subsidiaries and such amount shall be deemed to have been adjusted with retroactive effect to the maximum amount or rate of interest,
as the case may be, as would not be so prohibited by the applicable law. Such adjustment shall be effected, to the extent necessary,
by reducing or refunding, at the option of such Buyer, the amount of interest or any other amounts which would constitute unlawful
amounts required to be paid or actually paid to such Buyer under the Transaction Documents. For greater certainty, to the extent
that any interest, charges, fees, expenses or other amounts required to be paid to or received by such Buyer under any of the Transaction
Documents or related thereto are held to be within the meaning of “interest” or another applicable term to otherwise
be violative of applicable law, such amounts shall be pro-rated over the period of time to which they relate.

 

(e)          Entire
Agreement; Amendments. This Agreement, the other Transaction Documents and the schedules and exhibits attached hereto and thereto
and the instruments referenced herein and therein supersede all other prior oral or written agreements between the Buyers, the
Company, its Subsidiaries, their affiliates and Persons acting on their behalf solely with respect to the matters contained herein
and therein, and this Agreement, the other Transaction Documents, the schedules and exhibits attached hereto and thereto and the
instruments referenced herein and therein contain the entire understanding of the parties solely with respect to the matters covered
herein and therein; provided, however, nothing contained in this Agreement or any other Transaction Document shall (or shall be
deemed to) (i) have any effect on any agreements any Buyer has entered into with the Company or any of its Subsidiaries prior to
the date hereof with respect to any prior investment made by such Buyer in the Company or (ii) waive, alter, modify or amend in
any respect any obligations of the Company or any of its Subsidiaries, or any rights of or benefits to any Buyer or any other Person,
in any agreement entered into prior to the date hereof between or among the Company and/or any of its Subsidiaries and any Buyer
and all such agreements shall continue in full force and effect. Except as specifically set forth herein or therein, neither the
Company nor any Buyer makes any representation, warranty, covenant or undertaking with respect to such matters. For clarification
purposes, the Recitals are part of this Agreement. No provision of this Agreement may be amended other than by an instrument in
writing signed by the Company and the Required Holders (as defined below), and any amendment to any provision of this Agreement
made in conformity with the provisions of this Section 9(e) shall be binding on all Buyers and holders of Securities, as applicable,
provided that no such amendment shall be effective to the extent that it (1) applies to less than all of the holders of the Securities
then outstanding or (2) imposes any obligation or liability on any Buyer without such Buyer’s prior written consent (which
may be granted or withheld in such Buyer’s sole discretion). No waiver shall be effective unless it is in writing and signed
by an authorized representative of the waiving party, provided that the Required Holders may waive any provision of this Agreement,
and any waiver of any provision of this Agreement made in conformity with the provisions of this Section 9(e) shall be binding
on all Buyers and holders of Securities, as applicable, provided that no such waiver shall be effective to the extent that it (1)
applies to less than all of the holders of the Securities then outstanding (unless a party gives a waiver as to itself only) or
(2) imposes any obligation or liability on any Buyer without such Buyer’s prior written consent (which may be granted or
withheld in such Buyer’s sole discretion). No consideration shall be offered or paid to any Person to amend or consent to
a waiver or modification of any provision of any of the Transaction Documents unless the same consideration also is offered to
all of the parties to the Transaction Documents or all holders of the Notes. The Company has not, directly or indirectly, made
any agreements with any Buyers relating to the terms or conditions of the transactions contemplated by the Transaction Documents
except as set forth in the Transaction Documents. Without limiting the foregoing, the Company confirms that, except as set forth
in this Agreement, no Buyer has made any commitment or promise or has any other obligation to provide any financing to the Company,
any Subsidiary or otherwise. As a material inducement for each Buyer to enter into this Agreement, the Company expressly acknowledges
and agrees that (i) no due diligence or other investigation or inquiry conducted by a Buyer, any of its advisors or any of its
representatives shall affect such Buyer’s right to rely on, or shall modify or qualify in any manner or be an exception to
any of, the Company’s representations and warranties contained in this Agreement or any other Transaction Document and (ii)
unless a provision of this Agreement or any other Transaction Document is expressly preceded by the phrase “except as disclosed
in the SEC Documents,” nothing contained in any of the SEC Documents shall affect such Buyer’s right to rely on, or
shall modify or qualify in any manner or be an exception to any of, the Company’s representations and warranties contained
in this Agreement or any other Transaction Document. “Required Holders” means holders of a majority of the Registrable
Securities (excluding any Registrable Securities held by the Company or any of its Subsidiaries) issued or issuable hereunder or
pursuant to the Notes.

 

    	28

    	 

    

 

(f)          Notices.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must
be in writing and will be deemed to have been delivered: (i) upon receipt, if delivered personally; (ii) when sent, if sent by
facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party);
(iii) when sent, if sent by e-mail (provided that such sent e-mail is kept on file (whether electronically or otherwise) by the
sending party and the sending party does not receive an automatically generated message from the recipient’s e-mail server
that such e-mail could not be delivered to such recipient) and (iv) if sent by overnight courier service, one (1) Business Day
after deposit with an overnight courier service with next day delivery specified, in each case, properly addressed to the party
to receive the same. The addresses, facsimile numbers and e-mail addresses for such communications shall be:

 

If to the Company:

 

110 West 40th Street

Suite 2100

New York, New York 10018

Telephone: 212-221-7105

Facsimile: 212-221-7107

Email Address: jgeiger@crumbs.com

Attn: Julian R. Geiger, President
and CEO

 

With a copy (for informational
purposes only) to:

 

Gordon Feinblatt LLC

233 E. Redwood Street

Baltimore, MD 21202

Telephone: 410-576-4280

Facsimile: 410-576-4196

E-mail Address: abulgin@gfrlaw.com

Attn: Andrew D. Bulgin, Esq.

 

If to the Transfer Agent:

 

Continental Stock Transfer & Trust
Company

17 Battery Place

New York, New York 10004

Telephone: 212-845-3218

Facsimile: 212-616-7615

E-mail Address: jcomer@continentalstock.com

Attn: John W. Comer, Jr., Vice President
& Senior Account Manager

 

If to a Buyer, to its address and
facsimile number set forth on the Schedule of Buyers, with copies to such Buyer’s representatives as set forth on the Schedule
of Buyers,

 

    	29

    	 

    

 

with a copy (for informational
purposes only) to:

 

Mintz, Levin, Cohn, Ferris, Glovsky
and Popeo, P.C.

666 Third Avenue

New York, NY 10017

Telephone: (212) 935-3000

Facsimile: (212) 983-3115

Attn: Jeffrey P. Schultz, Esq.

 

or to such other address, facsimile number
or e-mail address and/or to the attention of such other Person as the recipient party has specified by written notice given to
each other party five (5) days prior to the effectiveness of such change, provided that Mintz Levin shall only be provided copies
of notices sent to the lead Buyer. Written confirmation of receipt (A) given by the recipient of such notice, consent, waiver or
other communication, (B) mechanically or electronically generated by the sender’s facsimile machine containing the time,
date, recipient facsimile number and an image of the first page of such transmission or (C) provided by an overnight courier service
shall be rebuttable evidence of personal service, receipt by facsimile or receipt from an overnight courier service in accordance
with clause (i), (ii) or (iv) above, respectively. A copy of the e-mail transmission containing the time, date and recipient e-mail
address shall be rebuttable evidence of receipt by e-mail in accordance with clause (iii) above.

 

(g)          Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and
assigns, including any purchasers of any of the Securities. The Company shall not assign this Agreement or any rights or obligations
hereunder without the prior written consent of the Required Holders including, without limitation, by way of a Fundamental Transaction
(as defined in the Notes) (unless the Company is in compliance with the applicable provisions governing Fundamental Transactions
set forth in the Notes). A Buyer (i) may assign some or all of its rights and obligation to purchase Notes hereunder to a Buyer
Assignee prior to a Closing Date without the consent of the Company, as provided in Section 1(e) hereof, and (ii) may assign some
or all of its rights hereunder in connection with any transfer of any of its Securities without the consent of the Company, in
which events such assignee shall be deemed to be a Buyer hereunder with respect to such assigned rights.

 

(h)          No
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted
successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, other than
the Indemnitees referred to in Section 9(k).

 

(i)          Survival.
The representations, warranties, agreements and covenants shall survive each Closing. Each Buyer shall be responsible only for
its own representations, warranties, agreements and covenants hereunder.

 

(j)          Further
Assurances. Each party shall use its reasonable best efforts to do and perform, or cause to be done and performed, all such
further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any
other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation
of the transactions contemplated hereby.

 

(k)          Indemnification.
In consideration of each Buyer’s execution and delivery of the Transaction Documents and acquiring the Securities thereunder
and in addition to all of the Company’s other obligations under the Transaction Documents, the Company shall defend, protect,
indemnify and hold harmless each Buyer and each holder of any Securities and all of their stockholders, partners, members, officers,
directors, employees and direct or indirect investors and any of the foregoing Persons’ agents or other representatives (including,
without limitation, those retained in connection with the transactions contemplated by this Agreement) (collectively, the “Indemnitees”)
from and against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages,
and expenses in connection therewith (irrespective of whether any such Indemnitee is a party to the action for which indemnification
hereunder is sought), and including reasonable attorneys’ fees and disbursements (the “Indemnified Liabilities”),
incurred by any Indemnitee as a result of, or arising out of, or relating to (a) any misrepresentation or breach of any representation
or warranty made by the Company or any Subsidiary in any of the Transaction Documents, (b) any breach of any covenant, agreement
or obligation of the Company or any Subsidiary contained in any of the Transaction Documents or (c) any cause of action, suit or
claim brought or made against such Indemnitee by a third party (including for these purposes a derivative action brought on behalf
of the Company or any Subsidiary) and arising out of or resulting from (i) the execution, delivery, performance or enforcement
of any of the Transaction Documents, (ii) any transaction financed or to be financed in whole or in part, directly or indirectly,
with the proceeds of the issuance of the Securities, (iii) any disclosure properly made by such Buyer pursuant to Section 4(i),
or (iv) the status of such Buyer or holder of the Securities as an investor in the Company pursuant to the transactions contemplated
by the Transaction Documents. To the extent that the foregoing undertaking by the Company may be unenforceable for any reason,
the Company shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is
permissible under applicable law. Except as otherwise set forth herein, the mechanics and procedures with respect to the rights
and obligations under this Section 9(k) shall be the same as those set forth in Section 6 of the Registration Rights Agreement.

 

    	30

    	 

    

 

(l)          Construction.
The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and
no rules of strict construction will be applied against any party. No specific representation or warranty shall limit the generality
or applicability of a more general representation or warranty. Each and every reference to share prices, shares of Common Stock
and any other numbers in this Agreement that relate to the Common Stock shall be automatically adjusted for stock splits, stock
combinations and other similar transactions that occur with respect to the Common Stock after the date of this Agreement.

 

(m)          Remedies.
Each Buyer and each holder of any Securities shall have all rights and remedies set forth in the Transaction Documents and all
rights and remedies which such holders have been granted at any time under any other agreement or contract and all of the rights
which such holders have under any law. Any Person having any rights under any provision of this Agreement shall be entitled to
enforce such rights specifically (without posting a bond or other security), to recover damages by reason of any breach of any
provision of this Agreement and to exercise all other rights granted by law. Furthermore, the Company recognizes that in the event
that it or any Subsidiary fails to perform, observe, or discharge any or all of its or such Subsidiary’s (as the case may
be) obligations under the Transaction Documents, any remedy at law may prove to be inadequate relief to the Buyers. The Company
therefore agrees that the Buyers shall be entitled to seek specific performance and/or temporary, preliminary and permanent injunctive
or other equitable relief from any court of competent jurisdiction in any such case without the necessity of proving actual damages
and without posting a bond or other security.

 

(n)          Withdrawal
Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) the Transaction
Documents, whenever any Buyer exercises a right, election, demand or option under a Transaction Document and the Company or any
Subsidiary does not timely perform its related obligations within the periods therein provided, then such Buyer may rescind or
withdraw, in its sole discretion from time to time upon written notice to the Company or such Subsidiary (as the case may be),
any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights.

 

(o)          Payment
Set Aside; Currency. To the extent that the Company makes a payment or payments to any Buyer hereunder or pursuant to any of
the other Transaction Documents or any of the Buyers enforce or exercise their rights hereunder or thereunder, and such payment
or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent
or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company,
a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, foreign, state or federal
law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally
intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement
or setoff had not occurred. Unless otherwise expressly indicated, all dollar amounts referred to in this Agreement and the other
Transaction Documents are in United States Dollars (“U.S. Dollars”), and all amounts owing under this Agreement
and all other Transaction Documents shall be paid in U.S. Dollars. All amounts denominated in other currencies (if any) shall be
converted into the U.S. Dollar equivalent amount in accordance with the Exchange Rate on the date of calculation. “Exchange
Rate” means, in relation to any amount of currency to be converted into U.S. Dollars pursuant to this Agreement, the
U.S. Dollar exchange rate as published in the Wall Street Journal on the relevant date of calculation.

 

(p)          [Intentionally
Omitted].

 

    	31

    	 

    

 

(q)          Independent
Nature of Buyers’ Obligations and Rights. The obligations of each Buyer under the Transaction Documents are several and
not joint with the obligations of any other Buyer, and no Buyer shall be responsible in any way for the performance of the obligations
of any other Buyer under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action
taken by any Buyer pursuant hereto or thereto, shall be deemed to constitute the Buyers as, and the Company acknowledges that the
Buyers do not so constitute, a partnership, an association, a joint venture or any other kind of group or entity, or create a presumption
that the Buyers are in any way acting in concert or as a group or entity with respect to such obligations or the transactions contemplated
by the Transaction Documents or any matters, and the Company acknowledges that the Buyers are not acting in concert or as a group,
and the Company shall not assert any such claim, with respect to such obligations or the transactions contemplated by the Transaction
Documents. The decision of each Buyer to purchase Securities pursuant to the Transaction Documents has been made by such Buyer
independently of any other Buyer. Each Buyer acknowledges that no other Buyer has acted as agent for such Buyer in connection with
such Buyer making its investment hereunder and that no other Buyer will be acting as agent of such Buyer in connection with monitoring
such Buyer’s investment in the Securities or enforcing its rights under the Transaction Documents. The Company and each Buyer
confirms that each Buyer has independently participated with the Company and its Subsidiaries in the negotiation of the transaction
contemplated hereby with the advice of its own counsel and advisors. Each Buyer shall be entitled to independently protect and
enforce its rights, including, without limitation, the rights arising out of this Agreement or out of any other Transaction Documents,
and it shall not be necessary for any other Buyer to be joined as an additional party in any proceeding for such purpose. The use
of a single agreement to effectuate the purchase and sale of the Securities contemplated hereby was solely in the control of the
Company, not the action or decision of any Buyer, and was done solely for the convenience of the Company and its Subsidiaries and
not because it was required or requested to do so by any Buyer. It is expressly understood and agreed that each provision contained
in this Agreement and in each other Transaction Document is between the Company, each Subsidiary and a Buyer, solely, and not between
the Company, its Subsidiaries and the Buyers collectively and not between and among the Buyers.

 

[signature pages follow]

 

    	32

    	 

    

 

IN WITNESS WHEREOF,
each Buyer and the Company have caused their respective signature page to this Agreement to be duly executed as of the date first
written above.

 

	 	COMPANY:
	 	 
	 	CRUMBS BAKE SHOP, INC.
	 	 
	 	By:	/s/ John D. Ireland 
	 	Name: John D. Ireland
	 	Title: Senior Vice President and CEO

 

    	 

    	 

    

 

IN WITNESS WHEREOF,
each Buyer and the Company have caused their respective signature page to this Agreement to be duly executed as of the date first
written above.

 

	 	BUYER:
	 	/s/ Michael Serruya
	 	 
	 	By:	 
	 	Name:
	 	Title:

 

    	 

    	 

    

 

SCHEDULE
OF Buyers

 

	(1)	 	(2)	 	 	(3)	 	(4)
	 	 	 	 	 	 	 	 
	Buyer	 	Address 

and 

Facsimile 

Number	 	 	Aggregate 

Original 

Principal 

Amount of 

Notes	 	Legal Representative’s

Address and Facsimile Number
	Michael Serruya	 	 	 	$	10,000,000	 	
        Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.,

        666 Third Avenue, New York, NY 10017

        212-983-3115

	TOTAL	 	 	 	$	10,000,000	 	 

  

    	 

    	 

    

 

SCHEDULE
OF Buyer assignees

 

	(1)	 	 	(2)		 	 	(3)		 	 	(4)		 	 	(5)		 	 	(6)		 	 	(7)		 	 	(8)	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Buyer	 	 	Address
                                                                                                                                            and
                                                                                                                                            

                                                                                                                                            Facsimile
                                                                                                                                            

                                                                                                                                            Number	 	 	 	Aggregate
                                                                                                                                            

                                                                                                                                            Original
                                                                                                                                            

                                                                                                                                            Principal
                                                                                                                                            

                                                                                                                                            Amount
                                                                                                                                            of
                                                                                                                                            

                                                                                                                                            Notes	 	 	 	First
                                                                                                                                            Closing
                                                                                                                                            

                                                                                                                                            Date
                                                                                                                                            Original
                                                                                                                                            

                                                                                                                                            Principal
                                                                                                                                            

                                                                                                                                            Amount
                                                                                                                                            of
                                                                                                                                            

                                                                                                                                            Notes
                                                                                                                                            

                                                                                                                                            Purchased	 	 	 	First
                                                                                                                                            Closing
                                                                                                                                            

                                                                                                                                            Date
                                                                                                                                            

                                                                                                                                            Purchase
                                                                                                                                            

                                                                                                                                            Price	 	 	 	[Subsequent
                                                                                                                                            

                                                                                                                                            Closing
                                                                                                                                            

                                                                                                                                            Date]  

                                                                                                                                            Original
                                                                                                                                            

                                                                                                                                            Principal
                                                                                                                                            

                                                                                                                                            Amount
                                                                                                                                            of
                                                                                                                                            

                                                                                                                                            Notes
                                                                                                                                            

                                                                                                                                            Purchased	 	 	 	[Subsequent
                                                                                                                                            

                                                                                                                                            Closing
                                                                                                                                            

                                                                                                                                            Date]
                                                                                                                                            

                                                                                                                                            Purchase
                                                                                                                                            

                                                                                                                                            Price	 	 	 	Legal
                                                                                                                                            

                                                                                                                                            Representative’s

                                                                                                                                            Address
                                                                                                                                            and
                                                                                                                                            

                                                                                                                                            Facsimile
                                                                                                                                            Number	 
	Front Street Investment Management Inc.	 	 		 	 	$	2,000,000	 	 	$	2,000,000	 	 	$	2,000,000	 	 	$	[               ]	 	 	$	[               ]	 	 	 	[               ]	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Aston Hill Asset Management Inc.	 	 	 	 	 	 	3,000,000	 	 	 	3,000,000	 	 	 	3,000,000	 	 	 	[               ]	 	 	 	[               ]	 	 	 	[               ]	 
	Personal Capital Management Corp.	 	 	 	 	 	 	1,000,000	 	 	 	1,000,000	 	 	 	1,000,000	 	 	 	 	 	 	 	 	 	 	 	 	 
	[Dynamic]	 	 	 	 	 	 	2,500,000	 	 	 	2,500,000	 	 	 	2,500,000	 	 	 	 	 	 	 	 	 	 	 	 	 
	TOTAL	 	 	 	 	 	$	8,500,000	 	 	 	 	 	 	$	8,500,000	 	 	 	 	 	 	 	 	 	 	 	 	 

 

    	 

    	 

    

 

EXHIBIT A

FORM OF SENIOR UNSECURED CONVERTIBLE
PROMISSORY NOTE

 

[FORM OF SENIOR CONVERTIBLE NOTE]

 

NEITHER THE ISSUANCE AND SALE OF THE
SECURITIES REPRESENTED BY THIS NOTE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED
OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933,
AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY THE COMPANY), IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY,
THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER
SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN
OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES. ANY TRANSFEREE OF THIS NOTE SHOULD CAREFULLY REVIEW THE TERMS OF THIS NOTE,
INCLUDING SECTIONS 3(c)(iii) AND 17(a) HEREOF. THE PRINCIPAL AMOUNT REPRESENTED BY THIS NOTE AND, ACCORDINGLY, THE SECURITIES ISSUABLE
UPON CONVERSION HEREOF MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 3(c)(iii) OF THIS NOTE.

 

CRUMBS BAKE SHOP, INC.

 

Senior
Convertible Note

 

	Issuance Date:  _____________, 2013	Original Principal Amount: U.S. $[         ]

 

FOR VALUE RECEIVED,
Crumbs Bake Shop, Inc., a Delaware corporation (the “Company”), hereby promises to pay to the order of [NAME
OF BUYER] or its registered assigns (“Holder”) the amount set out above as the Original Principal Amount (as
reduced pursuant to the terms hereof pursuant to redemption, conversion or otherwise, the “Principal”) when
due, whether upon the Maturity Date (as defined below), acceleration, redemption or otherwise (in each case in accordance with
the terms hereof) and to pay interest (“Interest”) on any outstanding Principal (as defined below) at the applicable
Interest Rate (as defined below) from the date set out above as the Issuance Date (the “Issuance Date”) until
the same becomes due and payable, whether upon an Interest Date (as defined below), the Maturity Date or acceleration, conversion,
redemption or otherwise (in each case in accordance with the terms hereof). This Senior Convertible Note (including all Senior
Convertible Notes issued in exchange, transfer or replacement hereof, this “Note”) is one of an issue of Senior
Convertible Notes issued pursuant to the Securities Purchase Agreement (as defined below) on the Closing Date (as defined below)
(collectively, the “Notes” and such other Senior Convertible Notes, the “Other Notes”). Certain
capitalized terms used herein are defined in Section 30.

 

 

1.      
    PAYMENTS OF PRINCIPAL. On the Maturity Date, the Company shall pay to the Holder an amount in
cash representing all outstanding Principal, accrued and unpaid Interest and accrued and unpaid Late Charges on such
Principal and Interest. Other than as specifically permitted by this Note, the Company may not prepay any portion of the
outstanding Principal, accrued and unpaid Interest or accrued and unpaid Late Charges on Principal and Interest, if any.

 

2.      
    INTEREST; INTEREST RATE.

 

(a)          Interest
on this Note shall commence accruing at the Interest Rate on the Issuance Date and shall be computed on the basis of a 360-day
year and twelve 30-day months, shall be payable in arrears for each Quarter on January 1, April 1, July 1 and October 1 of each
year (each, an “Interest Date”) with the first Interest Date being [             ],
2013, and shall compound on each Interest Date. Interest shall be payable on each Interest Date, to the record Holder of this Note
on the applicable Interest Date, in shares of Common Stock (“Interest Shares”) so long as there has been no
Equity Conditions Failure; provided however, that the Company may, at its option following written notice to the Holder, pay Interest
on any Interest Date in cash (“Cash Interest”), or a combination thereof. The Company shall deliver a written
notice (each, an “Interest Election Notice”) to each Holder of the Notes on or prior to the applicable Interest
Due Date (the date such notice is delivered to all of the Holders, the “Interest Notice Date”) which notice
(i) either (A) confirms that Interest to be paid on such Interest Date shall be paid entirely in Interest Shares, or (B) elects
to pay Interest as Cash Interest or a combination of Cash Interest and Interest Shares and specifies the amount of Interest that
shall be paid as Cash Interest and the amount of Interest, if any, to be paid in Interest Shares and (ii) if any Interest is to
be paid in Interest Shares, certifies that there has been no Equity Conditions Failure (in the case of Interest Shares). If an
Equity Conditions Failure has occurred as of the Interest Notice Date, then unless the Company has elected to pay such Interest
entirely as Cash Interest, the Interest Notice shall indicate that unless the Holder waives the Equity Conditions Failure, the
Interest shall be paid as Cash Interest. Notwithstanding anything herein to the contrary, if no Equity Conditions Failure has occurred
as of the Interest Notice Date but an Equity Conditions Failure occurs at any time prior to the Interest Date, (A) the Company
shall provide the Holder a subsequent notice to that effect and (B) unless the Holder waives the Equity Conditions Failure, the
Interest shall be paid in cash. Interest to be paid on an Interest Date in Interest Shares shall be paid in a number of fully paid
and nonassessable shares (rounded to the nearest whole share) of Common Stock equal to the quotient of (1) the amount of Interest
payable on such Interest Date less any Cash Interest and (2) the applicable Conversion Price in effect on the applicable Interest
Date.

 

    	 

    	 

    

 

(b)          When
any Interest Shares are to be paid on an Interest Date, the Company shall (i) (A) provided that the Company’s transfer agent
(the “Transfer Agent”) is participating in the Depository Trust Company (“DTC”) Fast Automated
Securities Transfer Program, credit such aggregate number of Interest Shares to which the Holder shall be entitled to the Holder’s
or its designee’s balance account with DTC through its Deposit/Withdrawal at Custodian system, or (B) if the Transfer Agent
is not participating in the DTC Fast Automated Securities Transfer Program, issue and deliver on the applicable Interest Date,
to the address set forth in the register maintained by the Company for such purpose pursuant to the Securities Purchase Agreement
or to such address as specified by the Holder in writing to the Company at least two (2) Business Days prior to the applicable
Interest Date, a certificate, registered in the name of the Holder or its designee, for the number of Interest Shares to which
the Holder shall be entitled and (ii) with respect to each Interest Date, pay to the Holder, in cash by wire transfer of immediately
available funds, the amount of any Cash Interest.

 

(c)          Prior
to the payment of Interest on an Interest Date, Interest on this Note shall accrue at the Interest Rate and be payable by way of
inclusion of the Interest in the Conversion Amount on each Conversion Date in accordance with Section 3(b)(i) or upon any
redemption in accordance with Section 11. From and after the occurrence and during the continuance of any Event of Default
(as defined in the Notes), the Interest Rate shall automatically be increased to eighteen percent (18.0%) (“Default Interest”).
In the event that such Event of Default is subsequently cured, the adjustment referred to in the preceding sentence shall cease
to be effective as of the calendar day immediately following the date of such cure; provided that the Interest as calculated and
unpaid at such increased rate during the continuance of such Event of Default shall continue to apply to the extent relating to
the days after the occurrence of such Event of Default through and including the date of such cure of such Event of Default. The
Company shall pay any and all taxes that may be payable with respect to the issuance and delivery of Interest Shares.

 

3.     
     CONVERSION OF NOTES. This Note shall be convertible into validly issued, fully paid and
non-assessable shares of the Company’s common stock, par value $0.0001 per share (the “Common
Stock”), on the terms and conditions set forth in this Section 3.

 

(a)          Conversion
Right. Subject to the provisions of Section 3(d), at any time or times on or after the Issuance Date, the Holder shall be entitled
to convert any portion of the outstanding and unpaid Conversion Amount (as defined below) into validly issued, fully paid and non-assessable
shares of Common Stock in accordance with Section 3(c), at the Conversion Rate (as defined below). The Company shall not issue
any fraction of a share of Common Stock upon any conversion. If the issuance would result in the issuance of a fraction of a share
of Common Stock, the Company shall round such fraction of a share of Common Stock up to the nearest whole share. The Company shall
pay any and all transfer, stamp, issuance and similar taxes that may be payable with respect to the issuance and delivery of Common
Stock upon conversion of any Conversion Amount.         

 

(b)          Conversion
Rate. The number of shares of Common Stock issuable upon conversion of any Conversion Amount pursuant to Section 3(a) shall
be determined by dividing (x) such Conversion Amount by (y) the Conversion Price (the “Conversion Rate”).

 

    	2

    	 

    

  

(i)          “Conversion
Amount” means the portion of the Principal to be converted, redeemed or otherwise with respect to which this determination
is being made, plus all accrued and unpaid Interest with respect to such portion of the Principal amount and accrued and unpaid
Late Charges with respect to such portion of such Principal and such Interest.

 

(ii)         “Conversion
Price” means, as of any Conversion Date (as defined below) or other date of determination, $1.55, subject to adjustment
as provided herein.

 

(c)          Mechanics
of Conversion.

 

(i)          Optional
Conversion. To convert any Conversion Amount into shares of Common Stock on any date (a “Conversion Date”),
the Holder shall deliver (whether via facsimile or otherwise), for receipt on or prior to 11:59 p.m., New York time, on such date,
a copy of an executed notice of conversion in the form attached hereto as Exhibit I (the “Conversion Notice”)
to the Company. If required by Section 3(c)(iii), within three (3) Trading Days following a conversion of this Note as aforesaid,
the Holder shall surrender this Note to a nationally recognized overnight delivery service for delivery to the Company (or an indemnification
undertaking with respect to this Note in the case of its loss, theft or destruction as contemplated by Section 17(b)). On or before
the third (3rd) Trading Day following the date of receipt of a Conversion Notice, the Company shall transmit by facsimile
an acknowledgment of confirmation, in the form attached hereto as Exhibit II, of receipt of such Conversion Notice to the Holder
and the Company’s transfer agent (the “Transfer Agent”). On or before the third (3rd) Trading Day following the
date of receipt of a Conversion Notice, the Company shall (1) provided that the Transfer Agent is participating in The DTC Fast
Automated Securities Transfer Program, credit such aggregate number of shares of Common Stock to which the Holder shall be entitled
to the Holder’s or its designee’s balance account with DTC through its Deposit/Withdrawal at Custodian system or (2)
if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, issue and deliver (via reputable
overnight courier) to the address as specified in the Conversion Notice, a certificate, registered in the name of the Holder or
its designee, for the number of shares of Common Stock to which the Holder shall be entitled. If this Note is physically surrendered
for conversion pursuant to Section 3(c)(iii) and the outstanding Principal of this Note is greater than the Principal portion of
the Conversion Amount being converted, then the Company shall as soon as practicable and in no event later than three (3) Business
Days after receipt of this Note and at its own expense, issue and deliver to the Holder (or its designee) a new Note (in accordance
with Section 17(d)) representing the outstanding Principal not converted. The Person or Persons entitled to receive the shares
of Common Stock issuable upon a conversion of this Note shall be treated for all purposes as the record holder or holders of such
shares of Common Stock on the Conversion Date.

 

(ii)         Company’s
Failure to Timely Convert. If the Company shall fail, for any reason or for no reason, to issue to the Holder within three
(3) Trading Days after the Company’s receipt of a Conversion Notice (whether via facsimile or otherwise), a certificate for
the number of shares of Common Stock to which the Holder is entitled pursuant to such Conversion Notice and register such shares
of Common Stock on the Company’s share register or to credit the Holder’s or its designee’s balance account with
DTC for such number of shares of Common Stock to which the Holder is entitled upon the Holder’s conversion of any Conversion
Amount (as the case may be) (a “Conversion Failure”), then, in addition to all other remedies available to the
Holder, (1) the Company shall pay in cash damages to the Holder on each day after such third (3rd) Trading Day that
the issuance of such shares of Common Stock is not timely effected an amount equal to 1.0% of the product of (A) the sum of the
number of shares of Common Stock not issued to the Holder on a timely basis and to which the Holder is entitled multiplied by (B)
the Closing Sale Price of the Common Stock on the Trading Day immediately preceding the last possible date which the Company could
have issued such shares of Common Stock to the Holder without violating Section 3(d) and (2) the Holder, upon written notice to
the Company, may void its Conversion Notice with respect to, and retain or have returned (as the case may be) any portion of this
Note that has not been converted pursuant to such Conversion Notice, provided that the voiding of a Conversion Notice shall not
affect the Company’s obligations to make any payments which have accrued prior to the date of such notice pursuant to this
Section 3(c)(ii) or otherwise. In addition to the foregoing, if within third (3) Trading Days after the Company’s receipt
of a Conversion Notice (whether via facsimile or otherwise), the Company shall fail to issue and deliver a certificate to the Holder
and register such shares of Common Stock on the Company’s share register or credit the Holder’s or its designee’s
balance account with DTC for the number of shares of Common Stock to which the Holder is entitled upon the Holder’s conversion
hereunder (as the case may be), and if on or after such third (3rd) Trading Day the Holder purchases (in an open market
transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of shares of Common Stock issuable
upon such conversion that the Holder anticipated receiving from the Company, then, in addition to all other remedies available
to the Holder, the Company shall, within three (3) Business Days after the Holder’s request and in the Holder’s discretion,
either (i) pay cash to the Holder in an amount equal to the Holder’s total purchase price (including brokerage commissions
and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (the “Buy-In Price”),
at which point the Company’s obligation to deliver such certificate (and to issue such shares of Common Stock) shall terminate,
or (ii) promptly honor its obligation to deliver to the Holder a certificate or certificates representing such shares of Common
Stock or credit the Holder’s balance account with DTC for the number of shares of Common Stock to which the Holder is entitled
upon the Holder’s conversion hereunder (as the case may be) and pay cash to the Holder in an amount equal to the excess (if
any) of the Buy-In Price over the product of (A) such number of shares of Common Stock multiplied by (B) the Closing Bid Price
of the Common Stock on the Trading Day immediately preceding the Conversion Date.

 

    	3

    	 

    

 

(iii)        Registration;
Book-Entry. The Company shall maintain a register (the “Register”) for the recordation of the names and
addresses of the Holders of each Note and the principal amount of the Notes held by such Holders (the “Registered Notes”).
The entries in the Register shall be conclusive and binding for all purposes absent manifest error. The Company and the Holders
of the Notes shall treat each Person whose name is recorded in the Register as the owner of a Note for all purposes, including,
without limitation, the right to receive payments of Principal and Interest hereunder, notwithstanding notice to the contrary.
A Registered Note may be assigned or sold in whole or in part only by registration of such assignment or sale on the Register.
Upon its receipt of a request to assign or sell all or part of any Registered Note by a Holder, the Company shall record the information
contained therein in the Register and issue one or more new Registered Notes in the same aggregate principal amount as the principal
amount of the surrendered Registered Note to the designated assignee or transferee pursuant to Section 17. Notwithstanding anything
to the contrary set forth in this Section 3, upon conversion of any portion of this Note in accordance with the terms hereof, the
Holder shall not be required to physically surrender this Note to the Company unless (A) the full Conversion Amount represented
by this Note is being converted (in which event this Note shall be delivered to the Company as contemplated by Section 3(c)(i))
or (B) the Holder has provided the Company with prior written notice (which notice may be included in a Conversion Notice) requesting
reissuance of this Note upon physical surrender of this Note. The Company shall update the Register to reflect the Principal, Interest
and Late Charges converted and/or paid (as the case may be) and the dates of such conversions and/or payments (as the case may
be) or shall use such other method, reasonably satisfactory to the Holder and the Company, so as not to require physical surrender
of this Note upon conversion.

 

(iv)        Pro
Rata Conversion; Disputes. In the event that the Company receives a Conversion Notice from more than one holder of Notes for
the same Conversion Date and the Company can convert some, but not all, of such portions of the Notes submitted for conversion,
the Company, subject to Section 3(d), shall convert from each holder of Notes electing to have Notes converted on such date a pro
rata amount of such holder’s portion of its Notes submitted for conversion based on the principal amount of Notes submitted
for conversion on such date by such holder relative to the aggregate principal amount of all Notes submitted for conversion on
such date. In the event of a dispute as to the number of shares of Common Stock issuable to the Holder in connection with a conversion
of this Note, the Company shall issue to the Holder the number of shares of Common Stock not in dispute and resolve such dispute
in accordance with Section 22.

 

    	4

    	 

    

 

(v)         Mandatory
Conversion. If at any time after the one-year anniversary of the Issuance Date, (i) the VWAP of the Common Stock listed on
the Principal Market exceeds 200% of the Conversion Price for thirty (30) consecutive Trading Days (the “Mandatory Conversion
Measuring Period”), and (ii) no Equity Conditions Failure then exists, the Company shall have the right to require the
Holder to convert all or a portion of the Conversion Amount of this Note, as designated in the Mandatory Conversion Notice (as
defined below) into fully paid, validly issued and nonassessable shares of Common Stock subject to compliance with Section 3(d)
hereof at the Conversion Rate as of the Mandatory Conversion Date (as defined below) (a “Mandatory Conversion”).
The Company may exercise its right to require conversion under this Section 3(c)(v) by delivering within not more than twenty (20)
Trading Days following the end of such Mandatory Conversion Measuring Period a written notice thereof by facsimile and overnight
courier to all, but not less than all, of the holders of Notes and the Transfer Agent (the “Mandatory Conversion Notice”
and the date all of the holders received such notice by facsimile is referred to as the “Mandatory Conversion Notice Date”).
The Mandatory Conversion Notice shall be irrevocable. The Mandatory Conversion Notice shall state (i) the Trading Day selected
for the Mandatory Conversion in accordance with this Section 3(c)(v), which Trading Day shall be no less than thirty (30) calendar
days and no more than forty (40) calendar days following the Mandatory Conversion Notice Date (the “Mandatory Conversion
Date”), (ii) the aggregate Conversion Amount of the Notes subject to mandatory conversion from the Holder (the “Mandatory
Conversion Amount”) and all of the holders of the Notes pursuant to this Section 3(c)(v) (and analogous provisions under
the Other Notes), (iii) the number of shares of Common Stock to be issued to such Holder on the Mandatory Conversion Date and (iv)
that there has been no Equity Conditions Failure; provided, however, that to the extent that such Mandatory Conversion would result
in the Holder exceeding the Maximum Percentage (as defined below), then such Mandatory Conversion may be effected only to the extent
so that such Holder does not exceed the Maximum Percentage. Notwithstanding the foregoing, the Company may effect only one (1)
Mandatory Conversion during any twenty (20) consecutive Trading Days. Any shares of Common Stock delivered in connection with a
Mandatory Conversion hereunder shall be accompanied by a payment in cash (the “Mandatory Conversion Interest”)
equal to the amount of any accrued and unpaid Interest with respect to such Conversion Amount subject to such Mandatory Conversion
and accrued and unpaid Late Charges, if any, with respect to such Conversion Amount and Interest. Notwithstanding anything herein
to the contrary, (i) if the Closing Bid Price of the Common Stock listed on the Principal Market fails to exceed 200% of the Conversion
Price for each Trading Day commencing on the Mandatory Conversion Notice Date and ending and including the Trading Day immediately
prior to the applicable Mandatory Conversion Date (a “Mandatory Conversion Price Failure”) or an Equity Conditions
Failure occurs at any time prior to the Mandatory Conversion Date, (A) the Company shall provide the Holder a subsequent notice
to that effect and (B) unless the Holder waives the applicable Equity Conditions Failure and/or Mandatory Conversion Price Failure,
as applicable, the Mandatory Conversion shall be cancelled and the applicable Mandatory Conversion Notice shall be null and void
and (ii) at any time prior to the date the Mandatory Conversion Amount is paid, in full, the Mandatory Conversion Amount may be
converted, in whole or in part, by the Holders into shares of Common Stock pursuant to Section 3. All Conversion Amounts converted
by the Holder after the Mandatory Conversion Notice Date shall reduce the Mandatory Conversion Amount of this Note required to
be redeemed on the Mandatory Conversion Date. Redemptions made pursuant to this Section 3(c)(v) shall be made in accordance with
Section 11. Notwithstanding anything in this Section 3(c)(v) to the contrary, the Holder may, at its sole option, at any time on
prior to the third (3rd) Trading Day prior to the Mandatory Conversion Date, by written notice to the Company, elect
to receive the Mandatory Conversion Interest in the form of Interest Shares, which Interest Shares shall be delivered by the Company
to the Holder in the manner provided in Section 2 as if the Mandatory Conversion Date was an “Interest Date”
for all purposes hereunder; provided, that nothing in this Section 3(c)(v) shall be deemed to amend or waive the Company’s
obligation to pay Interest hereunder on each Interest Date pursuant to Section 2 and the Mandatory Conversion Amount and Mandatory
Conversion Interest, as applicable, shall be adjusted for any Interest paid to the Holder prior to the Mandatory Conversion Date
in accordance with Section 2.

 

(d)          Limitations
on Conversions.

 

(i)          Beneficial
Ownership. Notwithstanding anything to the contrary contained in this Note, this Note shall not be convertible by the Holder
hereof, and the Company shall not effect any conversion of this Note or otherwise issue any shares of Common Stock pursuant hereto,
to the extent (but only to the extent) that after giving effect to such conversion or other share issuance hereunder the Holder
(together with its affiliates) would beneficially own in excess of 9.99% (the “Maximum Percentage”) of the Common
Stock. To the extent the above limitation applies, the determination of whether this Note shall be convertible (vis-à-vis
other convertible, exercisable or exchangeable securities owned by the Holder or any of its affiliates) shall, subject to such
Maximum Percentage limitation, be determined on the basis of the first submission to the Company for conversion, exercise or exchange
(as the case may be). No prior inability to convert this Note, or to issue shares of Common Stock, pursuant to this paragraph shall
have any effect on the applicability of the provisions of this paragraph with respect to any subsequent determination of convertibility.
For purposes of this paragraph, beneficial ownership and all determinations and calculations (including, without limitation, with
respect to calculations of percentage ownership) shall be determined in accordance with Section 13(d) of the 1934 Act (as defined
in the Securities Purchase Agreement) and the rules and regulations promulgated thereunder. The provisions of this paragraph shall
be implemented in a manner otherwise than in strict conformity with the terms of this paragraph to correct this paragraph (or any
portion hereof) which may be defective or inconsistent with the intended Maximum Percentage beneficial ownership limitation herein
contained or to make changes or supplements necessary or desirable to properly give effect to such Maximum Percentage limitation.
The limitations contained in this paragraph shall apply to a successor Holder of this Note. The holders of Common Stock shall be
third party beneficiaries of this paragraph and the Company may not waive this paragraph without the consent of holders of a majority
of its Common Stock. For any reason at any time, upon the written or oral request of the Holder, the Company shall within one (1)
Business Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding, including by virtue
of any prior conversion or exercise of convertible or exercisable securities into Common Stock, including, without limitation,
pursuant to this Note or securities issued pursuant to the Securities Purchase Agreement

 

    	5

    	 

    

  

(ii)         Principal
Market Regulation. The Company shall not be obligated to issue any shares of Common Stock upon conversion of this Note, and
the Holder of this Note shall not have the right to receive upon conversion of this Note any shares of Common Stock, if the issuance
of such shares of Common Stock would exceed the aggregate number of shares of Common Stock which the Company may issue upon conversion
of the Notes or as Interest Shares without breaching the Company's obligations under the rules or regulations of the Principal
Market (the “Exchange Cap”), except that such limitation shall not apply in the event that the Company (A) obtains
the approval of its stockholders as required by the applicable rules of the Principal Market for issuances of Common Stock in excess
of such amount or (B) obtains a written opinion from outside counsel to the Company that such approval is not required, which opinion
shall be reasonably satisfactory to the Holders of a majority in aggregate principal amount of the Notes then outstanding (“Majority
of Holders”). Until such approval or written opinion is obtained, no Holder shall be issued in the aggregate, upon conversion
of Notes, or as Interest Shares, shares of Common Stock in an amount greater than the product of the Exchange Cap multiplied by
a fraction, the numerator of which is the Principal amount of Notes issued to such Holder pursuant to the Securities Purchase Agreement
on the Closing Date and the denominator of which is the aggregate principal amount of all Notes issued to the Holders pursuant
to the Securities Purchase Agreement on the Closing Date (with respect to each Holder, the “Exchange Cap Allocation”).
In the event that any Holder shall sell or otherwise transfer any of such Holder's Notes, the transferee shall be allocated a pro
rata portion of such Holder's Exchange Cap Allocation, and the restrictions of the prior sentence shall apply to such transferee
with respect to the portion of the Exchange Cap Allocation allocated to such transferee. In the event that any holder of Notes
shall convert all of such holder's Notes into a number of shares of Common Stock which, in the aggregate, is less than such holder's
Exchange Cap Allocation, then the difference between such holder's Exchange Cap Allocation and the number of shares of Common Stock
actually issued to such holder shall be allocated to the respective Exchange Cap Allocations of the remaining holders of Notes
on a pro rata basis in proportion to the aggregate principal amount of the Notes then held by each such holder. Additionally, pursuant
to the Principal Market rules, the Buyers acknowledge that the Interest Shares and/or the Conversion Shares acquired prior to Stockholder
Approval may not be voted for the Resolutions at the Stockholder Meeting (each as defined in the Securities Purchase Agreement).

 

4.      
    RIGHTS UPON EVENT OF DEFAULT.

 

(a)          Event
of Default. Each of the following events shall constitute an “Event of Default”:

 

(i)          the
suspension from trading or the failure of the Common Stock to be trading or listed (as applicable) on an Eligible Market for a
period of five (5) consecutive days or for more than an aggregate of ten (10) days in any 365-day period;

 

(ii)         the
Company’s (A) failure to cure a Conversion Failure by delivery of the required number of shares of Common Stock within ten
(10) Trading Days after the applicable Conversion Date or (B) notice, written or oral, to any holder of the Notes, including, without
limitation, by way of public announcement or through any of its agents, at any time, of its intention not to comply, as required,
with a request for conversion of any Notes into shares of Common Stock that is requested in accordance with the provisions of the
Notes, other than pursuant to Section 3(d);

 

(iii)        at
any time following the tenth (10th) consecutive day that the Holder’s Authorized Share Allocation (as defined
herein) is less than the number of shares of Common Stock that the Holder would be entitled to receive upon a conversion of the
full Conversion Amount of this Note (without regard to any limitations on conversion set forth in Section 3(d) or otherwise);

 

(iv)        the
Company’s failure to pay to the Holder any amount of Principal, Interest, Late Charges or other amounts when and as due under
this Note (including, without limitation, the Company’s failure to pay any redemption payments or amounts hereunder) or any
other Transaction Document (as defined in the Securities Purchase Agreement) or any other agreement, document, certificate or other
instrument delivered in connection with the transactions contemplated hereby and thereby, except, in the case of a failure to pay
Interest and Late Charges when and as due, in which case only if such failure remains uncured for a period of at least five (5)
days;

 

    	6

    	 

    

 

(v)         the
Company fails to remove any restrictive legend on any certificate or any shares of Common Stock issued to the Holder upon conversion
or exercise (as the case may be) of any Securities acquired by the Holder under the Securities Purchase Agreement (including this
Note) as and when required by such Securities or the Securities Purchase Agreement, unless otherwise then prohibited by applicable
state or federal securities laws, and any such failure remains uncured for at least five (5) days;

 

(vi)        the
occurrence of any default under, redemption of or acceleration prior to maturity of any Indebtedness of the Company, other than
with respect to (A) any Other Notes, (B) with respect to unsecured Indebtedness only, payments contested by the Company in good
faith by proper proceedings and with respect to which adequate reserves have been set aside for the payment thereof in accordance
with GAAP, and/or (C) any amounts not in excess of an aggregate of $200,000;

 

(vii)       bankruptcy,
insolvency, reorganization or liquidation proceedings or other proceedings for the relief of debtors shall be instituted by or
against the Company or any Subsidiary (each, a “Bankruptcy Proceeding”) and, if instituted against the Company
or a Subsidiary by a third party, shall not be dismissed within thirty (30) days of their institution; provided, however, that
the institution of a Bankruptcy Proceeding by or against a Subsidiary other than Crumbs Holdings LLC (“Holdings”)
shall not constitute an Event of Default so long as Bankrtupcy Proceedings have not theretofore been instituted by or against five
(5) or more other Subsidiaries other than Holdings (or such greater number of Subsidiaries as the Majority of Holders may approve
in writing after consultation with the Company with respect thereto); provided further that, for purposes of determining whether
Bankruptcy Proceedings have been instituted by or against five (5) or more Subsidiaries, any Subsidiary other than Holdings that
is the subject of an Insolvency Proceeding (as defined below) or an Insolvency Order (as defined below) shall be included in that
determination;

 

(viii)      the
commencement by the Company or any Subsidiary of a voluntary case or proceeding under any applicable federal, state or foreign
bankruptcy, insolvency, reorganization or other similar law or of any other case or proceeding to be adjudicated a bankrupt or
insolvent, or the consent by it to the entry of a decree, order, judgment or other similar document in respect of the Company or
any Subsidiary in an involuntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization
or other similar law or to the commencement of any bankruptcy or insolvency case or proceeding against it, or the filing by it
of a petition or answer or consent seeking reorganization or relief under any applicable federal, state or foreign law, or the
consent by it to the filing of such petition or to the appointment of or taking possession by a custodian, receiver, liquidator,
assignee, trustee, sequestrator or other similar official of the Company or any Subsidiary or of any substantial part of its property,
or the making by it of an assignment for the benefit of creditors, or the execution of a composition of debts, or the occurrence
of any other similar federal, state or foreign proceeding, or the admission by it in writing of its inability to pay its debts
generally as they become due, the taking of corporate action by the Company or any Subsidiary in furtherance of any such action
or the taking of any action by any Person to commence a UCC foreclosure sale or any other similar action under federal, state or
foreign law (each, an “Insolvency Proceeding”); provided, however, that an Insolvency Proceeding with respect
to a Subsidiary other than Holdings shall not constitute an Event of Default so long as Insolvency Proceedings have not theretofore
been instituted by or against five (5) or more other Subsidiaries other than Holdings (or such greater number of Subsidiaries as
the Majority of Holders may approve in writing after consultation with the Company with respect thereto); provided further that,
for purposes of determining whether Insolvency Proceedings have been instituted with respect to five (5) or more Subsidiaries,
any Subsidiary other than Holdings that is the subject of a Bankruptcy Proceeding or with respect to which an Insolvency Order
has been entered shall be included in that determination;

 

    	7

    	 

    

  

(ix)         the
entry by a court of (i) a decree, order, judgment or other similar document in respect of the Company or any Subsidiary of a voluntary
or involuntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other
similar law or (ii) a decree, order, judgment or other similar document adjudging the Company or any Subsidiary as bankrupt or
insolvent, or approving as properly filed a petition seeking liquidation, reorganization, arrangement, adjustment or composition
of or in respect of the Company or any Subsidiary under any applicable federal, state or foreign law or (iii) a decree, order,
judgment or other similar document appointing a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar
official of the Company or any Subsidiary or of any substantial part of its property, or ordering the winding up or liquidation
of its affairs, and the continuance of any such decree, order, judgment or other similar document or any such other decree, order,
judgment or other similar document (each, an “Insolvency Order”) unstayed and in effect for a period of sixty
(60) consecutive days; provided, however, that the entry of an Insolvency Order with respect to a Subsidiary other than Holdings
shall not constitute an Event of Default so long as Insolvency Orders have not theretofore been entered with respect to five (5)
or more other Subsidiaries other than Holdings (or such greater number of Subsidiaries as the Majority of Holders may approve in
writing after consultation with the Company with respect thereto); provided further that, for purposes of determining whether an
Insolvency Order has been entered against five (5) or more Subsidiaries, any Subsidiary other than Holdings that is the subject
of a Bankruptcy Proceeding or an Insolvency Proceeding shall be included in that determination;

 

(x)          a
final judgment or judgments for the payment of money aggregating in excess of $200,000 are rendered against the Company and/or
any of its Subsidiaries and which judgments are not, within forty-five (45) days after the entry thereof, bonded, discharged or
stayed pending appeal, or are not discharged within thirty (30) days after the expiration of such stay; provided, however, that
any judgment which is covered by insurance or an indemnity from a credit worthy party shall not be included in calculating the
$200,000 amount set forth above so long as the Company provides the Holder with a written statement from such insurer or indemnity
provider (which written statement shall be reasonably satisfactory to the Holder) to the effect that such judgment is covered by
insurance or an indemnity and the Company and/or such Subsidiary (as the case may be) will receive the proceeds of such insurance
or indemnity within forty-five (45) days of the issuance of such judgment;

 

(xi)         the
Company or Holdings, individually or in the aggregate, either (i) fails to pay, when due, or within any applicable grace period,
any payment with respect to any of its Indebtedness in excess of $200,000 due to any third party (other than, with respect to unsecured
Indebtedness only, payments contested by the Company or Holdings in good faith by proper proceedings and with respect to which
adequate reserves have been set aside for the payment thereof in accordance with GAAP), or is otherwise in breach or violation
of any agreement for monies owed or owing in an amount in excess of $200,000, which breach or violation permits the other party
thereto to declare a default or otherwise accelerate amounts due thereunder, or (ii) suffers to exist any other circumstance or
event that would, with or without the passage of time or the giving of notice, result in a default or event of default under any
agreement binding on the Company or Holdings, which default or event of default would, or is likely to, have a Material Adverse
Effect on the Company or Holdings;

 

(xii)        any
Subsidiary other than Holdings, individually or in the aggregate with any other Subsidiaries other than Holdings, either (i) fails
to pay, when due, or within any applicable grace period, any payment with respect to any Indebtedness in excess of $200,000 due
to any third party (other than, with respect to unsecured Indebtedness only, payments contested by the Subsidiary in good faith
by proper proceedings and with respect to which adequate reserves have been set aside for the payment thereof in accordance with
GAAP) or is otherwise in breach or violation of any agreement for monies owed or owing in an amount in excess of $200,000, which
breach or violation permits the other party thereto to declare a default or otherwise accelerate amounts due thereunder, or (ii)
suffers to exist any other circumstance or event that would, with or without the passage of time or the giving of notice, result
in a default or event of default under any agreement binding on such Subsidiary that, individually or in the aggregate, would,
or is likely to, have a Material Adverse Effect on the Company or Holdings;

 

(xiii)       other
than as specifically set forth in another clause of this Section 4(a), (i) the Company or any Subsidiary breaches any covenant
or other term or condition of any Transaction Document, except, in the case of a breach of a covenant or other term or condition
that is curable, only if such breach remains uncured for a period of five (5) consecutive Business Days, or (ii) any representation
or warranty made by the Company in any Transaction Document, when made, contained any untrue statement of a material fact or omitted
to state a material fact necessary to make the statements contained in such representation or warranty, in light of the circumstances
under which it was made, not misleading;

 

(xiv)      a
false or inaccurate certification (including a false or inaccurate deemed certification) by the Company that the Equity Conditions
are satisfied, that there has been no Equity Conditions Failure or as to whether any Event of Default has occurred;

 

    	8

    	 

    

  

(xv)       any
breach or failure in any respect by the Company or any Subsidiary to comply with any provision of Section 13 of this Note, except,
in the case of a breach of Section 13 that is curable, only if such breach remains uncured for a period of five (5) consecutive
Business Days;

 

(xvi)      any
Material Adverse Effect occurs;

 

(xvii)     any
provision of any Transaction Document (including, without limitation, the Guaranties) shall at any time for any reason (other than
pursuant to the express terms thereof) cease to be valid and binding on or enforceable against the parties thereto, or the validity
or enforceability thereof shall be contested by any party thereto, or a proceeding shall be commenced by the Company or any Subsidiary
or any governmental authority having jurisdiction over any of them, seeking to establish the invalidity or unenforceability thereof,
or the Company or any Subsidiary shall deny in writing that it has any liability or obligation purported to be created under any
Transaction Document (including, without limitation, the Guaranties), if, in either case, the invalidity or unenforceability of
such provision materially impairs, or will materially impair, the rights of any Holder under any of the Transaction Documents;

 

(xviii)    any
Event of Default (as defined in the Other Notes) occurs with respect to any Other Notes; and

 

(xix)       A
failure by the Nominating Committee (as defined in the Securities Purchase Agreement) or the Company’s Board to satisfy their
respective Nomination Obligations (as defined in the Securities Purchase Agreement), unless such failure results from (i) the Designated
Nominee’s inability to satisfy all legal and governance requirements regarding service as a director of the Company or (ii)
a good faith determination by the Nominating Committee or the Board, respectively, after receipt of written advice of counsel,
that compliance with the Nomination Obligations would constitute a breach of fiduciary duty of the Nominating Committee or the
Board, respectively, under the laws of the State of Delaware.

 

(b)          Notice
of an Event of Default; Redemption Right. Upon the occurrence of an Event of Default with respect to this Note or any Other
Note, the Company shall within one (1) Business Day deliver written notice thereof via facsimile and overnight courier (with next
day delivery specified) (an “Event of Default Notice”) to the Holder. At any time after the earlier of the Holder’s
receipt of an Event of Default Notice and the Holder becoming aware of an Event of Default, the Holder may require the Company
to redeem (regardless of whether such Event of Default has been cured) all or any portion of this Note by delivering written notice
thereof (the “Event of Default Redemption Notice”) to the Company, which Event of Default Redemption Notice
shall indicate the portion of this Note the Holder is electing to require the Company to redeem. Each portion of this Note subject
to redemption by the Company pursuant to this Section 4(b) shall be redeemed by the Company in cash at a price equal to the Conversion
Amount of the Notes to be redeemed (including any Default Interest) (the “Event of Default Redemption Price”).
Redemptions required by this Section 4(b) shall be made in accordance with the provisions of Section 11. To the extent redemptions
required by this Section 4(b) are deemed or determined by a court of competent jurisdiction to be prepayments of the Note by the
Company, such redemptions shall be deemed to be voluntary prepayments.

 

5.       
   RIGHTS UPON FUNDAMENTAL TRANSACTION AND CHANGE OF CONTROL.

 

(a)          Assumption.
The Company shall not enter into or be party to a Fundamental Transaction unless (i) the Successor Entity assumes in writing all
of the obligations of the Company under this Note and the other Transaction Documents in accordance with the provisions of this
Section 5(a) pursuant to written agreements in form and substance satisfactory to the Holder and approved by the Holder prior to
such Fundamental Transaction, including agreements to deliver to each holder of Notes in exchange for such Notes a security of
the Successor Entity evidenced by a written instrument substantially similar in form and substance to the Notes, including, without
limitation, having a principal amount and interest rate equal to the principal amounts then outstanding and the interest rates
of the Notes held by such holder, having similar conversion rights as the Notes and having similar ranking to the Notes, and satisfactory
to the Holder and (ii) the Successor Entity (including its Parent Entity) is a publicly traded corporation whose common stock is
quoted on or listed for trading on an Eligible Market. Upon the occurrence of any Fundamental Transaction, the Successor Entity
shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this
Note and the other Transaction Documents referring to the “Company” shall refer instead to the Successor Entity), and
may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Note and the
other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein. Upon consummation
of a Fundamental Transaction, the Successor Entity shall deliver to the Holder confirmation that there shall be issued upon conversion
or redemption of this Note at any time after the consummation of such Fundamental Transaction, in lieu of the shares of the Company’s
Common Stock (or other securities, cash, assets or other property (except such items still issuable under Sections 6 and 15, which
shall continue to be receivable thereafter) issuable upon the conversion or redemption of the Notes prior to such Fundamental Transaction,
such shares of the publicly traded common stock (or their equivalent) of the Successor Entity (including its Parent Entity) which
the Holder would have been entitled to receive upon the happening of such Fundamental Transaction had this Note been converted
immediately prior to such Fundamental Transaction (without regard to any limitations on the conversion of this Note), as adjusted
in accordance with the provisions of this Note. Notwithstanding the foregoing, the Holder may elect, at its sole option, by delivery
of written notice to the Company to waive this Section 5(a) to permit the Fundamental Transaction without the assumption of this
Note. The provisions of this Section 5 shall apply similarly and equally to successive Fundamental Transactions and shall be applied
without regard to any limitations on the conversion or redemption of this Note.

 

    	9

    	 

    

 

(b)          Notice
of a Change of Control; Redemption Right. No sooner than fifteen (15) days nor later than ten (10) days prior to the consummation
of a Change of Control, but not prior to the public announcement of such Change of Control, the Company shall deliver written notice
thereof via facsimile and overnight courier to the Holder (a “Change of Control Notice”). At any time during
the period beginning on the earlier to occur of (x) any oral or written agreement by the Company or any of its Subsidiaries, which
upon consummation of the transaction contemplated thereby would reasonably be expected to result in a Change of Control and (y)
the Holder’s receipt of a Change of Control Notice and ending twenty (20) Trading Days after the date of the consummation
of such Change of Control, the Holder may require the Company to redeem all or any portion of this Note by delivering written notice
thereof (“Change of Control Redemption Notice”) to the Company, which Change of Control Redemption Notice shall
indicate the Conversion Amount the Holder is electing to require the Company to redeem. The portion of this Note subject to redemption
pursuant to this Section 5(b) shall be redeemed by the Company in cash at a price equal to (A) the product of (x) the Change of
Control Redemption Premium multiplied by (y) the aggregate Principal amount then outstanding that is being redeemed, plus
(B) all accrued and unpaid Interest with respect to such portion of the Principal amount and all accrued and unpaid Late Charges
with respect to such portion of the Principal amount (the “Change of Control Redemption Price”). Redemptions
required by this Section 5 shall be made in accordance with the provisions of Section 11 and shall have priority to payments to
stockholders in connection with a Change of Control. To the extent redemptions required by this Section 5(b) are deemed or determined
by a court of competent jurisdiction to be prepayments of the Note by the Company, such redemptions shall be deemed to be voluntary
prepayments. Notwithstanding anything to the contrary in this Section 5, but subject to Section 3(d), until the Change of Control
Redemption Price (together with any Late Charges thereon) is paid in full, the Conversion Amount submitted for redemption under
this Section 5(b) (together with any Late Charges thereon) may be converted, in whole or in part, by the Holder into Common Stock
pursuant to Section 3. The parties hereto agree that in the event of the Company’s redemption of any portion of the Note
under this Section 5(b), the Holder’s damages would be uncertain and difficult to estimate because of the parties’
inability to predict future interest rates and the uncertainty of the availability of a suitable substitute investment opportunity
for the Holder. Accordingly, any Change of Control Redemption Premium due under this Section 5(b) is intended by the parties to
be, and shall be deemed, a reasonable estimate of the Holder’s actual loss of its investment opportunity and not as a penalty.

 

6.   
       RIGHTS UPON ISSUANCE OF PURCHASE RIGHTS AND OTHER
CORPORATE EVENTS MANDATORY CONVERSION.

 

(a)          Distribution
of Assets. If the Company shall declare or make any dividend or other distributions of its assets (or rights to acquire its
assets) on the outstanding shares of Common Stock to the holders thereof, by way of return of capital or otherwise (including without
limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (the “Distributions”), then the
Holder will be entitled, concurrently with the Distribution to the holders of Common Stock, to such Distributions as if the Holder
had held the number of shares of Common Stock acquirable upon complete conversion of this Note (without taking into account any
limitations or restrictions on the convertibility of this Note) immediately prior to the date on which a record is taken for such
Distribution or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined for such
Distributions; provided, however, that to the extent that the Holder’s right to participate in any such Distribution would
result in the Holder exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Distribution
to such extent (or beneficial ownership of such shares of Common Stock as a result of such Distribution to such extent) and the
portion of such Distribution shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not
result in the Holder exceeding the Maximum Percentage.

 

    	10

    	 

    

  

(b)          Purchase
Rights. If at any time the Company grants, issues or sells any Options, Convertible Securities or rights to purchase stock,
warrants, securities or other property pro rata to the record holders of any class of Common Stock (the “Purchase Rights”),
then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which
the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete conversion
of this Note (without taking into account any limitations or restrictions on the convertibility of this Note) immediately prior
to the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken,
the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase
Rights (provided, however, that to the extent that the Holder’s right to participate in any such Purchase Right would result
in the Holder exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Purchase Right to
such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such
Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not
result in the Holder exceeding the Maximum Percentage, at which time the Holder shall be granted such right to the same extent
as if there had been no such limitation).

 

(c)          Other
Corporate Events. In addition to and not in substitution for any other rights hereunder, prior to the consummation of any Fundamental
Transaction pursuant to which holders of shares of Common Stock are entitled to receive securities or other assets with respect
to or in exchange for shares of Common Stock (a “Corporate Event”), the Company shall make appropriate provision
to insure that the Holder will thereafter have the right to receive upon a conversion of this Note, at the Holder’s option,
(i) in addition to the shares of Common Stock receivable upon such conversion, such securities or other assets to which the Holder
would have been entitled with respect to such shares of Common Stock had such shares of Common Stock been held by the Holder upon
the consummation of such Corporate Event (without taking into account any limitations or restrictions on the convertibility of
this Note) or (ii) in lieu of the shares of Common Stock otherwise receivable upon such conversion, such securities or other assets
received by the holders of shares of Common Stock in connection with the consummation of such Corporate Event in such amounts as
the Holder would have been entitled to receive had this Note initially been issued with conversion rights for the form of such
consideration (as opposed to shares of Common Stock) at a conversion rate for such consideration commensurate with the Conversion
Rate. Provision made pursuant to the preceding sentence shall be in a form and substance satisfactory to the Majority of Holders.
The provisions of this Section shall apply similarly and equally to successive Corporate Events and shall be applied without regard
to any limitations on the conversion or redemption of this Note.

 

7.  
        RIGHTS UPON ISSUANCE OF OTHER SECURITIES 

 

(a)          Adjustment
of Conversion Price upon Subdivision or Combination of Common Stock. If the Company at any time on or after the Subscription
Date subdivides (by any stock split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares
of Common Stock into a greater number of shares, the Conversion Price in effect immediately prior to such subdivision will be proportionately
reduced. If the Company at any time on or after the Subscription Date combines (by combination, reverse stock split or otherwise)
one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Conversion Price in effect immediately
prior to such combination will be proportionately increased.

 

(b)          Other
Events. If any event occurs of the type contemplated by the provisions of this Section 7 but not expressly provided for by
such provisions (including, without limitation, the granting of stock appreciation rights, phantom stock rights or other rights
with equity features), then the Company’s Board of Directors will make an appropriate adjustment in the Conversion Price
so as to protect the rights of the Holder under this Note; provided that no such adjustment will increase the Conversion Price
as otherwise determined pursuant to this Section 7.

 

    	11

    	 

    

  

(c)          Voluntary
Adjustment By Company. Subject to any approval requirements of the Principal Market, the Company may at any time during the
term of this Note reduce the then current Conversion Price to any amount and for any period of time deemed appropriate by the Board
of Directors of the Company.

 

8.      
    NONCIRCUMVENTION. The Company hereby covenants and agrees that the Company will not, by
amendment of its Charter (as defined in the Securities Purchase Agreement), Bylaws (as defined in the Securities Purchase
Agreement) or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution,
issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of
the terms of this Note, and will at all times in good faith carry out all of the provisions of this Note and take all action
as may be required to protect the rights of the Holder of this Note. Without limiting the generality of the foregoing, the
Company (i) shall not increase the par value of any shares of Common Stock receivable upon conversion of this Note above the
Conversion Price then in effect, (ii) shall take all such actions as may be necessary or appropriate in order that the
Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the conversion of this Note,
and (iii) shall, so long as any of the Notes are outstanding, take all action necessary to reserve and keep available out of
its authorized and unissued shares of Common Stock, solely for the purpose of effecting the conversion of the Notes, the
maximum number of shares of Common Stock as shall from time to time be necessary to effect the conversion of the Notes then
outstanding (without regard to any limitations on conversion).

 

9.      
    RESERVATION OF AUTHORIZED SHARES.

 

(a)          Reservation.
The Company shall initially reserve out of its authorized and unissued Common Stock a number of shares of Common Stock for each
of the Notes equal to 125% of the entire Conversion Rate with respect to the entire Conversion Amount of each such Note as of the
Issuance Date. So long as any of the Notes are outstanding, the Company shall take all action reasonably necessary to reserve
and keep available out of its authorized and unissued Common Stock, solely for the purpose of effecting the conversion of the Notes,
of the number of shares of Common Stock as shall from time to time be necessary to effect the conversion of all of the Notes then
outstanding, provided that at no time shall the number of shares of Common Stock so reserved be less than the number of shares
required to be reserved by the previous sentence (without regard to any limitations on conversions) (the “Required Reserve
Amount”). The initial number of shares of Common Stock reserved for conversions of the Notes and each increase in the
number of shares so reserved shall be allocated pro rata among the holders of the Notes based on the original principal amount
of the Notes held by each holder on the Closing Date or increase in the number of reserved shares (as the case may be) (the “Authorized
Share Allocation”). In the event that a holder shall sell or otherwise transfer any of such holder’s Notes, each
transferee shall be allocated a pro rata portion of such holder’s Authorized Share Allocation. Any shares of Common Stock
reserved and allocated to any Person which ceases to hold any Notes shall be allocated to the remaining holders of Notes, pro rata
based on the principal amount of the Notes then held by such holders.

 

(b)          Insufficient
Authorized Shares. If, notwithstanding Section 9(a), and not in limitation thereof, at any time while any of the Notes remain
outstanding the Company does not have a sufficient number of authorized and unreserved shares of Common Stock to satisfy its obligation
to reserve for issuance upon conversion of the Notes at least a number of shares of Common Stock equal to the Required Reserve
Amount (an “Authorized Share Failure”), then the Company shall immediately take all action necessary to increase
the Company’s authorized shares of Common Stock to an amount sufficient to allow the Company to reserve the Required Reserve
Amount for the Notes then outstanding. Without limiting the generality of the foregoing sentence, as soon as practicable after
the date of the occurrence of an Authorized Share Failure, but in no event later than sixty (60) days after the occurrence of such
Authorized Share Failure, the Company shall hold a meeting of its stockholders for the approval of an increase in the number of
authorized shares of Common Stock. In connection with such meeting, the Company shall provide each stockholder with a proxy statement
and shall use its reasonable best efforts to solicit its stockholders’ approval of such increase in authorized shares of
Common Stock and to cause its board of directors to recommend to the stockholders that they approve such proposal. In the event
that the Company is prohibited from issuing shares of Common Stock upon any conversion due to the failure by the Company to have
sufficient shares of Common Stock available out of the authorized but unissued shares of Common Stock (such unavailable number
of shares of Common Stock, the “Authorization Failure Shares”), in lieu of delivering such Authorization Failure
Shares to the Holder, the Company shall pay cash in exchange for the redemption of such portion of the Conversion Amount convertible
into such Authorized Failure Shares at a price equal to the sum of (i) the product of (x) such number of Authorization Failure
Shares and (y) the Closing Sale Price on the Trading Day immediately preceding the date the Holder delivers the applicable Conversion
Notice with respect to such Authorization Failure Shares to the Company and (ii) to the extent the Holder purchases (in an open
market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of Authorization Failure
Shares, any brokerage commissions and other out-of-pocket expenses, if any, of the Holder incurred in connection therewith.

 

    	12

    	 

    

 

10.         COMPANY
OPTIONAL REDEMPTION. If at any time after the first anniversary of the Issuance Date (the “Company Redemption Eligibility
Date”), no Equity Conditions Failure exists, the Company shall have the right to redeem all (except in accordance with
a Company Optional Redemption Blocker Notice (as defined below)) or a portion, of the Conversion Amount then remaining under this
Note (the “Company Optional Redemption Amount”) on the Company Optional Redemption Date (each as defined below)
(a “Company Optional Redemption”); provided that, notwithstanding the foregoing, if the Company Optional Redemption
Amount for such Company Optional Redemption exceeds such portion of the Conversion Amount remaining under this Note that the Holder
would be permitted to convert into Common Stock pursuant to Section 3 on the Company Optional Redemption Notice Date (as defined
below) without violating Section 3(d) (the “Permitted Company Optional Redemption Amount”), the Holder, at its
sole option, may deliver a written notice to the Company (a “Company Optional Redemption Blocker Notice”) stating
that such Company Optional Redemption Amount set forth in the applicable Company Optional Redemption Notice (as defined below)
exceeds the Permitted Company Optional Redemption Amount and, thereafter, the applicable Company Optional Redemption Amount shall
be automatically reduced to the Permitted Company Optional Redemption Amount set forth in the applicable Company Optional Redemption
Blocker Notice. The portion of this Note subject to redemption pursuant to this Section 10 shall be redeemed by the Company in
cash at a price (the “Company Optional Redemption Price”) equal to (i) 100% of the Principal amount being redeemed,
plus (ii) a premium equal to 25% of the Principal amount being redeemed, plus (iii) all accrued and unpaid Interest
with respect to such portion of the Principal amount and accrued and unpaid Late Charges with respect to such portion of such Principal
and such Interest. The Company may exercise its right to require redemption under this Section 10 by delivering an irrevocable
written notice thereof by facsimile and overnight courier to all, but not less than all, of the holders of Notes (the “Company
Optional Redemption Notice” and the date all of the holders of Notes received such notice is referred to as the “Company
Optional Redemption Notice Date”). The Company may deliver only one Company Optional Redemption Notice during any thirty
day period hereunder. The Company Optional Redemption Notice shall (x) state the date on which the Company Optional Redemption
shall occur (the “Company Optional Redemption Date”) which date shall not be less than twenty (20) days nor
more than thirty (30) days following the Company Optional Redemption Notice Date, (y) certify that no Equity Conditions Failure
exists as of the date of the Company Optional Redemption Notice, and (z) state the aggregate Conversion Amount of the Notes which
is being redeemed in such Company Optional Redemption from the Holder and all of the other holders of the Notes pursuant to this
Section 10 (and analogous provisions under the Other Notes) on the Company Optional Redemption Date. Notwithstanding anything herein
to the contrary, (i) if an Equity Conditions Failure occurs at any time prior to the Company Optional Redemption Date, (A) the
Company shall provide the Holder a subsequent notice to that effect and (B) unless the Holder waives the applicable Equity Conditions
Failure occurrence, as applicable, the Company Optional Redemption shall be cancelled and the applicable Company Optional Redemption
Notice shall be null and void and (ii) at any time prior to the date the Company Optional Redemption Price is paid, in full, the
Company Optional Redemption Amount may be converted, in whole or in part, by the Holders into Common Shares pursuant to Section
3. All Conversion Amounts converted by the Holder after the Company Optional Redemption Notice Date shall reduce the Company Optional
Redemption Amount of this Note required to be redeemed on the Company Optional Redemption Date. Redemptions made pursuant to this
Section 10 shall be made in accordance with Section 11.

 

11.         REDEMPTIONS.

 

(a)          Mechanics.
The Company shall deliver the applicable Event of Default Redemption Price to the Holder in cash within five (5) Business Days
after the Company’s receipt of the Holder’s Event of Default Redemption Notice. If the Holder has submitted a Change
of Control Redemption Notice in accordance with Section 5(b), the Company shall deliver the applicable Change of Control Redemption
Price to the Holder in cash concurrently with the consummation of such Change of Control if such notice is received prior to the
consummation of such Change of Control and within five (5) Business Days after the Company’s receipt of such notice otherwise.
The Company shall deliver the applicable Company Optional Redemption Price to the Holder in cash on the applicable Company Optional
Redemption Date. In the event of a redemption of less than all of the Conversion Amount of this Note, the Company shall promptly
cause to be issued and delivered to the Holder a new Note (in accordance with Section 17(d)) representing the outstanding Principal
which has not been redeemed. In the event that the Company does not pay the applicable Redemption Price to the Holder within the
time period required, at any time thereafter and until the Company pays such unpaid Redemption Price in full, the Holder shall
have the option, in lieu of redemption, to require the Company to promptly return to the Holder all or any portion of this Note
representing the Conversion Amount that was submitted for redemption and for which the applicable Redemption Price (together with
any Late Charges thereon) has not been paid. Upon the Company’s receipt of such notice, (x) the applicable Redemption Notice
shall be null and void with respect to such Conversion Amount, (y) the Company shall immediately return this Note, or issue a new
Note (in accordance with Section 17(d)), to the Holder, and in each case the principal amount of this Note or such new Note (as
the case may be) shall be increased by an amount equal to the difference between (1) the applicable Event of Default Redemption
Price or Change of Control Redemption Price (as the case may be) minus (2) the Principal portion of the Conversion Amount submitted
for redemption and (z) the Conversion Price of this Note or such new Notes (as the case may be) shall be automatically adjusted
with respect to each conversion effected thereafter by the Holder to the the Conversion Price as in effect on the date on which
the applicable Redemption Notice is voided. The Holder’s delivery of a notice voiding a Redemption Notice and exercise of
its rights following such notice shall not affect the Company’s obligations to make any payments of Late Charges which have
accrued prior to the date of such notice with respect to the Conversion Amount subject to such notice.

 

    	13

    	 

    

 

(b)          Redemption
by Other Holders. Upon the Company’s receipt of notice from any of the holders of the Other Notes for redemption or repayment
as a result of an event or occurrence substantially similar to the events or occurrences described in Section 4(b), Section 5(b)
or Section 10 (each, an “Other Redemption Notice”), the Company shall immediately, but no later than one (1)
Business Day of its receipt thereof, forward to the Holder by facsimile a copy of such notice. If the Company receives a Redemption
Notice and one or more Other Redemption Notices, during the seven (7) Business Day period beginning on and including the date which
is three (3) Business Days prior to the Company’s receipt of the Holder’s applicable Redemption Notice and ending on
and including the date which is three (3) Business Days after the Company’s receipt of the Holder’s applicable Redemption
Notice and the Company is unable to redeem all principal, interest and other amounts designated in such Redemption Notice and such
Other Redemption Notices received during such seven (7) Business Day period, then the Company shall redeem a pro rata amount from
each holder of the Notes (including the Holder) based on the principal amount of the Notes submitted for redemption pursuant to
such Redemption Notice and such Other Redemption Notices received by the Company during such seven (7) Business Day period.

 

12.         VOTING
RIGHTS. The Holder shall have no voting rights as the holder of this Note, except as required by law (including, without limitation,
the Delaware General Corporation Law) and as expressly provided in this Note.

 

13.         COVENANTS.
Until all of the Notes have been converted, redeemed or otherwise satisfied in accordance with their terms:

 

(a)          Rank.
All payments due under this Note (i) shall rank pari passu with all Other Notes and (ii) shall be senior to all other Indebtedness
of the Company and its Subsidiaries except for Indebtedness described in Section 28(bb)(iv) of this Note.

 

(b)          Incurrence
of Indebtedness. The Company shall not, and the Company shall cause each of its Subsidiaries to not, directly or indirectly,
incur or guarantee, assume or suffer to exist any Indebtedness other than (i) the Indebtedness evidenced by this Note and the Other
Notes and (ii) other Permitted Indebtedness.

 

(c)          Existence
of Liens. The Company shall not, and the Company shall cause each of its Subsidiaries to not, directly or indirectly, allow
or suffer to exist any mortgage, lien, pledge, charge, security interest or other encumbrance upon or in any property or assets
(including accounts and contract rights) owned by the Company or any of its Subsidiaries (collectively, “Liens”)
other than Permitted Liens.

 

(d)          Restricted
Payments. The Company shall not, and the Company shall cause each of its Subsidiaries to not, directly or indirectly, redeem,
defease, repurchase, repay or make any payments in respect of, by the payment of cash or cash equivalents (in whole or in part,
whether by way of open market purchases, tender offers, private transactions or otherwise), all or any portion of any Indebtedness
(other than the Notes), whether by way of payment in respect of principal of (or premium, if any) or interest on, such Indebtedness
if at the time such payment is due or is otherwise made or, after giving effect to such payment, (i) an event constituting an Event
of Default has occurred and is continuing or (ii) an event that with the passage of time and without being cured would constitute
an Event of Default has occurred and is continuing.

 

    	14

    	 

    

 

(e)          Restriction
on Redemption and Cash Dividends. The Company shall not, and the Company shall cause each of its Subsidiaries to not, directly
or indirectly, redeem, repurchase or declare or pay any cash dividend or distribution on any of its capital stock (other than dividends
and distributions by direct or indirect wholly-owned Subsidiaries of the Company made to the Company or any other direct or indirect
wholly-owned Subsidiary of the Company) without the prior express written consent of the Majority of Holders; provided, however,
that the foregoing restrictions shall not apply to or impair the Company’s or any Subsidiary’s rights or obligations
with respect to (i) redemptions, repurchases, dividends or distributions made under or pursuant to any Approved Stock Plan, (ii)
the Company’s redemption, at par value, of up to 674,000 shares (subject to the anti-dilution and other adjustment provisions
thereof) of its Series A Voting Preferred Stock, par value $.0001 per share, upon the exchange of New Crumbs Class B Exchangeable
Units of Holdings for shares of Common Stock pursuant to the LLC Agreement, the Certificate of Designation and the Exchange and
Support Agreement, (iii) to the extent such distribution is deemed to constitute a direct or indirect redemption, dividend or other
distribution of or with respect to any capital stock, a distribution pursuant to the Tax Receivable Agreement or (iv) “Tax
Distributions” as that term is defined in the LLC Agreement that Holdings is required to make pursuant to Section 4.4 of
the LLC Agreement, so long as Holdings (A) does not admit any new Members (as defined in the LLC Agreement) after the date hereof
or (B) effect any additional issuances of Units (as defined in the LLC Agreement) after the date hereof pursuant to Section 3.2(b)
of the LLC Agreement; and provided further that the foregoing restrictions shall apply to any and all amendments or modifications
of any Approved Stock Plan, the LLC Agreement, the Certificate of Designation, the Exchange and Support Agreement and/or the Tax
Receivable Agreement made after the date hereof.

 

(f)          Restriction
on Transfer of Assets. The Company shall not, and the Company shall cause each of its Subsidiaries to not, directly or indirectly,
sell, lease, license, assign, transfer, spin-off, split-off, close, convey or otherwise dispose of any material assets or rights
of the Company or any Subsidiary owned or hereafter acquired whether in a single transaction or a series of related transactions,
other than (i) sales, leases, licenses, assignments, transfers, conveyances and other dispositions of such assets or rights by
the Company and its Subsidiaries in the ordinary course of business, (ii) sales of inventory in the ordinary course of business
and (iii) certificates of deposit that are pledged, consistent with the past practices of the Company and the Subsidiaries, to
secure letters of credit and related obligations in respect of real property operating leases of the Company and its Subsidiaries.

 

(g)          Maturity
of Indebtedness. The Company shall not, and the Company shall cause each of its Subsidiaries to not, directly or indirectly,
permit any Indebtedness of the Company or any of the Subsidiaries to mature or accelerate prior to the Maturity Date other than
Indebtedness described in clauses (iv) and (v) of Section 28(bb).

 

(h)          Change
in Nature of Business. The Company shall not, and the Company shall cause each of its Subsidiaries to not, directly or indirectly,
engage in any material line of business substantially different from those lines of business conducted by the Company and each
of its Subsidiaries on the Issuance Date or any business substantially related or incidental thereto. The Company shall not, and
the Company shall cause each of its Subsidiaries to not, directly or indirectly, modify its or their corporate structure or purpose.

 

(i)          Preservation
of Existence, Etc. The Company shall maintain and preserve, and cause each of its Subsidiaries to maintain and preserve, its
existence, rights and privileges, and become or remain, and cause each of its Subsidiaries to become or remain, duly qualified
and in good standing in each jurisdiction in which the character of the properties owned or leased by it or in which the transaction
of its business makes such qualification necessary.

 

(j)          Maintenance
of Properties, Etc. The Company shall maintain and preserve, and cause each of its Subsidiaries to maintain and preserve, all
of its properties which are necessary or useful in the proper conduct of its business in good working order and condition, ordinary
wear and tear excepted, and comply, and cause each of its Subsidiaries to comply, at all times with the provisions of all leases
to which it is a party as lessee or under which it occupies property, so as to prevent any loss or forfeiture thereof or thereunder.

 

    	15

    	 

    

 

(k)          Maintenance
of Intellectual Property. The Company will, and will cause each of its Subsidiaries to, take all action reasonably necessary
or advisable to maintain all of the Intellectual Property Rights (as defined in the Securities Purchase Agreement) of the Company
and/or any of its Subsidiaries that are necessary or material to the conduct of its business in full force and effect.

 

(l)          Maintenance
of Insurance. The Company shall maintain, and cause each of its Subsidiaries to maintain, insurance with responsible and reputable
insurance companies or associations (including, without limitation, comprehensive general liability, hazard, rent and business
interruption insurance) with respect to its properties (including all real properties leased or owned by it) and business, in such
amounts and covering such risks as is required by any governmental authority having jurisdiction with respect thereto or as is
carried generally in accordance with sound business practice by companies in similar businesses similarly situated.

 

(m)          Transactions
with Affiliates. The Company shall not, nor shall it permit any of its Subsidiaries to, enter into, renew, extend or be a party
to, any transaction or series of related transactions (including, without limitation, the purchase, sale, lease, transfer or exchange
of property or assets of any kind or the rendering of services of any kind) with any affiliate, except in the ordinary course of
business in a manner and to an extent consistent with past practice and necessary or desirable for the prudent operation of its
business, for fair consideration and on terms no less favorable to it or its Subsidiaries than would be obtainable in a comparable
arm’s length transaction with a Person that is not an affiliate thereof.

 

(n)          Restricted
Issuances. The Company shall not, directly or indirectly, without the prior written consent of the Majority of Holders, (i)
issue any Notes (other than as contemplated by the Securities Purchase Agreement and the Notes) or (ii) issue any other securities
that would cause a breach or default under the Notes.

 

14.         [Intentionally
Omitted]

 

15.         GUARANTIES.
Each existing and future Subsidiary shall jointly and severally unconditionally guarantee all obligations under the Notes on a
senior basis pursuant to the Guaranties.

 

16.         AMENDING
THE TERMS OF THIS NOTE. The prior written consent of the Holder shall be required for any change or amendment to this Note.
No consideration shall be offered or paid to the Holder to amend or consent to a waiver or modification
of any provision of this Note unless the same consideration is also offered to all of the holders of the Other Notes. The
Holder shall be entitled, at its option, to the benefit of any amendment to any of the Other Notes.

 

17.         TRANSFER.
This Note and any shares of Common Stock issued upon conversion of this Note may be offered, sold, assigned or transferred by the
Holder without the consent of the Company, subject only to the provisions of Section 2(g) of the Securities Purchase Agreement.

 

18.         REISSUANCE
OF THIS NOTE.

 

(a)          Transfer.
If this Note is to be transferred, the Holder shall surrender this Note to the Company, whereupon the Company will forthwith issue
and deliver upon the order of the Holder a new Note (in accordance with Section 17(d)), registered as the Holder may request, representing
the outstanding Principal being transferred by the Holder and, if less than the entire outstanding Principal is being transferred,
a new Note (in accordance with Section 17(d)) to the Holder representing the outstanding Principal not being transferred. The Holder
and any assignee, by acceptance of this Note, acknowledge and agree that, by reason of the provisions of Section 3(c)(iii) following
conversion or redemption of any portion of this Note, the outstanding Principal represented by this Note may be less than the Principal
stated on the face of this Note.

 

(b)          Lost,
Stolen or Mutilated Note. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft,
destruction or mutilation of this Note (as to which a written certification and the indemnification contemplated below shall suffice
as such evidence), and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Company
in customary and reasonable form and, in the case of mutilation, upon surrender and cancellation of this Note, the Company shall
execute and deliver to the Holder a new Note (in accordance with Section 17(d)) representing the outstanding Principal.

 

    	16

    	 

    

  

(c)          Note
Exchangeable for Different Denominations. This Note is exchangeable, upon the surrender hereof by the Holder at the principal
office of the Company, for a new Note or Notes (in accordance with Section 17(d) and in principal amounts of at least $1,000) representing
in the aggregate the outstanding Principal of this Note, and each such new Note will represent such portion of such outstanding
Principal as is designated by the Holder at the time of such surrender.

 

(d)          Issuance
of New Notes. Whenever the Company is required to issue a new Note pursuant to the terms of this Note, such new Note (i) shall
be of like tenor with this Note, (ii) shall represent, as indicated on the face of such new Note, the Principal remaining outstanding
(or in the case of a new Note being issued pursuant to Section 17(a) or Section 17(c), the Principal designated by the Holder which,
when added to the principal represented by the other new Notes issued in connection with such issuance, does not exceed the Principal
remaining outstanding under this Note immediately prior to such issuance of new Notes), (iii) shall have an issuance date, as indicated
on the face of such new Note, which is the same as the Issuance Date of this Note, (iv) shall have the same rights and conditions
as this Note, and (v) shall represent accrued and unpaid Interest and Late Charges on the Principal and Interest of this Note,
from the Issuance Date.

 

    	17

    	 

    

 

19.         REMEDIES,
CHARACTERIZATIONS, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF. The remedies provided in this Note shall be cumulative
and in addition to all other remedies available under this Note and any of the other Transaction Documents at law or in equity
(including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the Holder’s
right to pursue actual and consequential damages for any failure by the Company to comply with the terms of this Note. The Company
covenants to the Holder that there shall be no characterization concerning this instrument other than as expressly provided herein.
Amounts set forth or provided for herein with respect to payments, conversion and the like (and the computation thereof) shall
be the amounts to be received by the Holder and shall not, except as expressly provided herein, be subject to any other obligation
of the Company (or the performance thereof). The Company acknowledges that a breach by it of its obligations hereunder will cause
irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that,
in the event of any such breach or threatened breach, the Holder shall be entitled, in addition to all other available remedies,
to an injunction restraining any such breach or any such threatened breach, without the necessity of showing economic loss and
without any bond or other security being required. The Company shall provide all information and documentation to the Holder that
is requested by the Holder to enable the Holder to confirm the Company’s compliance with the terms and conditions of this
Note (including, without limitation, compliance with Section 7).

 

20.         PAYMENT
OF COLLECTION, ENFORCEMENT AND OTHER COSTS. If (a) this Note is placed in the hands of an attorney for collection or enforcement
or is collected or enforced through any legal proceeding or the Holder otherwise takes action to collect amounts due under this
Note or to enforce the provisions of this Note or (b) there occurs any bankruptcy, reorganization, receivership of the Company
or other proceedings affecting Company creditors’ rights and involving a claim under this Note, then the Company shall pay
the reasonable costs incurred by the Holder for such collection, enforcement or action or in connection with such bankruptcy, reorganization,
receivership or other proceeding, including, without limitation, reasonable attorneys’ fees and disbursements. The Company
expressly acknowledges and agrees that no amounts due under this Note shall be affected, or limited, by the fact that the purchase
price paid for this Note was less than the original Principal amount hereof.

 

21.         CONSTRUCTION;
HEADINGS. This Note shall be deemed to be jointly drafted by the Company and the Holder and shall not be construed against
any Person as the drafter hereof. The headings of this Note are for convenience of reference and shall not form part of, or affect
the interpretation of, this Note. Terms used in this Note but defined in the other Transaction Documents shall have the meanings
ascribed to such terms on the Closing Date in such other Transaction Documents unless otherwise consented to in writing by the
Holder.

 

22.         FAILURE
OR INDULGENCE NOT WAIVER. No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder
shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other
or further exercise thereof or of any other right, power or privilege. No waiver shall be effective unless it is in writing and
signed by an authorized representative of the waiving party.

 

23.         DISPUTE
RESOLUTION. In the case of a dispute as to the determination of the Conversion Price, any Redemption Price, the Closing Bid
Price, the Closing Sale Price or fair market value (as the case may be) or the arithmetic calculation of the Conversion Rate or
the applicable Redemption Price (as the case may be), the Company or the Holder (as the case may be) shall submit the disputed
determinations or arithmetic calculations (as the case may be) via facsimile (i) within two (2) Business Days after receipt of
the applicable notice giving rise to such dispute to the Company or the Holder (as the case may be) or (ii) if no notice gave rise
to such dispute, at any time after the Holder learned of the circumstances giving rise to such dispute. If the Holder and the Company
are unable to agree upon such determination or calculation within two (2) Business Days of such disputed determination or arithmetic
calculation (as the case may be) being submitted to the Company or the Holder (as the case may be), then the Company shall, within
two (2) Business Days, submit via facsimile (a) the disputed determination of the Conversion Price, any Redemption Price, the Closing
Bid Price, the Closing Sale Price or fair market value (as the case may be) to an independent, reputable investment bank selected
by the Company and approved by the Holder or (b) the disputed arithmetic calculation of the Conversion Rate or any Redemption Price
(as the case may be) to the Company’s independent, outside accountant. The Company shall cause at its expense the investment
bank or the accountant (as the case may be) to perform the determinations or calculations (as the case may be) and notify the Company
and the Holder of the results no later than ten (10) Business Days from the time it receives such disputed determinations or calculations
(as the case may be). Such investment bank’s or accountant’s determination or calculation (as the case may be) shall
be binding upon all parties absent demonstrable error.

 

    	18

    	 

    

  

24.         NOTICES;
CURRENCY; PAYMENTS.

 

(a)          Notices.
Whenever notice is required to be given under this Note, unless otherwise provided herein, such notice shall be given in accordance
with Section 9(f) of the Securities Purchase Agreement. The Company shall provide the Holder with prompt written notice of all
actions taken pursuant to this Note, including in reasonable detail a description of such action and the reason therefore. Without
limiting the generality of the foregoing, the Company will give written notice to the Holder (i) immediately upon any adjustment
of the Conversion Price, setting forth in reasonable detail, and certifying, the calculation of such adjustment and (ii) at least
fifteen (15) days prior to the date on which the Company closes its books or takes a record (A) with respect to any dividend or
distribution upon the Common Stock, (B) with respect to any grant, issuances, or sales of any Options, Convertible Securities or
rights to purchase stock, warrants, securities or other property to holders of shares of Common Stock or (C) for determining rights
to vote with respect to any Change of Control, dissolution or liquidation, provided in each case that such information shall be
made known to the public prior to or in conjunction with such notice being provided to the Holder.

 

(b)          Currency.
All dollar amounts referred to in this Note are in United States Dollars (“U.S. Dollars”), and all amounts owing
under this Note shall be paid in U.S. Dollars. All amounts denominated in other currencies (if any) shall be converted in the U.S.
Dollar equivalent amount in accordance with the Exchange Rate on the date of calculation (each, a “US Dollar Equivalent”).
“Exchange Rate” means, in relation to any amount of currency to be converted into U.S. Dollars pursuant
to this Note, the U.S. Dollar exchange rate as published in the Wall Street Journal on the relevant date of calculation (it being
understood and agreed that where an amount is calculated with reference to, or over, a period of time, the date of calculation
shall be the final date of such period of time).

 

(c)          Payments.
Whenever any payment of cash is to be made by the Company to any Person pursuant to this Note, unless otherwise expressly set forth
herein, such payment shall be made in lawful money of the United States of America by a certified check drawn on the account of
the Company and sent via overnight courier service to such Person at such address as previously provided to the Company in writing
(which address, in the case of each of the initial Holders, shall initially be as set forth on the Schedule of Buyers attached
to the Securities Purchase Agreement), provided that the Holder may elect to receive a payment of cash via wire transfer of immediately
available funds by providing the Company with prior written notice setting out such request and the Holder’s wire transfer
instructions. Whenever any amount expressed to be due by the terms of this Note is due on any day which is not a Business Day,
the same shall instead be due on the next succeeding day which is a Business Day. Any amount of Principal or other amounts due
under the Transaction Documents which is not paid when due shall result in a late charge being incurred and payable by the Company
in an amount equal to interest on such amount at the rate of eighteen percent (18%) per annum from the date such amount was due
until the same is paid in full (“Late Charge”).

 

25.         CANCELLATION.
After all Principal, accrued Interest, Late Charges and other amounts at any time owed on this Note have been paid in full, this
Note shall automatically be deemed canceled, shall be surrendered to the Company for cancellation and shall not be reissued.

 

26.         WAIVER
OF NOTICE. To the extent permitted by law, the Company hereby irrevocably waives demand, notice, presentment, protest and all
other demands and notices in connection with the delivery, acceptance, performance, default or enforcement of this Note and the
Securities Purchase Agreement.

 

    	19

    	 

    

 

27.         GOVERNING
LAW. This Note shall be construed and enforced in accordance with, and all questions concerning the construction, validity,
interpretation and performance of this Note shall be governed by, the internal laws of the State of New York, without giving effect
to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would
cause the application of the laws of any jurisdictions other than the State of New York. The Company hereby irrevocably submits
to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication
of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby
irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to
the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue
of such suit, action or proceeding is improper. Nothing contained herein shall be deemed to limit in any way any right to serve
process in any manner permitted by law. In the event that any provision of this Note is invalid or unenforceable under any applicable
statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall
be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under
any law shall not affect the validity or enforceability of any other provision of this Note. Nothing contained herein shall be
deemed or operate to preclude the Holder from bringing suit or taking other legal action against the Company in any other jurisdiction
to collect on the Company’s obligations to the Holder, to realize on any collateral or any other security for such obligations,
or to enforce a judgment or other court ruling in favor of the Holder. THE COMPANY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY
HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING
OUT OF THIS NOTE OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

28.         MAXIMUM
PAYMENTS. Nothing contained herein shall be deemed to establish or require the payment of a rate of interest or other charges
in excess of the maximum permitted by applicable law. In the event that the rate of interest required to be paid or other charges
hereunder exceed the maximum permitted by such law, any payments in excess of such maximum shall be credited against amounts owed
by the Company to the Holder and thus refunded to the Company.

 

29.         CERTAIN
DEFINITIONS. For purposes of this Note, the following terms shall have the following meanings:

 

(a)          “Approved
Stock Plan” means any employee benefit plan or employment agreement which has been approved by the board of directors
of the Company prior to or subsequent to the date hereof pursuant to which shares of Common Stock and standard options to purchase
Common Stock may be issued to any employee, officer or director for services provided to the Company in their capacity as such.

 

(b)          “Bankruptcy
Proceeding” means, with respect to any Person, (i) the occurrence of a voluntary case or proceeding under any applicable
federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or of any other case or proceeding to be
adjudicated a bankrupt or insolvent, or the consent by it to the entry of a decree, order, judgment or other similar document in
respect of such Person in an involuntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency,
reorganization or other similar law or to the commencement of any bankruptcy or insolvency case or proceeding against it, or the
filing by it of a petition or answer or consent seeking reorganization or relief under any applicable federal, state or foreign
law, or the consent by it to the filing of such petition or to the appointment of or taking possession by a custodian, receiver,
liquidator, assignee, trustee, sequestrator or other similar official of such Person or of any substantial part of its property,
or the making by it of an assignment for the benefit of creditors, or the execution of a composition of debts, or the occurrence
of any other similar federal, state or foreign proceeding, or the admission by it in writing of its inability to pay its debts
generally as they become due, the taking of corporate action by such Person in furtherance of any such action or the taking of
any action by any Person to commence a UCC foreclosure sale or any other similar action under federal, state or foreign law or
(ii) the entry by a court of (A) a decree, order, judgment or other similar document in respect of such Person of a voluntary or
involuntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar
law or (B) a decree, order, judgment or other similar document adjudging such Person as bankrupt or insolvent, or approving as
properly filed a petition seeking liquidation, reorganization, arrangement, adjustment or composition of or in respect of such
Person under any applicable federal, state or foreign law or (C) a decree, order, judgment or other similar document appointing
a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of such Person or of any substantial
part of its property, or ordering the winding up or liquidation of its affairs, and the continuance of any such decree, order,
judgment or other similar document or any such other decree, order, judgment or other similar document unstayed and in effect for
a period of thirty (30) consecutive days.

 

(c)          “Bloomberg”
means Bloomberg, L.P.

 

(d)          “Business
Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed.

 

    	20

    	 

    

  

(e)          “Certificate
of Designation” means the Amended and Restated Certificate of Designation in respect of the Company’s Series A
Voting Preferred Stock, par value $.0001 per share.

 

(f)          “Change
of Control” means any Fundamental Transaction other than (i) any reorganization, recapitalization or reclassification
of the Common Stock in which holders of the Company’s voting power immediately prior to such reorganization, recapitalization
or reclassification continue after such reorganization, recapitalization or reclassification to hold publicly traded securities
and, directly or indirectly, are, in all material respect, the holders of the voting power of the surviving entity (or entities
with the authority or voting power to elect the members of the board of directors (or their equivalent if other than a corporation)
of such entity or entities) after such reorganization, recapitalization or reclassification or (ii) pursuant to a migratory merger
effected solely for the purpose of changing the jurisdiction of incorporation of the Company.

 

(g)          “Change
of Control Redemption Premium” means: (i) 115% of the aggregate principal amount then outstanding under the Notes on
the occurrence of a Change of Control between the Closing Date and the one-year anniversary of the Closing Date; (ii) 110% of the
aggregate principal amount then outstanding under the Notes on the occurrence of a Change of Control between the one-year anniversary
of the Closing Date and the two-year anniversary of the Closing Date; (iii) 105% of the aggregate principal amount then outstanding
under the Notes on the occurrence of a Change of Control between the two-year anniversary of the Closing Date and the three-year
anniversary of the Closing Date; and (iv) 100% of the aggregate principal amount then outstanding under the Notes on the occurrence
of a Change of Control between the three-year anniversary of the Closing Date and the Maturity Date.

 

(h)          “Closing
Bid Price” and “Closing Sale Price” means, for any security as of any date, the last closing bid price
and last closing trade price, respectively, for such security on the Principal Market, as reported by Bloomberg, or, if the Principal
Market begins to operate on an extended hours basis and does not designate the closing bid price or the closing trade price (as
the case may be) then the last bid price or last trade price, respectively, of such security prior to 4:00:00 p.m., New York time,
as reported by Bloomberg, or, if the Principal Market is not the principal securities exchange or trading market for such security,
the last closing bid price or last trade price, respectively, of such security on the principal securities exchange or trading
market where such security is listed or traded as reported by Bloomberg, or if the foregoing do not apply, the last closing bid
price or last trade price, respectively, of such security in the over-the-counter market on the electronic bulletin board for such
security as reported by Bloomberg, or, if no closing bid price or last trade price, respectively, is reported for such security
by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market makers for such security as reported
in the “pink sheets” by OTC Markets Group Inc. (formerly Pink Sheets LLC). If the Closing Bid Price or the Closing
Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Bid Price or the
Closing Sale Price (as the case may be) of such security on such date shall be the fair market value as mutually determined by
the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then
such dispute shall be resolved in accordance with the procedures in Section 22. All such determinations shall be appropriately
adjusted for any stock dividend, stock split, stock combination or other similar transaction during such period.

 

(i)          “Closing
Date” shall have the meaning set forth in the Securities Purchase Agreement, which date is the date the Company initially
issued Notes pursuant to the terms of the Securities Purchase Agreement.

 

(j)          “Code”
means the Uniform Commercial Code as in effect from time to time in the State of New York.

 

(k)          “Common
Stock” means (i) the Company’s shares of common stock, $0.0001 par value per share, and (ii) any capital stock
into which such common stock shall have been changed or any share capital resulting from a reclassification of such common stock.

 

(l)          “Contingent
Obligation” means, as to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect
to any Indebtedness, lease, dividend or other obligation of another Person if the primary purpose or intent of the Person incurring
such liability, or the primary effect thereof, is to provide assurance to the obligee of such liability that such liability will
be paid or discharged, or that any agreements relating thereto will be complied with, or that the holders of such liability will
be protected (in whole or in part) against loss with respect thereto.

 

    	21

    	 

    

 

(m)          “Convertible
Securities” means any stock or other security (other than Options) that is at any time and under any circumstances, directly
or indirectly, convertible into, exercisable or exchangeable for, or which otherwise entitles the holder thereof to acquire, any
shares of Common Stock.

 

(n)          “Eligible
Market” means The New York Stock Exchange, The New York Stock Exchange, the NYSE MKT, the Nasdaq Global Select Market,
the Nasdaq Global Market or the Principal Market.

 

(o)          “Equity
Conditions” means: (i) on each day during the period beginning one month prior to the applicable date of determination
and ending on and including the applicable date of determination either (x) one or more Registration
Statements filed pursuant to the Registration Rights Agreement shall be effective and the prospectus contained therein shall be
available for the resale by the Holder of all of the Registrable Securities (which, solely for clarification purposes, includes
all shares of Common Stock issuable upon conversion of this Note) in accordance with the terms
of the Registration Rights Agreement and there shall not have been during such period any Grace Periods
(as defined in the Registration Rights Agreement) or (y) all Registrable Securities shall be
eligible for sale without restriction under Rule 144 (as defined in the Securities Purchase Agreement) (including, without
limitation, volume restrictions) and without the need for current public information required by Rule 144(c)(1) (or Rule 144(i)(2),
if applicable) and without the need for registration under any applicable federal or state securities
laws (in each case, disregarding any limitation on conversion of the Notes); (ii) on each day during the period beginning
three months prior to the applicable date of determination and ending on and including the applicable date of determination (the
“Equity Conditions Measuring Period”), the Common Stock (including all Registrable Securities)
is listed or designated for quotation (as applicable) on an Eligible Market and shall not have been suspended from trading on an
Eligible Market (other than suspensions of not more than two (2) days and occurring prior to the applicable date of determination
due to business announcements by the Company) nor shall delisting or suspension by an Eligible Market have been threatened (with
a reasonable prospect of delisting occurring) or pending either (A) in writing by such Eligible Market or (B) by falling below
the minimum listing maintenance requirements of the Eligible Market on which the Common Stock is then listed or designated for
quotation (as applicable); (iii) on the date of determination , the Company shall have delivered all shares of Common Stock issuable
upon conversion of this Note as set forth in Section 3 hereof and all other shares of capital stock required to be delivered by
the Company on a timely basis as set forth in the other Transaction Documents; (iv) any shares of Common Stock to be issued in
connection with the event requiring determination may be issued in full within the limits of Section 3(d) hereof; (v) any shares
of Common Stock to be issued in connection with the event requiring determination may be issued in full without violating the rules
or regulations of the Eligible Market on which the Common Stock is then listed or designated for quotation (as applicable); (vi)
on each day during the Equity Conditions Measuring Period, no public announcement of a pending, proposed or intended Fundamental
Transaction shall have occurred which has not been abandoned, terminated or consummated; (vii) the Company
shall have no knowledge of any fact that would reasonably be expected to cause (1) any Registration Statement required to be filed
pursuant to the Registration Rights Agreement to not be effective or any prospectus contained therein to not be available for the
resale of all of the Registrable Securities in accordance with the terms of the Registration Rights Agreement or (2) any Registrable
Securities to not be eligible for sale without restriction pursuant to Rule 144 (including, without limitation, volume restrictions)
and without the need for current public information required by Rule 144(c)(1) (or Rule 144(i)(2), if applicable)
or any applicable state securities laws (in each case, disregarding any limitation on conversion of the Notes); (viii) the Holder
shall not be in (and no other Holder shall be in) possession of any material, non-public information provided to any of them by
the Company, any of its affiliates or any of their respective employees, officers, representatives, agents or the like; (ix) if
required, the Stockholder Approval shall have occurred on or prior to the Stockholder Approval Deadline; (x) on the date
of determination, the Company otherwise shall be in compliance with each Transaction Document; and (xi) on each day during the
Equity Conditions Measuring Period, there shall not have occurred an Event of Default that has not been waived or an event that
with the passage of time or giving of notice would constitute an Event of Default.

 

(p)          “Equity
Conditions Failure” means, with respect to a particular date of determination, that on any day during the period commencing
twenty (20) Trading Days immediately prior to such date of determination, the Equity Conditions have not been satisfied (or waived
in writing by the Holder).

 

(q)          “Exchange
and Support Agreement” means that certain Exchange and Support Agreement, dated as of May 5, 2011, by and among the Company,
Holdings, and the members of Holdings named therein, as modified by that certain Accession Agreement, dated as of November 14,
2011, by and among the Company, Holdings and Julian R. Geiger.

 

    	22

    	 

    

 

(r)          “Fundamental
Transaction” means that (i) the Company or any of its Subsidiaries shall, directly or indirectly, in one or more related
transactions, (1) consolidate or merge with or into (whether or not the Company or any of its Subsidiaries is the surviving corporation)
any other Person, or (2) sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of its
respective properties or assets to any other Person, or (3) allow any other Person to make a purchase, tender or exchange offer
that is accepted by the holders of more than 50% of the outstanding shares of Voting Stock of the Company (not including any shares
of Voting Stock of the Company held by the Person or Persons making or party to, or associated or affiliated with the Persons making
or party to, such purchase, tender or exchange offer), or (4) consummate a stock or share purchase agreement or other business
combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with any other
Person whereby such other Person acquires more than 50% of the outstanding shares of Voting Stock of the Company (not including
any shares of Voting Stock of the Company held by the other Person or other Persons making or party to, or associated or affiliated
with the other Persons making or party to, such stock or share purchase agreement or other business combination), or (5) reorganize,
recapitalize or reclassify the Common Stock, or (ii) any “person” or “group” (as these terms are used for
purposes of Sections 13(d) and 14(d) of the 1934 Act and the rules and regulations promulgated thereunder) is or shall become the
“beneficial owner” (as defined in Rule 13d-3 under the 1934 Act), directly or indirectly, of 50% of the aggregate ordinary
voting power represented by issued and outstanding Voting Stock of the Company.

 

(s)          “GAAP”
means United States generally accepted accounting principles, consistently applied.

 

(t)          [Intentionally
Omitted]

 

(u)          “Indebtedness”
of any Person means, without duplication (i) all indebtedness for borrowed money, (ii) all obligations issued, undertaken or assumed
as the deferred purchase price of property or services, including (without limitation) “capital leases” in accordance
with GAAP (other than trade payables entered into in the ordinary course of business), (iii) all reimbursement or payment obligations
with respect to letters of credit, surety bonds and other similar instruments, (iv) all obligations evidenced by notes, bonds,
debentures or similar instruments, including obligations so evidenced incurred in connection with the acquisition of property,
assets or businesses, (v) all indebtedness created or arising under any conditional sale or other title retention agreement, or
incurred as financing, in either case with respect to any property or assets acquired with the proceeds of such indebtedness (even
though the rights and remedies of the seller or bank under such agreement in the event of default are limited to repossession or
sale of such property), (vi) all monetary obligations under any leasing or similar arrangement which, in connection with GAAP,
consistently applied for the periods covered thereby, is classified as a capital lease, (vii) all indebtedness referred to in clauses
(i) through (vi) above secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise,
to be secured by) any mortgage, lien, pledge, charge, security interest or other encumbrance upon or in any property or assets
(including accounts and contract rights) owned by any Person, even though the Person which owns such assets or property has not
assumed or become liable for the payment of such indebtedness, and (viii) all Contingent Obligations in respect of indebtedness
or obligations of others of the kinds referred to in clauses (i) through (vii) above; provided, however, that the term “Indebtedness”
shall not include any unsecured obligation of the Company or any Subsidiary owed under or with respect to real estate operating
leases.

 

(v)         “Interest
Rate” means six and one-half percent (6.5%) per annum.

 

(w)          “LLC
Agreement” means Holdings’ Third Amended and Restated Limited Liability Company Agreement, dated as of May 5, 2011.

 

(x)          “Material
Adverse Effect” shall mean (i) with respect to the Company, any material adverse effect on (i) the business, properties,
assets, liabilities, operations (including results thereof), condition (financial or otherwise) or prospects of the Company and
its Subsidiaries, taken as a whole, and (ii) with respect to Holdings, any material adverse effect on (i) the business, properties,
assets, liabilities, operations (including results thereof), condition (financial or otherwise) or prospects of Holdings.

 

    	23

    	 

    

 

(y)          “Maturity
Date” shall mean [           ]1; provided, however,
the Maturity Date may be extended at the option of the Holder (i) in the event that, and for so long as, an Event of Default shall
have occurred and be continuing or any event shall have occurred and be continuing that with the passage of time and the failure
to cure would result in an Event of Default or (ii) through the date that is twenty (20) Business Days after the consummation
of a Fundamental Transaction in the event that a Fundamental Transaction is publicly announced or a Fundamental Transaction Notice
is delivered prior to the Maturity Date, provided further that if a Holder elects to convert some or all of this Note pursuant
to Section 3 hereof, and the Conversion Amount would be limited pursuant to Section 3(d) hereunder, the Maturity Date shall automatically
be extended until such time as such provision shall not limit the conversion of this Note.

 

(z)          “Options”
means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities.

 

(aa)         “Parent
Entity” of a Person means an entity that, directly or indirectly, controls the applicable Person and whose common stock
or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity,
the Person or Parent Entity with the largest public market capitalization as of the date of consummation of the Fundamental Transaction.

 

(bb)         “Permitted
Indebtedness” means (i) Indebtedness evidenced by this Note and the Other Notes, (ii) Indebtedness secured by Permitted
Liens described in clauses (v) and (vi) of the definition of Permitted Liens, in an aggregate amount not to exceed $200,000, (iii)
Indebtedness outstanding as of the Issuance Date and described on Schedule 3(s) to the Securities Purchase Agreement, (iv) Indebtedness
not to exceed $575,000 plus accrued interest and late charges from time to time outstanding under that certain Commercial Loan
Agreement, dated as of May 5, 2011, by and between Holdings and Southeastern Bank evidencing a $575,000 revolving line of credit
(the “Commercial Loan Agreement”) and secured by a $575,000 certificate of deposit, (v) Indebtedness of the
Company from time to time outstanding pursuant to the Tax Receivable Agreement, and (vi) unsecured Indebtedness incurred by the
Company that is made expressly subordinate in right of payment to the Indebtedness evidenced by this Note, as reflected in a written
agreement acceptable to the Holder and approved by the Holder in writing, and which Indebtedness does not provide at any time for
(A) the payment, prepayment, repayment, repurchase or defeasance, directly or indirectly, of any principal or premium, if any,
thereon until ninety-one (91) days after the Maturity Date or later and (B) total Interest and fees at a rate in excess of 6.00%
per annum.

 

(cc)         “Permitted
Liens” means (i) any Lien for taxes not yet due or delinquent or being contested in good faith by appropriate proceedings
for which adequate reserves have been established in accordance with GAAP, (ii) any statutory Lien arising in the ordinary course
of business by operation of law with respect to a liability that is not yet due or delinquent, (iii) any Lien created by operation
of law, such as materialmen’s liens, mechanics’ liens and other similar liens, arising in the ordinary course of business
with respect to a liability that is not yet due or delinquent or that are being contested in good faith by appropriate proceedings,
(iv) Liens securing obligations from time to time outstanding under the Commercial Loan Agreement, (v) Liens (A) upon or in any
equipment acquired or held by the Company or any of its Subsidiaries to secure the purchase price of such equipment or indebtedness
incurred solely for the purpose of financing the acquisition or lease of such equipment, or (B) existing on such equipment at the
time of its acquisition, provided that the Lien is confined solely to the property so acquired and improvements thereon, and the
proceeds of such equipment, and (vi) Liens incurred in connection with the extension, renewal or refinancing of the indebtedness
secured by Liens of the type described in clause (v) above, provided that any extension, renewal or replacement Lien shall be limited
to the property encumbered by the existing Lien and the principal amount of the Indebtedness being extended, renewed or refinanced
does not increase.

 

(dd)         “Person”
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization,
any other entity or a government or any department or agency thereof.

 

(ee)         “Principal
Market” means the NASDAQ Capital Market.

 

(ff)         “Quarter”
means each of: (i) the period beginning on and including January 1 and ending on and including March 31; (ii) the period beginning
on and including April 1 and ending on and including June 30; (iii) the period beginning on and including July 1 and ending on
and including September 30; and (iv) the period beginning on and including October 1 and ending on and including December 31.

 

1Insert five year anniversary of the Issuance Date.

 

    	24

    	 

    

 

(gg)         “Redemption
Notices” means, collectively, Event of Default Redemption Notices, the Company Optional Redemption Notices and the Change
of Control Redemption Notices, and each of the foregoing, individually, a “Redemption Notice.”

 

(hh)         [Intentionally
Omitted]

 

(ii)         “Redemption
Prices” means, collectively, Event of Default Redemption Prices, the Change of Control Redemption Prices and the Company
Optional Redemption Prices, and each of the foregoing, individually, a “Redemption Price.”

 

(jj)         “Registration
Rights Agreement” means that certain registration rights agreement, dated as of the Closing Date, by and among the Company
and the initial holders of the Notes relating to, among other things, the registration of the resale of the Common Stock issuable
upon conversion of the Notes or otherwise pursuant to the terms of the Notes, as may be amended from time to time.

 

(kk)         “SEC”
means the United States Securities and Exchange Commission or the successor thereto.

 

(ll)         “Securities
Purchase Agreement” means that certain securities purchase agreement, dated as of the Subscription Date, by and among
the Company and the initial holders of the Notes pursuant to which the Company issued the Notes, as may be amended from time to
time.

 

(mm)         “Subscription
Date” means April [  ], 2013.

 

(a)          “Subsidiary”
means, as of any date of determination, any Person in which the Company, directly or indirectly, (i) owns a majority of the outstanding
capital stock or holds a majority of equity or similar interest of such Person or (ii) controls or operates all or any part of
the business, operations or administration of such Person.

 

(nn)         “Successor
Entity” means the Person (or, if so elected by the Holder, the Parent Entity) formed by, resulting from or surviving
any Fundamental Transaction or the Person (or, if so elected by the Holder, the Parent Entity) with which such Fundamental Transaction
shall have been entered into.

 

(oo)         “Tax
Receivable Agreement” means that certain Tax Receivable Agreement, dated as of May 5, 2011,
by and among the Company, Holdings and the members of Holdings identified therein.

 

(pp)         “Trading
Day” means any day on which the Common Stock is traded on the Principal Market, or, if the Principal Market is not the
principal trading market for the Common Stock, then on the principal securities exchange or securities market on which the Common
Stock is then traded, provided that “Trading Day” shall not include any day on which the Common Stock is scheduled
to trade on such exchange or market for less than 4.5 hours or any day that the Common Stock is suspended from trading during the
final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the closing time
of trading on such exchange or market, then during the hour ending at 4:00:00 p.m., New York time) unless such day is otherwise
designated as a Trading Day in writing by the Holder.

 

(qq)         “Voting
Stock” of a Person means capital stock of such Person of the class or classes pursuant to which the holders thereof have
the general voting power to elect, or the general power to appoint, at least a majority of the board of directors, managers, trustees
or other similar governing body of such Person (irrespective of whether or not at the time capital stock of any other class or
classes shall have or might have voting power by reason of the happening of any contingency).

 

    	25

    	 

    

 

(rr)         “VWAP”
means, for any security as of any date, the dollar volume-weighted average price for such security on the Principal Market (or,
if the Principal Market is not the principal trading market for such security, then on the principal securities exchange or securities
market on which such security is then traded) during the period beginning at 9:30:01 a.m., New York time, and ending at 4:00:00
p.m., New York time, as reported by Bloomberg through its “Volume at Price” function or, if the foregoing does not
apply, the dollar volume-weighted average price of such security in the over-the-counter market on the electronic bulletin board
for such security during the period beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported
by Bloomberg, or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the average
of the highest closing bid price and the lowest closing ask price of any of the market makers for such security as reported in
the “pink sheets” by OTC Markets Group Inc. (formerly Pink Sheets LLC). If the VWAP cannot be calculated for such security
on such date on any of the foregoing bases, the VWAP of such security on such date shall be the fair market value as mutually determined
by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then
such dispute shall be resolved in accordance with the procedures in Section 23. All such determinations shall be appropriately
adjusted for any stock dividend, stock split, stock combination or other similar transaction during such period.

 

30.         DISCLOSURE.
Upon receipt or delivery by the Company of any notice in accordance with the terms of this Note, unless the Company has in good
faith determined that the matters relating to such notice do not constitute material, non-public information relating to the Company
or any of its Subsidiaries, the Company shall within four (4) Business Days after any such receipt or delivery publicly disclose
such material, non-public information on a Current Report on Form 8-K or otherwise. In the event that the Company believes that
a notice contains material, non-public information relating to the Company or any of its Subsidiaries, the Company so shall indicate
to such Holder contemporaneously with delivery of such notice, and in the absence of any such indication, the Holder shall be allowed
to presume that all matters relating to such notice do not constitute material, non-public information relating to the Company
or its Subsidiaries. Nothing contained in this Section 29 shall limit any obligations of the Company, or any rights of the Holder,
under Section 4(i) of the Securities Purchase Agreement.

 

[signature page follows]

 

    	26

    	 

    

 

IN WITNESS WHEREOF,
the Company has caused this Note to be duly executed as of the Issuance Date set out above.

 

	 	CRUMBS BAKE SHOP, INC. 
	 	 
	 	By: 	 
	 	 	Name:
	 	 	Title:

  

    	 

    	 

    

 

EXHIBIT I

 

CRUMBS BAKE SHOP, INC.

CONVERSION NOTICE

 

Reference is made to
the Senior Secured Convertible Note (the “Note”) issued to the undersigned by Crumbs Bake Shop, Inc. (the “Company”).
In accordance with and pursuant to the Note, the undersigned hereby elects to convert the Conversion Amount (as defined in the
Note) of the Note indicated below into shares of Common Stock, $0.0001 par value per share (the “Common Stock”),
of the Company, as of the date specified below.

 

	Date of Conversion:	 
	Aggregate Principal to be converted:	 
	Aggregate accrued and unpaid Interest and accrued and unpaid Late Charges with respect to such portion of the Aggregate Principal and such Aggregate Interest to be converted:	 
	AGGREGATE CONVERSION AMOUNT

 TO BE CONVERTED:	 
	Please confirm the following information:
	Conversion Price:	 
	Number of shares of Common Stock to be issued:	 

 

Notwithstanding anything to the contrary
contained herein, this Conversion Notice shall constitute a representation by the Holder of the Note submitting this Conversion
Notice that, after giving effect to the conversion provided for in this Conversion Notice, such Holder (together with its affiliates)
will not have beneficial ownership (together with the beneficial ownership of such Person’s affiliates) of a number of Common
Shares which exceeds the Maximum Percentage (as defined in the Note) of the total outstanding Common Shares of the Company as determined
pursuant to the provisions of Section 3(d) of the Note.

 

    	Exh-I-1

    	 

    

 

Please issue the Common Stock into which
the Note is being converted in the following name and to the following address:

 

	Issue to:	 
	 	 
	 	 

	Facsimile Number:	 

	Holder:	 

	By:	 

	Title:	 

	Dated:	 

	Account Number:	 

	  (if electronic book entry transfer)	 

	Transaction Code Number:	 

	  (if electronic book entry transfer)	 

 

    	Exh-I-2

    	 

    

 

EXHIBIT II

 

ACKNOWLEDGMENT

 

The Company hereby acknowledges this Conversion Notice and hereby
directs _________________ to issue the above indicated number of shares of Common Stock in accordance with the Transfer Agent Instructions
dated _____________, 20__ from the Company and acknowledged and agreed to by ________________________.

 

	 	CRUMBS BAKE SHOP, INC.  
	 	 
	 	By: 	 
	 	 	Name:

Title:

  

    	Exh-II-1

    	 

    

 

EXHIBIT B

FORM OF REGISTRATION RIGHTS AGREEMENT

 

REGISTRATION RIGHTS AGREEMENT

 

This Registration Rights
Agreement (the “Agreement”) is made and entered into as of this __ day of ____________, 2013 by and among Crumbs
Bake Shop, Inc., a Delaware corporation (the “Company”), and the “Buyers” named in those certain Securities
Purchase Agreements, dated as of April [25], 2013, by and among the Company and the Buyers party thereto (the “Purchase
Agreement”).

 

RECITALS

 

A.           In
connection with the Purchase Agreement, the Company has agreed, upon the terms and subject to the conditions of the Purchase Agreement,
to issue and sell to each Buyer the Notes (as defined in the Purchase Agreement) which will be convertible into Conversion Shares
(as defined in the Purchase Agreement) in accordance with the terms of the Notes.

 

B.           The
Notes may be entitled to interest and certain other amounts, which, at the option of the Company and subject to certain conditions,
may be paid in shares of Common Stock (as defined in the Purchase Agreement) that have been registered for resale (the “Interest
Shares”) or in cash.

 

C.           To
induce the Buyers to consummate the transactions contemplated by the Purchase Agreement, the Company has agreed to provide certain
registration rights under the Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor
statute (collectively, the “ 1933 Act ”), and applicable state securities laws.

 

AGREEMENT

 

NOW, THEREFORE, in
consideration of the premises and the mutual covenants contained herein and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Company and each of the Buyers hereby agree as follows::

 

1.     
      Certain Definitions.

 

In addition to those
terms defined above and elsewhere in this Agreement, the terms set forth below shall, for purposes of this Agreement, have the
respective meanings indicated. Capitalized terms used but not defined herein shall have the respective meanings specified in the
Purchase Agreement.

 

“Buyer”
means each investor party to this Agreement and any Affiliate or permitted transferee of any Buyer who is a subsequent holder of
any Registrable Securities.

 

“Common Stock”
means the Company’s common stock, par value $0.0001 per share, and any securities into which such shares may hereinafter
be reclassified.

 

“Prospectus”
means (i) the prospectus included in any Registration Statement, as amended or supplemented by any prospectus supplement, with
respect to the terms of the offering of any portion of the Registrable Securities covered by such Registration Statement and by
all other amendments and supplements to the prospectus, including post-effective amendments and all material incorporated by reference
in such prospectus, and (ii) any “free writing prospectus” as defined in Rule 405 under the 1933 Act.

 

    	 

    	 

    

 

“Register,”
“registered” and “registration” refer to a registration made by preparing and filing a Registration
Statement or similar document in compliance with the 1933 Act (as defined below), and the declaration or ordering of effectiveness
of such Registration Statement or document.

 

“Registrable
Securities” means (i) the Conversion Shares, (ii) the Interest Shares, and (iii) any capital stock of the Company issued
or issuable with respect to the Conversion Shares, the Interest Shares or the Notes, including, without limitation, (1) as a result
of any stock split, stock dividend, recapitalization, exchange or similar event or otherwise and (2) shares of capital stock of
the Company into which the shares of Common Stock are converted or exchanged and shares of capital stock of a successor entity
into which the shares of Common Stock are converted or exchanged, in each case, without regard to any limitations on conversion
of the Notes; provided that a security shall cease to be a Registrable Security upon (A) sale of such Registrable Security
pursuant to a Registration Statement or Rule 144 under the 1933 Act, (B) with respect to a Registrable Security held by any particular
Person, when such Person is permitted to sell such Registrable Security without restriction pursuant to Rule 144, (C) when the
Registrable Security is resold to the Company for cash, or (D) when the Registrable Security otherwise ceases to be outstanding.

 

“Registration
Statement” means any registration statement of the Company filed under the 1933 Act that covers the resale of any of
the Registrable Securities pursuant to the provisions of this Agreement, amendments and supplements to such Registration Statement,
including post-effective amendments, all exhibits and all material incorporated by reference in such Registration Statement.

 

“Required
Buyers” means the Buyers beneficially owning a majority of the Registrable Securities.

 

“SEC”
means the U.S. Securities and Exchange Commission.

 

“1933 Act”
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“1934 Act”
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

    	-2-

    	 

    

 

 

2.     
      Registration.

 

(a)          Registration
Statement. Promptly following the closing of the purchase and sale of the Notes contemplated by the Purchase Agreement (the
“Closing Date”) but no later than thirty (30) days after the Closing Date (the “Filing
Deadline”), the Company shall prepare and file with the SEC one Registration Statement on Form S-3 (or, if Form S-3 is
not then available to the Company, on such form of registration statement as is then available to effect a registration for resale
of the Registrable Securities), covering the resale of the Registrable Securities. Subject to any SEC comments, such Registration
Statement shall include the plan of distribution attached hereto as Exhibit A; provided, however, that no
Buyer shall be named as an “underwriter” in the Registration Statement without the Buyer’s prior written consent.
Such Registration Statement shall not include any shares of Common Stock or other securities for the account of any other holder
without the prior written consent of the Required Buyers. The Registration Statement (and each amendment or supplement thereto,
and each request for acceleration of effectiveness thereof) shall be provided in accordance with Section 3(c) to the Buyers and
their counsel prior to its filing or other submission. If a Registration Statement covering the Registrable Securities is not filed
with the SEC on or prior to the Filing Deadline, the Company will make pro rata payments to each Buyer, as liquidated damages and
not as a penalty, in an amount equal to 1.5% of the aggregate amount invested by such Buyer pursuant to the Purchase Agreement
(or the purchase price of the Registrable Securities purchased by any Person not an original party to this Agreement) for each
30-day period (or pro rata for any portion thereof) following the Filing Deadline for which no Registration Statement is filed
with respect to the Registrable Securities. Such payments shall constitute the Buyers’ exclusive monetary remedy for such
events, but shall not affect the right of the Buyers to seek injunctive relief. Such payments shall be made to each Buyer in cash
no later than three (3) Business Days after the end of each 30-day period.

 

(b)          Expenses.
The Company will pay all expenses associated with effecting the registration of the Registrable Securities, including filing and
printing fees, the Company’s counsel and accounting fees and expenses, costs associated with clearing the Registrable Securities
for sale under applicable state securities laws, listing fees, and, subject to Section 4(g) of the Purchase Agreement, fees and
expenses of one counsel to the Buyers, but excluding discounts, commissions, fees of underwriters, selling brokers, dealer managers
or similar securities industry professionals with respect to the Registrable Securities being sold.

 

(c)          Effectiveness.

 

(i)          The
Company shall use its reasonable best efforts to have the Registration Statement declared effective as soon as practicable. The
Company shall notify the Buyers by facsimile or e-mail as promptly as practicable, and in any event, within twenty-four (24) hours,
after any Registration Statement is declared effective and shall simultaneously provide the Buyers with copies of any related
Prospectus to be used in connection with the sale or other disposition of the securities covered thereby. If (A) a Registration
Statement covering the Registrable Securities is not declared effective by the SEC prior to the earlier of (i) five (5) Business
Days after the SEC shall have informed the Company that no review of the Registration Statement will be made or that the SEC has
no further comments on the Registration Statement or (ii) the 90th day after the Closing Date (the 120th
day if the SEC reviews the Registration Statement) (the “Effectiveness Deadline”) or
(B) after a Registration Statement has been declared effective by the SEC, sales cannot be made pursuant to such Registration
Statement for any reason (including without limitation by reason of a stop order, or the Company’s failure to update the
Registration Statement), other than because of (i) an Allowed Delay (as defined below) or (ii) the inability of any Buyer to sell
the Registrable Securities covered thereby due to market conditions, then
the Company will make pro rata payments to each Buyer, as liquidated damages and not as a penalty, in an amount equal to 1.5%
of the aggregate amount invested by such Buyer pursuant to the Purchase Agreement (or the purchase price of the Registrable Securities
purchased by any Person not an original party to this Agreement) for each 30-day period (or pro rata for any portion thereof)
following the Effectiveness Deadline (the “Blackout Period”). Such payments shall constitute the Buyers’
exclusive monetary remedy for such events, but shall not affect the right of the Buyers to seek injunctive relief. The amounts
payable as liquidated damages pursuant to this paragraph shall be paid monthly within three (3) Business Days of the last day
of each month following the commencement of the Blackout Period until the termination of the Blackout Period. Such payments shall
be made to each Buyer in cash.

 

    	-3-

    	 

    

 

(ii)         For
not more than twenty (20) consecutive days or for a total of not more than forty-five (45) days in any twelve (12) month period,
the Company may suspend the use of any Prospectus included in any Registration Statement contemplated by this Section in the event
that the Company determines in good faith that such suspension is necessary to (A) delay the disclosure of material non-public
information concerning the Company, the disclosure of which at the time is not, in the good faith opinion of the Company, in the
best interests of the Company or (B) amend or supplement the affected Registration Statement or the related Prospectus so that
such Registration Statement or Prospectus shall not include an untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements therein, in the case of the Prospectus in light of the circumstances
under which they were made, not misleading (an “Allowed Delay”); provided that the Company shall promptly
(a) notify each Buyer in writing of the commencement of an Allowed Delay, but shall not (without the prior written consent of an
Buyer) disclose to such Buyer any material non-public information giving rise to an Allowed Delay, (b) advise the Buyers in writing
to cease all sales under the Registration Statement until the end of the Allowed Delay and (c) use its reasonable best efforts
to terminate an Allowed Delay as promptly as practicable.

 

(d)          Rule
415; Cutback If at any time the SEC takes the position that the offering of some or all of the Registrable Securities in a
Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 under the 1933
Act or requires any Buyer to be named as an “underwriter”, the Company shall use its best efforts to persuade the SEC
that the offering contemplated by the Registration Statement is a valid secondary offering and not an offering “by or on
behalf of the issuer” as defined in Rule 415 and that none of the Buyers is an “underwriter”. The Buyers shall
have the right to participate or have their counsel participate in any meetings or discussions with the SEC regarding the SEC’s
position and to comment or have their counsel comment on any written submission made to the SEC with respect thereto. No such written
submission shall be made to the SEC to which the Buyers’ counsel reasonably objects. In the event that, despite the Company’s
best efforts and compliance with the terms of this Section 2(d), the SEC refuses to alter its position, the Company shall (i) remove
from the Registration Statement such portion of the Registrable Securities (the “Cut Back Shares”) and/or (ii)
agree to such restrictions and limitations on the registration and resale of the Registrable Securities as the SEC may require
to assure the Company’s compliance with the requirements of Rule 415 (collectively, the “SEC Restrictions”);
provided, however, that the Company shall not agree to name any Buyer as an “underwriter” in such
Registration Statement without the prior written consent of such Buyer. Any cut-back imposed on the Buyers pursuant to this Section
2(d) shall be allocated among the Buyers on a pro rata basis, unless the SEC Restrictions otherwise require or provide or the Buyers
otherwise agree. No liquidated damages shall accrue as to any Cut Back Shares until such date as the Company is able to effect
the registration of such Cut Back Shares in accordance with any SEC Restrictions (such date, the “Restriction Termination
Date” of such Cut Back Shares). From and after the Restriction Termination Date applicable to any Cut Back Shares, all
of the provisions of this Section 2 (including the liquidated damages provisions) shall again be applicable to such Cut Back Shares;
provided, however, that (i) the Filing Deadline for the Registration Statement including such Cut Back Shares shall
be ten (10) Business Days after such Restriction Termination Date, and (ii) the date by which the Company is required to obtain
effectiveness with respect to such Cut Back Shares under Section 2(c) shall be the 90th day immediately after the Restriction
Termination Date.

 

    	-4-

    	 

    

 

(e)          Right
to Piggyback Registration.

 

(i)          If
at any time following the date of this Agreement that any Registrable Securities remain outstanding (A) there is not one or more
effective Registration Statements covering all of the Registrable Securities and (B) the Company proposes for any reason to register
any shares of Common Stock under the 1933 Act (other than pursuant to a registration statement on Form S-4 or Form S-8 (or a similar
or successor form)) with respect to an offering of Common Stock by the Company for its own account or for the account of any of
its stockholders, it shall at each such time promptly give written notice to the holders of the Registrable Securities of its intention
to do so (but in no event less than thirty (30) days before the anticipated filing date) and, to the extent permitted under the
provisions of Rule 415 under the 1933 Act, include in such registration all Registrable Securities with respect to which the Company
has received written requests for inclusion therein within fifteen (15) days after receipt of the Company’s notice (a “Piggyback
Registration”). Such notice shall offer the holders of the Registrable Securities the opportunity to register such number
of shares of Registrable Securities as each such holder may request and shall indicate the intended method of distribution of such
Registrable Securities.

 

(ii)         Notwithstanding
the foregoing, (A) if such registration involves an underwritten public offering, the Buyers must sell their Registrable Securities
to, if applicable, the underwriter(s) at the same price and subject to the same underwriting discounts and commissions that apply
to the other securities sold in such offering (it being acknowledged that the Company shall be responsible for other expenses as
set forth in Section 2(b)) and subject to the Buyers entering into customary underwriting documentation for selling stockholders
in an underwritten public offering, and (B) if, at any time after giving written notice of its intention to register any Registrable
Securities pursuant to Section 2(e)(i) and prior to the effective date of the registration statement filed in connection with such
registration, the Company shall determine for any reason not to cause such registration statement to become effective under the
1933 Act, the Company shall deliver written notice to the Buyers and, thereupon, shall be relieved of its obligation to register
any Registrable Securities in connection with such registration; provided, however, that nothing contained
in this Section 2(e)(ii) shall limit the Company’s liabilities and/or obligations under this Agreement, including, without
limitation, the obligation to pay liquidated damages under this Section 2.

 

    	-5-

    	 

    

 

(iii)        If,
in connection with any underwritten public offering for the account of the Company or for stockholders of the Company that have
contractual rights to require the Company to register shares of Common Stock, the managing underwriter(s) thereof shall impose
a limitation on the number of shares of Common Stock which may be included in a Registration Statement because, in the judgment
of such underwriter(s), marketing or other factors dictate such limitation is necessary to facilitate such offering, then the Company
shall be obligated to include in the Registration Statement only such limited portion of the Registrable Securities with respect
to which each Buyer has requested inclusion hereunder as such underwriter(s) shall permit. Any exclusion of Registrable Securities
shall be made pro rata among the Buyers seeking to include Registrable Securities in a Registration Statement, in proportion to
the number of Registrable Securities sought to be included by such Buyers; provided, however, that the Company shall
not exclude any Registrable Securities unless the Company has first excluded all outstanding securities, the holders of which are
not entitled to inclusion of such securities in the Registration Statement or are not entitled to pro rata inclusion with the Registrable
Securities; and provided further that, after giving effect to the immediately preceding proviso, any exclusion of
Registrable Securities shall be made pro rata with holders of other securities having the right to include such securities in the
Registration Statement.

 

3.   
       Company Obligations. The Company will use its reasonable best efforts
to effect the registration of the Registrable Securities in accordance with the terms hereof, and pursuant thereto the
Company will, as expeditiously as possible:

 

(a)          use
its reasonable best efforts to cause such Registration Statement to become effective and to remain continuously effective for a
period that will terminate upon the earlier of (i) the date on which all Registrable Securities covered by such Registration Statement
as amended from time to time, have been sold, and (ii) the date on which all Registrable Securities covered by such Registration
Statement may be sold without restriction pursuant to Rule 144 by the holders thereof (the “Effectiveness Period”)
and advise the Buyers in writing when the Effectiveness Period has expired;

 

(b)          prepare
and file with the SEC such amendments and post-effective amendments to the Registration Statement and the Prospectus as may be
necessary to keep the Registration Statement effective for the Effectiveness Period and to comply with the provisions of the 1933
Act and the 1934 Act with respect to the distribution of all of the Registrable Securities covered thereby;

 

(c)          provide
copies to and permit counsel designated by the Buyers to review each Registration Statement and all amendments and supplements
thereto no fewer than seven (7) days prior to their filing with the SEC and not file any document to which such counsel reasonably
objects;

 

(d)          furnish
to the Buyers and their legal counsel (i) promptly after the same is prepared and publicly distributed, filed with the SEC, or
received by the Company (but not later than two (2) Business Days after the filing date, receipt date or sending date, as the case
may be) one (1) copy of any Registration Statement and any amendment thereto, each preliminary prospectus and Prospectus and each
amendment or supplement thereto, and each letter written by or on behalf of the Company to the SEC or the staff of the SEC, and
each item of correspondence from the SEC or the staff of the SEC, in each case relating to such Registration Statement (other than
any portion of any thereof which contains information for which the Company has sought confidential treatment), and (ii) such number
of copies of a Prospectus, including a preliminary prospectus, and all amendments and supplements thereto and such other documents
as each Buyer may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such Buyer that
are covered by the related Registration Statement;

 

    	-6-

    	 

    

 

(e)          use
its reasonable best efforts to (i) prevent the issuance of any stop order or other suspension of effectiveness and, (ii) if such
order is issued, obtain the withdrawal of any such order at the earliest possible moment;

 

(f)          prior
to any public offering of Registrable Securities, use its reasonable best efforts to register or qualify or cooperate with the
Buyers and their counsel in connection with the registration or qualification of such Registrable Securities for offer and sale
under the securities or blue sky laws of such jurisdictions requested by the Buyers and do any and all other commercially reasonable
acts or things necessary or advisable to enable the distribution in such jurisdictions of the Registrable Securities covered by
the Registration Statement; provided,
however, that the Company shall not be required in connection therewith or as a condition thereto to (i) qualify to do
business in any jurisdiction where it would not otherwise be required to qualify but for this Section 3(f), (ii) subject itself
to general taxation in any jurisdiction where it would not otherwise be so subject but for this Section 3(f), or (iii) file a
general consent to service of process in any such jurisdiction;

 

(g)          use
its reasonable best efforts to cause all Registrable Securities covered by a Registration Statement to be listed on each securities
exchange, interdealer quotation system or other market on which similar securities issued by the Company are then listed;

 

(h)          immediately
notify the Buyers, at any time prior to the end of the Effectiveness Period, upon discovery that, or upon the happening of any
event as a result of which, the Prospectus includes an untrue statement of a material fact or omits to state any material fact
required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing,
and promptly prepare, file with the SEC and furnish to such holder a supplement to or an amendment of such Prospectus as may be
necessary so that such Prospectus shall not include an untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing;

 

(i)          otherwise
use its reasonable best efforts to comply with all applicable rules and regulations of the SEC under the 1933 Act and the 1934
Act, including, without limitation, Rule 172 under the 1933 Act, file any final Prospectus, including any supplement or amendment
thereof, with the SEC pursuant to Rule 424 under the 1933 Act, promptly inform the Buyers in writing if, at any time during the
Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Buyers are
required to deliver a Prospectus in connection with any disposition of Registrable Securities and take such other actions as may
be reasonably necessary to facilitate the registration of the Registrable Securities hereunder; and make available to its security
holders, as soon as reasonably practicable, but not later than the Availability Date (as defined below), an earnings statement
covering a period of at least twelve (12) months, beginning after the effective date of each Registration Statement, which earnings
statement shall satisfy the provisions of Section 11(a) of the 1933 Act, including Rule 158 promulgated thereunder (for the purpose
of this subsection 3(i), “Availability Date” means the 45th day following the end of the fiscal quarter
that includes the effective date of such Registration Statement, except that, if quarter is the last quarter of the Company’s
fiscal year, “Availability Date” means the 90th day after the end of such fiscal year); and

 

    	-7-

    	 

    

 

(j)          with
a view to making available to the Buyers the benefits of Rule 144 (or its successor rule) and any other rule or regulation of the
SEC that may at any time permit the Buyers to sell Registrable Securities to the public without registration, the Company covenants
and agrees to: (i) make and keep public information available, as those terms are understood and defined in Rule 144, until the
earlier of (A) six months after such date as all of the Registrable Securities may be sold without restriction by the holders thereof
pursuant to Rule 144 or any other rule of similar effect or (B) such date as all of the Registrable Securities shall have been
resold; (ii) file with the SEC in a timely manner all reports and other documents required of the Company under the 1934 Act; and
(iii) furnish to each Buyer upon request, as long as such Buyer owns any Registrable Securities, (A) a written statement by the
Company that it has complied with the reporting requirements of the 1934 Act, (B) a copy of the Company’s most recent Annual
Report on Form 10-K or Quarterly Report on Form 10-Q, and (C) such other information as may be reasonably requested in order to
avail such Buyer of any rule or regulation of the SEC that permits the selling of any such Registrable Securities without registration.

 

4.            Due
Diligence Review; Information. The Company shall make available, during normal business hours, for inspection and review by
the Buyers, advisors to and representatives of the Buyers (who may or may not be affiliated with the Buyers and who are reasonably
acceptable to the Company), all financial and other records, all SEC Filings (as defined in the Purchase Agreement) and other filings
with the SEC, and all other corporate documents and properties of the Company as may be reasonably necessary for the purpose of
such review, and cause the Company’s officers, directors and employees, within a reasonable time period, to supply all such
information reasonably requested by the Buyers or any such representative, advisor or underwriter in connection with such Registration
Statement (including, without limitation, in response to all questions and other inquiries reasonably made or submitted by any
of them), prior to and from time to time after the filing and effectiveness of the Registration Statement for the sole purpose
of enabling the Buyers and such representatives, advisors and underwriters and their respective accountants and attorneys to conduct
initial and ongoing due diligence with respect to the Company and the accuracy of such Registration Statement; provided,
however, that the Company shall not disclose material nonpublic information to the Buyers, or to advisors to or representatives
of the Buyers, unless prior to disclosure of such information the Company identifies such information as being material nonpublic
information and provides the Buyers, such advisors and representatives with the opportunity to accept or refuse to accept such
material nonpublic information for review and any Buyer wishing to obtain such information enters into an appropriate confidentiality
agreement with the Company with respect thereto.

 

5.            Obligations
of the Buyers.

 

(a)          Each
Buyer shall furnish in writing to the Company such information regarding itself, the Registrable Securities held by it and the
intended method of disposition of the Registrable Securities held by it, as shall be reasonably required to effect the registration
of such Registrable Securities and shall execute such documents in connection with such registration as the Company may reasonably
request. At least five (5) Business Days prior to the first anticipated filing date of any Registration Statement, the Company
shall notify each Buyer of the information the Company requires from such Buyer if such Buyer elects to have any of the Registrable
Securities included in the Registration Statement. An Buyer shall provide such information to the Company at least two (2) Business
Days prior to the first anticipated filing date of such Registration Statement if such Buyer elects to have any of the Registrable
Securities included in the Registration Statement.

 

    	-8-

    	 

    

 

 

(b)          Each
Buyer, by its acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably requested by the Company
in connection with the preparation and filing of a Registration Statement hereunder, unless such Buyer has notified the Company
in writing of its election to exclude all of its Registrable Securities from such Registration Statement.

 

(c)          Each
Buyer agrees that, upon receipt of any notice from the Company of either (i) the commencement of an Allowed Delay pursuant to Section
2(c)(ii) or (ii) the happening of an event pursuant to Section 3(h) hereof, such Buyer will immediately discontinue disposition
of Registrable Securities pursuant to the Registration Statement covering such Registrable Securities, until the Buyer is advised
by the Company that such dispositions may again be made.

 

6.            Indemnification.

 

(a)          Indemnification
by the Company. The Company will indemnify and hold harmless each Buyer and its officers, directors, members, employees and
agents, successors and assigns, and each other Person, if any, who controls such Buyer within the meaning of the 1933 Act, against
any losses, claims, damages or liabilities, joint or several, to which they may become subject under the 1933 Act or otherwise,
insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon: (i) any
untrue statement or alleged untrue statement or omission or alleged omission of any material fact contained in any Registration
Statement, any preliminary Prospectus or final Prospectus, or any amendment or supplement thereof; (ii) any blue sky application
or other document executed by the Company specifically for that purpose or based upon written information furnished by the Company
filed in any state or other jurisdiction in order to qualify any or all of the Registrable Securities under the securities laws
thereof (any such application, document or information herein called a “Blue Sky Application”); (iii) the omission
or alleged omission to state in a Blue Sky Application a material fact required to be stated therein or necessary to make the statements
therein not misleading; (iv) any violation by the Company or its agents of any rule or regulation promulgated under the 1933 Act
applicable to the Company or its agents and relating to action or inaction required of the Company in connection with such registration;
or (v) any failure to register or qualify the Registrable Securities included in any such Registration Statement in any state where
the Company or its agents has affirmatively undertaken or agreed in writing that the Company will undertake such registration or
qualification on an Buyer’s behalf and will reimburse such Buyer, and each such officer, director or member and each such
controlling Person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any
such loss, claim, damage, liability or action; provided, however, that the Company will not be liable in any such
case if and to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or
alleged untrue statement or omission or alleged omission so made in conformity with information furnished by such Buyer or any
such controlling Person in writing specifically for use in such Registration Statement or Prospectus.

 

    	-9-

    	 

    

 

(b)          Indemnification
by the Buyers. Each Buyer agrees, severally but not jointly, to indemnify and hold harmless, to the fullest extent permitted
by law, the Company, its directors, officers, employees, stockholders and each Person who controls the Company (within the meaning
of the 1933 Act) against any losses, claims, damages, liabilities and expense (including reasonable attorney fees) resulting from
any untrue statement of a material fact or any omission of a material fact required to be stated in the Registration Statement
or Prospectus or preliminary Prospectus or amendment or supplement thereto or necessary to make the statements therein not misleading,
to the extent, but only to the extent that such untrue statement or omission is contained in any information furnished in writing
by such Buyer to the Company specifically for inclusion in such Registration Statement or Prospectus or amendment or supplement
thereto. In no event shall the liability of an Buyer be greater in amount than the dollar amount of the proceeds (net of all expenses
paid by such Buyer in connection with any claim relating to this Section 6 and the amount of any damages such Buyer has otherwise
been required to pay by reason of such untrue statement or omission) received by such Buyer upon the sale of the Registrable Securities
included in the Registration Statement giving rise to such indemnification obligation.

 

(c)          Conduct
of Indemnification Proceedings. Any Person entitled to indemnification hereunder shall (i) give prompt notice to the indemnifying
party of any claim with respect to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense
of such claim with counsel reasonably satisfactory to the indemnified party; provided that any Person entitled to indemnification
hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses
of such counsel shall be at the expense of such Person unless (a) the indemnifying party has agreed to pay such fees or expenses,
or (b) the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory
to such Person or (c) in the reasonable judgment of any such Person, based upon written advice of its counsel, a conflict of interest
exists between such Person and the indemnifying party with respect to such claims (in which case, if the Person notifies the indemnifying
party in writing that such Person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying
party shall not have the right to assume the defense of such claim on behalf of such Person); and provided, further,
that the failure of any indemnified party to give notice as provided herein shall not relieve the indemnifying party of its obligations
hereunder, except to the extent that such failure to give notice shall materially adversely affect the indemnifying party in the
defense of any such claim or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding
in the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for all such indemnified
parties. No indemnifying party will, except with the consent of the indemnified party, consent to entry of any judgment or enter
into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified
party of a release from all liability in respect of such claim or litigation.

 

    	-10-

    	 

    

 

(d)          Contribution.
If for any reason the indemnification provided for in the preceding paragraphs (a) and (b) is unavailable to an indemnified party
or insufficient to hold it harmless, other than as expressly specified therein, then the indemnifying party shall contribute to
the amount paid or payable by the indemnified party as a result of such loss, claim, damage or liability in such proportion as
is appropriate to reflect the relative fault of the indemnified party and the indemnifying party, as well as any other relevant
equitable considerations. No Person guilty of fraudulent misrepresentation within the meaning of Section 11(f) of the 1933 Act
shall be entitled to contribution from any Person not guilty of such fraudulent misrepresentation. In no event shall the contribution
obligation of a holder of Registrable Securities be greater in amount than the dollar amount of the proceeds (net of all expenses
paid by such holder in connection with any claim relating to this Section 6 and the amount of any damages such holder has otherwise
been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission) received by it upon
the sale of the Registrable Securities giving rise to such contribution obligation.

 

7.            Miscellaneous.

 

(a)          Amendments
and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either
generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company
and the Required Buyers. Any amendment or waiver effected in accordance with this Section 7(a) shall be binding upon each holder
of any Registrable Securities at the time outstanding, each future holder of any Registrable Securities, and the Company. The Company
may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company shall
have obtained the written consent to such amendment, action or omission to act, of the Required Buyers.

 

(b)          Notices.
All notices and other communications provided for or permitted hereunder shall be made as set forth in Section 9(f) of the Purchase
Agreement.

 

(c)          Assignments
and Transfers by Buyers. The provisions of this Agreement shall be binding upon and inure to the benefit of the Buyers and
their respective successors and assigns. An Buyer may transfer or assign, in whole or from time to time in part, to one or more
Persons its rights hereunder in connection with the transfer of Registrable Securities by such Buyer to such Person, provided that
such Buyer complies with all laws applicable thereto and provides written notice of assignment to the Company promptly after such
assignment is effected.

 

(d)          Assignments
and Transfers by the Company. This Agreement may not be assigned by the Company (whether by operation of law or otherwise)
without the prior written consent of the Required Buyers, provided, however, that in the event that the Company is
a party to a merger, consolidation, share exchange or similar business combination transaction in which the Common Stock is converted
into the equity securities of another Person, from and after the effective time of such transaction, such Person shall, by virtue
of such transaction, be deemed to have assumed the obligations of the Company hereunder, the term “Company” shall be
deemed to refer to such Person and the term “Registrable Securities” shall be deemed to include the securities received
by the Buyers in connection with such transaction unless such securities are otherwise freely tradable by the Buyers after giving
effect to such transaction.

 

    	-11-

    	 

    

 

(e)          Benefits
of the Agreement. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective
permitted successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any
party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities
under or by reason of this Agreement, except as expressly provided in this Agreement.

 

(f)          Counterparts;
Facsimile. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. The exchange of copies of this Agreement and of signature pages by
facsimile or PDF transmission shall constitute effective execution and delivery of this Agreement as to the Parties and may be
used in lieu of an original of this Agreement for all purposes. Signatures of the Parties transmitted by facsimile or PDF transmission
shall be deemed to be their original signatures for all purposes.

 

(g)          Titles
and Subtitles; Construction. The titles and subtitles used in this Agreement are used for convenience only. They form no part
of this Agreement and shall not affect its construction or interpretation. All references to Sections, subsections, paragraphs,
clauses or other subdivisions in this Agreement refer to the corresponding Sections, subsections, paragraphs, clauses or other
subdivisions of this Agreement. All words used in this Agreement shall be construed to be of such gender or number as the circumstances
require. As used in this Agreement, the words “hereby”, “herein”, hereof”, “hereunder”
and words of similar import refer to this Agreement as a whole and not to any particular provision of this Agreement.

 

(h)          Severability.
Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective
to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted
as if it were written so as to be enforceable to the maximum extent permitted by applicable law, and any such prohibition or unenforceability
in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent permitted
by applicable law, the parties hereby waive any provision of law which renders any provisions hereof prohibited or unenforceable
in any respect.

 

(i)          Further
Assurances. The parties shall execute and deliver all such further instruments and documents and take all such other actions
as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements
herein contained.

 

(j)          Entire
Agreement. This Agreement and the Purchase Agreement, together with its Exhibits and Disclosure Schedules, constitute the entire
agreement among the parties hereof with respect to the subject matter hereof and thereof and supersede all prior agreements and
understandings, both oral and written, between the parties with respect to the subject matter hereof and thereof.

 

    	-12-

    	 

    

 

(k)          Governing
Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by, and construed in accordance with,
the internal laws of the State of New York without regard to the choice of law principles thereof. Each of the parties hereto irrevocably
submits to the exclusive jurisdiction of the courts of the State of New York located in New York County and the United States District
Court for the Southern District of New York for the purpose of any suit, action, proceeding or judgment relating to or arising
out of this Agreement and the transactions contemplated hereby. Service of process in connection with any such suit, action or
proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices
under this Agreement. Each of the parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action
or proceeding and to the laying of venue in such court. Each party hereto irrevocably waives any objection to the laying of venue
of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding
brought in any such court has been brought in an inconvenient forum.  EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST
A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS
TO THIS WAIVER.

 

[Signature Pages Follow]

 

    	-13-

    	 

    

 

IN WITNESS WHEREOF,
the parties have executed this Agreement or caused their duly authorized officers to execute this Agreement as of the date first
above written.

 

	The Company:	CRUMBS BAKE SHOP, INC.
	 	 	 	 
	 	By:	 	 
	 	Name:	Julian Geiger
	 	Title:	Chief Executive Officer

 

[Buyer Signature Page Immediately Follows]

 

    	-14-

    	 

    

 

Counterpart
Signature Page

 

	FOR ENTITY INVESTORS:	 	FOR INDIVIDUAL INVESTORS:
	 	 	 	 
	 	 	Signature:	 
	[Name of Entity]	 	Name:	 

 

	By:	 	 
	Name:	 	 
	Title:	 	 

 

    	-15-

    	 

    

 

Exhibit A

 

Plan of Distribution

 

    	 

    	 

    

 

EXHIBIT C

FORM OF GUARANTY

 

GUARANTY

 

This Guaranty (the
“Guaranty”) is made as of [__________], 2013, by such guarantors listed on the signature pages hereof (collectively,
jointly and severally, “Guarantors,” and each, individually, a “Guarantor”), in favor of
each of the investors listed on the Schedule of Buyers attached to the Securities Purchase Agreement (as defined herein) (each,
individually, a “Buyer” and together with their respective successors, assigns, endorsees and transferees, the
“Buyers”).

 

RECITALS

 

WHEREAS, pursuant
to the Securities Purchase Agreements, dated as of April [25], 2013 (as amended, restated, supplemented, or otherwise modified
from time to time, including all schedules thereto, collectively, the “Securities Purchase Agreement”),
by and among Crumbs Bake Shop, Inc., a Delaware corporation (“Parent”), and each of the Buyers, Parent has sold,
and Buyers have purchased, severally and not jointly, up to $10,000,000 principal amount of Notes;

 

WHEREAS, each
Guarantor is a direct or indirect Subsidiary of Parent and will receive direct and substantial benefits from the purchase by Buyers
of the Notes;

 

WHEREAS, in
order to induce Buyers to purchase, severally and not jointly, the Notes as provided for in the Securities Purchase Agreement,
Parent has agreed to cause its future Subsidiaries to jointly and severally guaranty all of Parent’s obligations under and
with respect to the Notes, the Securities Purchase Agreement and the other Transaction Documents.

 

AGREEMENTS

 

NOW, THEREFORE,
for and in consideration of the recitals made above and other good and valuable consideration, the receipt, sufficiency and adequacy
of which are hereby acknowledged, each Guarantor hereby agrees as follows:

 

1.          Definitions.
All capitalized terms used herein that are not otherwise defined herein shall have the meanings given them in the Securities Purchase
Agreement.

 

2.          Guaranteed
Obligations. Guarantors jointly and severally hereby fully, irrevocably and unconditionally
guaranty to Buyers the due and punctual Satisfaction in Full of the Guaranteed Obligations (as defined below). “Guaranteed
Obligations” means, collectively, all of the present and future payment obligations of each Obligor arising under the
Securities Purchase Agreement, any and all Notes payable to Buyer and the other Transaction Documents, including, without limitation,
reasonable attorneys’ fees and expenses and any interest, fees, or expenses that accrue after the filing of an Insolvency
Proceeding, regardless of whether allowed or allowable in whole or in part as a claim in any Insolvency Proceeding. “Insolvency
Proceeding” means any proceeding commenced by or against any Person under any provision of title 11 of the United States
Code, as in effect from time to time (the “Bankruptcy Code”), or under any other state or federal bankruptcy
or insolvency law or any equivalent laws in any other jurisdiction, assignments for the benefit of creditors, formal or informal
moratoria, compositions, extensions generally with creditors, or proceedings seeking reorganization, arrangement, or other similar
relief.

 

    	 

    	 

    

 

3.          Guarantors’
Representations and Warranties. Each Guarantor represents and warrants to Buyers that
such Guarantor has received or expects to derive substantial benefits from the Notes purchased under the Securities Purchase Agreement
and the other transactions contemplated hereby and by the other Transaction Documents. Buyers may rely conclusively on a continuing
warranty, hereby made, that such Guarantor continues to be benefited by this Guaranty and Buyers shall have no duty to inquire
into or confirm the receipt of any such benefits, and this Guaranty shall be effective and enforceable by Buyers without regard
to the receipt, nature or value of any such benefits.

 

4.          Unconditional
Nature. No act or thing need occur to establish any Guarantor’s liability hereunder,
and no act or thing, except Satisfaction in Full of the Guaranteed Obligations (as defined below), shall in any way exonerate any
Guarantor hereunder or modify, reduce, limit or release any Guarantor’s liability hereunder. This is an absolute, unconditional
and continuing guaranty of payment of the Guaranteed Obligations and shall continue to be in force and be binding upon each Guarantor
until Satisfaction in Full of the Guaranteed Obligations. Each Guarantor agrees that this Guaranty is a guaranty of Satisfaction
in Full of the Guaranteed Obligations and not of collection, and that its obligations under this Guaranty shall be primary, absolute
and unconditional.  In addition to the terms set forth herein, it is expressly understood and agreed that, if, at maturity
and at any time during the continuance of an Event of Default (as defined in the Notes), the outstanding amount of the Guaranteed
Obligations under the Transaction Documents (including, without limitation, all accrued interest thereon, all accrued late charges
thereon and all premiums due in respect thereof) is declared to be immediately due and payable, then Guarantors shall, within ten
(10) days after notice of such acceleration, without further demand, pay to each Buyer the entire outstanding portion of the Guaranteed
Obligations that is due and owing to such Buyer.

 

5.          Subrogation.
No Guarantor will exercise or enforce any right of contribution, reimbursement, recourse or subrogation available to such Guarantor
as to any of the Guaranteed Obligations, or against any Person liable therefor, or as to any collateral security therefor, unless
and until Satisfaction in Full of the Guaranteed Obligations.

 

6.          Enforcement
Expenses. Each Guarantor shall pay or reimburse each Buyer for all costs, expenses
and reasonable attorneys’ fees paid or incurred by such Buyer in endeavoring to collect and enforce the Guaranteed Obligations
and in enforcing this Guaranty.

 

    	2

    	 

    

 

7.          Obligations
Absolute. Each Guarantor agrees that its obligations hereunder are irrevocable, absolute,
independent and unconditional and shall not be affected by any circumstance which constitutes a legal or equitable discharge of
a guarantor or surety other than Satisfaction in Full of the Guaranteed Obligations. In furtherance of the foregoing and without
limiting the generality thereof, each Guarantor agrees that none of its obligations hereunder shall be affected or impaired by
any of the following acts or things (which each Buyer is expressly authorized to do, omit or suffer from time to time, without
consent or approval by or notice to any Guarantor): (a) any acceptance of collateral security, guarantors, accommodation parties
or sureties for any or all of the Guaranteed Obligations; (b) one or more extensions or renewals of the Guaranteed Obligations
(whether or not for longer than the original period) or any modification of the interest rates, maturities, if any, or other contractual
terms applicable to any of the Guaranteed Obligations or any amendment or modification of any of the terms or provisions of any
of the Transaction Documents; (c) any waiver or indulgence granted to Parent or any other Obligor, any delay or lack of diligence
in the enforcement of the Guaranteed Obligations, or any failure to institute proceedings, file a claim, give any required notices
or otherwise protect any of the Guaranteed Obligations; (d) any full or partial release of, compromise or settlement with,
or agreement not to sue, Parent, any other Obligor or any other Person liable in respect of any of the Guaranteed Obligations;
(e) any release, surrender, cancellation or other discharge of any evidence of the Guaranteed Obligations or the acceptance
of any instrument in renewal or substitution therefor; (f) any failure to obtain collateral security (including rights of
setoff) for the Guaranteed Obligations, or to see to the proper or sufficient creation and perfection thereof, or to establish
the priority thereof, or to preserve, protect, insure, care for, exercise or enforce any collateral security; or any modification,
alteration, substitution, exchange, surrender, cancellation, termination, release or other change, impairment, limitation, loss
or discharge of any collateral security; (g) any collection, sale, lease or disposition of, or any other foreclosure or enforcement
of or realization on, any collateral security; (h) any assignment, pledge or other transfer of any of the Guaranteed Obligations
or any evidence thereof; or (i) any manner, order or method of application of any payments or credits upon the Guaranteed
Obligations. Each Guarantor waives any and all defenses and discharges available to a surety, guarantor or accommodation co-obligor.

 

8.          Waivers
by Guarantors. Each Guarantor waives any and all defenses, claims, setoffs and discharges
of, and/or against, Parent, or any other Obligor or Person (including, without limitation, Buyer), pertaining to the Guaranteed
Obligations, except the defense of discharge by indefeasible satisfaction and discharge in full. Without limiting the generality
of the foregoing, no Guarantor will assert, plead or enforce against any Buyer any defense of waiver, release, discharge or disallowance
in any Insolvency Proceeding, statute of limitations, res judicata, statute of frauds, anti-deficiency statute, fraud, incapacity,
minority, usury, illegality or unenforceability which may be available to Parent or any other Obligor or Person liable in respect
of any of the Guaranteed Obligations, or any setoff available to any Buyer against Parent or any other such Obligor or Person,
whether or not on account of a related transaction. Each Guarantor expressly agrees that such Guarantor shall be and remain liable
for any deficiency remaining after foreclosure of any mortgage or security interest securing the Guaranteed Obligations, whether
or not the liability of Parent or any other Obligor or Person for such deficiency is discharged pursuant to statute or judicial
decision. The liability of each Guarantor shall not be affected or impaired by, and each Guarantor waives and agrees it shall not
at any time insist upon, plead or in any manner claim or take the benefit of, any voluntary or involuntary liquidation, dissolution,
sale or other disposition of all or substantially all of the assets, marshalling of assets and liabilities, any valuation, appraisal,
stay, receivership, insolvency, bankruptcy, assignment for the benefit of creditors, reorganization, arrangement, composition or
readjustment of, or other similar event or proceeding affecting, Parent or any of its assets. No Guarantor will assert, plead or
enforce against any Buyer any claim, defense or setoff available to such Guarantor against Parent. Except as otherwise provided
herein, each Guarantor waives presentment, demand for payment, notice of dishonor or nonpayment and protest of any instrument evidencing
the Guaranteed Obligations. Buyers shall not be required first to resort for payment of the Guaranteed Obligations to Parent or
any other Person, or their properties, or first to enforce, realize upon or exhaust any collateral security for the Guaranteed
Obligations, before enforcing this Guaranty.

 

    	3

    	 

    

 

9.  
        If Payments Set Aside, etc.
If any payment applied by a Buyer to the Guaranteed Obligations is thereafter set aside, recovered, rescinded or required to
be returned for any reason (including, without limitation, the bankruptcy, insolvency or reorganization of Parent or any
other Obligor or Person), the Guaranteed Obligations to which such payment was applied shall for the purpose of this Guaranty
be deemed to have continued in existence, notwithstanding such application, and this Guaranty shall be enforceable as to such
Guaranteed Obligations as fully as if such application had never been made.

 

10.     
   Additional Obligation of Guarantors. Each
Guarantor’s liability under this Guaranty is in addition to and shall be cumulative with all other liabilities of such
Guarantor to Buyers as guarantor, surety, endorser, accommodation co-obligor or otherwise of any of the Guaranteed
Obligations, without any limitation as to amount.

 

11.  
      No Duties Owed by Buyer. Each
Guarantor acknowledges and agrees that Buyers (a) have not made any representations or warranties with respect to,
(b) do not assume any responsibility to such Guarantor for, and (c) have no duty to provide information to such
Guarantor regarding, the enforceability of any of the Guaranteed Obligations or the financial condition of Parent or any
other Obligor or Person. Each Guarantor has independently determined the creditworthiness of Parent and the enforceability of
the Guaranteed Obligations and until Satisfaction in Full of the Guaranteed Obligations will independently, and without
reliance on any Buyer, continues to make such determinations.

 

12.   
     Miscellaneous.

 

(a)          This
Guaranty may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and
shall become effective when counterparts have been signed by each party and delivered to the other party. In the event that any
signature is delivered by facsimile transmission or by an e-mail which contains a portable document format (.pdf) file of an executed
signature page, such signature page shall create a valid and binding obligation of the party executing (or on whose behalf such
signature is executed) with the same force and effect as if such signature page were an original thereof. Any party delivering
an executed counterpart of this Guaranty by facsimile or other electronic method of transmission also shall deliver an original
executed counterpart of this Guaranty but the failure to deliver an original executed counterpart shall not affect the validity,
enforceability, and binding effect of this Guaranty.

 

(b)          Any
provision of this Guaranty which is prohibited or unenforceable shall be ineffective to the extent of such prohibition or unenforceability
without invalidating the remaining provisions hereof in that jurisdiction or affecting the validity or enforceability of such provision
in any other jurisdiction.

 

(c)          Headings
used in this Guaranty are for convenience only and shall not be used in connection with the interpretation of any provision hereof.

 

    	4

    	 

    

 

(d)          The
pronouns used herein shall include, when appropriate, either gender and both singular and plural, and the grammatical construction
of sentences shall conform thereto.

 

(e)          Unless
the context of this Guaranty or any other Transaction Document clearly requires otherwise, references to the plural include the
singular, references to the singular include the plural, the terms “includes” and “including” are not limiting,
and the term “or” has, except where otherwise indicated, the inclusive meaning represented by the phrase “and/or.”
The words “hereof,” “herein,” “hereby,” “hereunder,” and similar terms in this
Guaranty or any other Transaction Document refer to this Guaranty or such other Transaction Document, as the case may be, as a
whole and not to any particular provision of this Guaranty or such other Transaction Document, as the case may be. Section, subsection,
clause, schedule, and exhibit references herein are to this Guaranty unless otherwise specified. Any reference in this Guaranty
or in any other Transaction Document to any agreement, instrument, or document shall include all alterations, amendments, changes,
extensions, modifications, renewals, replacements, substitutions, joinders, and supplements, thereto and thereof, as applicable
(subject to any restrictions on such alterations, amendments, changes, extensions, modifications, renewals, replacements, substitutions,
joinders, and supplements set forth herein). “Satisfaction in Full of the Guaranteed Obligations”
shall mean the indefeasible payment in full in cash and discharge, or other satisfaction in accordance with the terms of the Transaction
Documents and discharge, of all Guaranteed Obligations in full.

 

(f)          This
Guaranty shall become effective as to each Guarantor upon execution by such Guarantor and delivery to each Buyer, without further
act, condition or acceptance by such Buyer, and shall be binding upon each such Guarantor and the successors and assigns of each
such Guarantor, and shall inure to the benefit of each Buyer and its participants, successors and assigns. This Guaranty may not
be waived, modified, amended, terminated, released or otherwise changed except by a writing signed by each Guarantor and each Buyer.

 

(g)          The
language used in this Guaranty will be deemed to be the language chosen by the parties to express their mutual intent, and no rules
of strict construction will be applied against any party. For clarification purposes, the Recitals are part of this Guaranty.

 

(h)          All
dollar amounts referred to in this Guaranty and the other Transaction Documents (as defined in the Securities Purchase Agreement)
are in United States Dollars (“U.S. Dollars”), and all amounts owing under
this Guaranty and all other Transaction Documents shall be paid in U.S. Dollars. All amounts denominated in other currencies shall
be converted into the U.S. Dollar equivalent amount in accordance with the Exchange Rate on the date of calculation. “Exchange
Rate” means, in relation to any amount of currency to be converted into U.S. Dollars pursuant
to this Guaranty, the U.S. Dollar exchange rate as published in the Wall Street Journal on the relevant date of calculation.

 

    	5

    	 

    

 

(i)          Judgment
Currency.

 

(i)          If
for the purpose of obtaining or enforcing judgment against any Guarantor in any court in any jurisdiction it becomes necessary
to convert into any other currency (such other currency being hereinafter in this Section 12(i) referred to as the “Judgment
Currency”) an amount due in U.S. Dollars under this Guaranty or any other Transaction Document, the conversion shall
be made at the Exchange Rate prevailing on the Trading Day (as defined in the Note) immediately preceding: (1) the date actual
payment of the amount due, in the case of any proceeding in the courts of New York or in the courts of any other jurisdiction that
will give effect to such conversion being made on such date or (2) the date on which the foreign court determines, in the case
of any proceeding in the courts of any other jurisdiction (the date as of which such conversion is made pursuant to this Section
12(i)(i) being hereinafter referred to as the “Judgment Conversion Date”).

 

(ii)         If
in the case of any proceeding in the court of any jurisdiction referred to in Section 12(i)(i) above, there is a change in the
Exchange Rate prevailing between the Judgment Conversion Date and the date of actual payment of the amount due, the applicable
party shall pay such adjusted amount as may be necessary to ensure that the amount paid in the Judgment Currency, when converted
at the Exchange Rate prevailing on the date of payment, will produce the amount of U.S. Dollars which could have been purchased
with the amount of Judgment Currency stipulated in the judgment or judicial order at the Exchange Rate prevailing on the Judgment
Conversion Date.

 

(iii)        Any
amount due from any Guarantor under this provision shall be due as a separate debt and shall not be affected by judgment being
obtained for any other amounts due under or in respect of this Guaranty or any other Transaction Document.

 

(j)          Taxes.

 

(i)          Any
and all payments by any Guarantor hereunder or under any other Transaction Document shall be made free and clear of and without
deduction for any and all present or future taxes, levies, imposts, deductions, charges or withholdings, and all liabilities with
respect thereto, imposed under any applicable law (collectively referred to as “Taxes”) unless the applicable
Guarantor is required to withhold or deduct any amounts for, or on account of, Taxes pursuant to any applicable law. If such Guarantor
shall be required to withhold or deduct any Taxes from or in respect of any sum payable hereunder to Buyer, (i) the sum payable
shall be increased by the amount by which the sum payable would otherwise have to be increased (the “tax make-whole amount”)
to ensure that after making all required withholdings and deductions (including deductions applicable to the tax make-whole amount)
each Buyer would receive an amount equal to the sum it would have received had no such deductions been made, (ii) such Guarantor
shall make such deductions and (iii) such Guarantor shall pay the full amount withheld or deducted to the relevant governmental
authority within the time required.

 

    	6

    	 

    

 

(ii)         In
addition, each Guarantor agrees to pay to the relevant governmental authority in accordance with applicable law any present or
future stamp or documentary taxes or any other excise or property taxes, charges or similar levies that arise from any payment
made hereunder or in connection with the execution, delivery, registration or performance of, or otherwise with respect to, this
Guaranty and the other Transaction Documents (“Other Taxes”).

 

(iii)        Each
Guarantor shall deliver to Buyers official receipts, if any, in respect of any Taxes and Other Taxes payable hereunder promptly
after payment of such Taxes and Other Taxes or other evidence of payment reasonably acceptable to Buyer.

 

(iv)        If
a Guarantor fails to pay any amounts in accordance with this Section 12(j), such Guarantor
shall indemnify Buyers within ten (10) calendar days after written demand therefor, for the full amount of any Taxes or Other Taxes,
plus any related interest or penalties, that are paid by Buyers to the relevant governmental authority or other relevant governmental
authority as a result of such failure.

 

(v)         The
obligations of each Guarantor under this Section 12(j) shall survive the termination of this
Guaranty and the Satisfaction in Full of the Guaranteed Obligations.

 

13.         Notices.
All notices and other communications provided for hereunder shall be given in the form and manner, and delivered to such addresses,
as specified in the Securities Purchase Agreement.

 

14.         Governing
Law; Jurisdiction; Service of Process; Jury Trial. All questions concerning the construction,
validity, enforcement and interpretation of this Guaranty shall be governed by the internal laws of the State of New York, without
giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions)
that would cause the application of the laws of any jurisdictions other than the State of New York. Each Guarantor hereby irrevocably
submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan, for
the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein,
and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that
the venue of such suit, action or proceeding is improper; provided, however, any suit seeking enforcement of this Guaranty may
be brought, at a Buyer’s option, in the courts of any jurisdiction where such Buyer elects to bring such action. Each Guarantor
hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
by mailing a copy thereof to such party at the address for such notices to it under this Guaranty and agrees that such service
shall constitute good and sufficient service of process and notice thereof. Without limitation of the foregoing, each Guarantor
hereby irrevocably appoints Parent as such Guarantor’s agent for purposes of receiving and accepting any service of process
hereunder. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.
EACH GUARANTOR HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION
OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

  

[signature page follows]

 

    	7

    	 

    

 

IN
WITNESS WHEREOF, this Guaranty has been duly executed by each Guarantor as of the date set
forth above.

 

	 	CRUMBS HOLDINGS LLC, a Delaware limited liability company
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 
	 	 	 
	 	[_______________], a [________] corporation
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 

 

    	 

    	 

    

 

EXHIBIT D

ACCREDITED INVESTOR LETTER

 

___________, 2013

 

Crumbs Bake Shop, Inc.

110 West 40th Street, Suite 2100

New York, NY 10018

 

Ladies and Gentlemen:

 

In connection with the possible purchase
by the undersigned Buyer of senior unsecured convertible promissory notes (the “Notes”) of Crumbs Bake Shop,
Inc. (the “Company”) in a transaction exempt from the registration requirements of the Securities Act of 1933,
as amended (the “1933 Act”), the undersigned Investor makes the following representations and warranties to
the Company:

 

1.          The
Investor is an “accredited investor” within the meaning of Rule 501 of Regulation D under the 1933 Act, and has checked
the box(es) below which are next to the category or categories under which the Investor qualifies as an accredited investor:

 

For Individuals

 

 ̈        A
natural person whose individual net worth, or joint net worth with that person’s spouse, at the time of his purchase exceeds
$1,000,000. For such purposes, the value of one’s primary residence should not be counted as an asset and the amount of the
mortgage on such primary residence, to the extent that it does not exceed the value of the residence, should not be counted as
a liability.

 

 ̈        A
natural person with individual income (without including any income of the Investor’s spouse) in excess of $200,000, or joint
income with spouse in excess of $300,000, in each of the two most recent years and who reasonably expects to reach the same income
level in the current year.

 

For Entities

 

 ̈        An
entity, including a grantor trust, in which all of the equity owners are accredited investors (for this purpose, a beneficiary
of a trust is not an equity owner, but the grantor of a grantor trust is an equity owner).

 

 ̈        A
corporation, Massachusetts or similar business trust, or partnership, not formed for the specific purpose of acquiring Notes, or
an organization described in Section 501(c)(3) of the Internal Revenue Code, with total assets in excess of $5 million.

 

 ̈        A
bank as defined in Section 3(a)(2) of the Securities Act, or any savings and loan association or other institution as defined in
Section 3(a)(5)(A) of the Securities Act whether acting in its individual or fiduciary capacity.

 

 ̈      An
insurance company as defined in Section 2(a)(13) of the Securities Act.

 

 ̈        A
broker-dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934.

 

 ̈      An
investment company registered under the Investment Company Act of 1940 (the “Investment Company Act”).

 

 ̈        A
business development company as defined in Section 2(a)(48) of the Investment Company Act of 1940.

 

    	 

    	 

    

 

 ̈      A
small business investment company licensed by the Small Business Administration under Section 301(c) or (d) of the Small Business
Investment Act of 1958.

 

 ̈        A
private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940.

 

 ̈        A
trust with total assets in excess of $5 million not formed for the specific purpose of acquiring Notes, whose purchase is directed
by a person with such knowledge and experience in financial and business matters as to be capable of evaluating the merits and
risks of an investment in the Notes.

 

 ̈        An
employee benefit plan within the meaning of ERISA if the decision to invest in the Company is made by a plan fiduciary, as defined
in Section 3(21) of ERISA, which is either a bank, savings and loan association, insurance company, or registered investment adviser,
or if the employee benefit plan has total assets in excess of $5 million or, if a self-directed plan, with investment decisions
made solely by persons that are accredited investors.

 

 ̈      A
plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political
subdivisions for the benefit of its employees, if the plan has total assets in excess of $5 million.

 

2.          The
Investor, if a natural person, has his or her principal residence in the State of _________________; and, if an entity, has its
principal office in the State of _________________.

 

3.          As
of the date hereof and prior to the possible investment, the Investor beneficially owns (as determined pursuant to Rule 13d-3 under
the Securities Exchange Act of 1934, as amended) ____________ shares of the Company’s common stock.

 

The Investor understands and agrees that
the Company will rely on the foregoing representations and warranties in consummating the possible sale and purchase of the Notes.

 

	 	Sincerely yours,
	 	 
	 	FOR INDIVIDUAL INVESTORS:
	 	 
	 	Signature:	 
	 	Name:	 

 

	 	FOR ENTITY INVESTORS:
	 	 
	 	 
	 	[Name of Entity]

 

	 	By:	 
	 	Name:	 
	 	Title:	 

 

    	 

    	 

    

 

CRUMBS BAKE SHOP, INC. DISCLOSURE SCHEDULES

 

The disclosures made in these Disclosure
Schedules are made pursuant to Section 3 of the attached Securities Purchase Agreement, dated as of April 29, 2013, by and between
Crumbs Bake Shop, Inc. (the “Company”) and each of the Investors identified therein (the “Agreement”).
Capitalized terms used but not defined in these Disclosure Schedules shall have the meanings given such terms in the Agreement.

 

Nothing in these Disclosure Schedules is
intended to broaden the scope of any representation or warranty of the Company contained in the Agreement or to create any covenant
on the part of the Company. Inclusion of any item in these Disclosure Schedules shall not constitute or be deemed to be an admission
to any third party concerning such item by the Company or any Subsidiary.

 

These Disclosure Schedules are arranged
and numbered to correspond with the subsections of Section 3 of the Agreement.

 

    	 

    	 

    

 

SCHEDULE 3(a) - LIST
OF SUBSIDIARIES

 

Crumbs Holdings LLC, a Delaware limited liability
company

Crumbs 17th Street, LLC, a District
of Columbia limited liability company

Crumbs 42nd Street, LLC, a New
York limited liability company

Crumbs 92nd Street, LLC, a New
York limited liability company

Crumbs Americana, LLC, a California limited
liability company

Crumbs Beverly Hills, LLC, a California limited
liability company

Crumbs Broad Street, LLC, a New York limited
liability company

Crumbs Broadway LLC, a New York limited liability
company

Crumbs Brooklyn Heights LLC, a New York limited
liability company

Crumbs Calabasas, LLC, a California limited
liability company

Crumbs Catering LLC, a New York limited liability
company

Crumbs Clarendon LLC, a Virginia limited liability
company

Crumbs Columbia LLC, a New York limited liability
company (f/k/a Crumbs 125th Street, LLC)

Crumbs Columbus LLC, a New York limited liability
company

Crumbs Douglaston Plaza, LLC, a New York limited
liability company

Crumbs Downtown II, LLC, a New York limited
liability company

Crumbs East Bakeshop II, LLC, a New York limited
liability company

Crumbs East End, LLC, a District of Columbia
limited liability company

Crumbs E-Commerce LLC, a New York limited
liability company

Crumbs Federal Street LLC, a Delaware limited
liability company

Crumbs Garment Center LLC, a New York limited
liability company

Crumbs Grand Central LLC, a New York limited
liability company

Crumbs Greenvale LLC, a New York limited liability
company

Crumbs Greenwich, LLC, a Connecticut limited
liability company

Crumbs Hoboken, LLC, a New Jersey limited
liability company

Crumbs Hollywood LLC, a California limited
liability company

Crumbs Huntington LLC, a New York limited
liability company

Crumbs II, LLC, a New York limited liability
company

Crumbs International Place, LLC, a Delaware
limited liability company

Crumbs L Street, LLC, a District of Columbia
limited liability company

Crumbs Larchmont, LLC, a California limited
liability company

Crumbs LaSalle, LLC, an Illinois limited liability
company

Crumbs L’Enfant Plaza, LLC, a District
of Columbia limited liability company

Crumbs Lexington LLC, a New York limited liability
company

Crumbs Madison LLC, a New York limited liability
company

Crumbs Malibu, LLC, a California limited liability
company

Crumbs Newark LLC, a New Jersey limited liability
company

Crumbs New Canaan, LLC, a California limited
liability company

Crumbs Oak Park, LLC, an Illinois limited
liability company

Crumbs Park Avenue LLC, a New York limited
liability company

Crumbs Park Avenue South, LLC, a New York
limited liability company

Crumbs Queens Center, LLC, a New York limited
liability company

Crumbs Retail Bake Shops, LLC, a Delaware
limited liability company (f/k/a Crumbs Fulton Street, LLC

Crumbs Ridgewood, LLC, a New Jersey limited
liability company

Crumbs Rittenhouse Square, LLC, a Delaware
limited liability company

Crumbs River North, LLC, an Illinois limited liability company

Crumbs Rockville Town Square, LLC, a Delaware limited liability
company

Crumbs Sixth Avenue, LLC, a New York limited liability company

Crumbs South Clark, LLC, an Illinois limited liability company

Crumbs Stamford, LLC, a Connecticut limited liability company

Crumbs Third Avenue LLC, a New York limited
liability company

Crumbs Times Square LLC, a New York limited
liability company

 

    	 

    	 

    

 

 

Crumbs Union Square LLC, a New York limited
liability company

Crumbs Union Station LLC, a District of Columbia
limited liability company

Crumbs Wall Street II, LLC, a New York limited
liability company

Crumbs West Madison, LLC, an Illinois limited liability company

Crumbs Westfield LLC, a New Jersey limited liability company

Crumbs Westport, LLC, a Connecticut limited liability company

Crumbs Wholesale II, LLC, a New York limited
liability company

Crumbs Woodbury LLC, a New York limited liability
company

 

    	 

    	 

    

 

SCHEDULE 3(g) –
PLACEMENT AGENT FEES

 

The Company is a party to a letter agreement,
dated as of August 24, 2012, with Janney Scott Montgomery LLC (“Janney”) pursuant to which the Company appointed Janney
as its lead financial advisor and, in connection with the transactions contemplated by the 2012 SPA (as defined in Schedule 3(r)),
(a) paid Janney an advisory fee of 7.00% of the gross proceeds raised in such transactions, subject to certain exclusions, (b)
reimbursed Janney for its expenses, up to $50,000.00. The letter agreement has a 12 month term. In addition, the Company agreed
to pay Janney the advisory fee described above in the event the Company sells, within 12 months following the termination of the
Janney letter agreement, securities similar to the securities covered by the 2012 SPA to a person who was introduced to the Company
by Janney. Because the Janney letter agreement contemplated a single private placement, which occurred on October 10, 2012, and
the Buyer was not identified to the Company by Janney, the Company does not believe that any payments are due to Janney in connection
with the transactions contemplated by the Agreement.

 

    	 

    	 

    

 

SCHEDULE 3(k)—SEC
DOCUMENTS; FINANCIAL STATEMENTS

 

On April 15, 2013, the Company filed (i) an
amended Form 10-Q for each of the quarters ended June 30, 2011, September 30, 2011, March 31, 2012, June 30, 2012 and September
30, 2012, and (ii) an amended Form 10-K for the year ended December 31, 2011, in each case, to restate the Company’s consolidated
financial statements contained therein.

 

    	 

    	 

    

 

SCHEDULE 3(n)—CONDUCT
OF BUSINESS; REGULATORY PERMITS

 

None

 

    	 

    	 

    

 

SCHEDULE 3(r) –CAPITALIZATION

 

Capitalization of the Company

	 	 	Shares	 
	Preferred Stock, par value $.0001 per share	 	 	 	 
	Authorized	 	 	1,000,000	 
	Issued	 	 	234,000	 
	Outstanding(1)	 	 	234,000	 
	 	 	 	 	 
	Potentially Dilutive Securities:	 	 	 	 
	 	 	 	 	 
	Reserved for issuance to members if Contingency Consideration were to vest(2) (3)	 	 	440,000	 
	 	 	 	 	 
	Common Stock, par value $.0001 per share	 	 	 	 
	Authorized	 	 	100,000,000	 
	Issued(4)	 	 	13,577,437	 
	Outstanding	 	 	11,982,853	 
	 	 	 	 	 
	Potentially Dilutive Securities:	 	 	 	 
	 	 	 	 	 
	Authorized for issuance pursuant to Equity Incentive Plan	 	 	578,295	 
	Issuable upon exercise of outstanding warrants	 	 	5,456,300	 
	Reserved for conversion of New Crumbs Class B Exchangeable Units by	 	 	 	 
	Crumbs Holdings' members(1)	 	 	2,340,000	 
	Reserved for issuance to members upon exchange of Contingency Consideration that could be paid to members if such Contingency Consideration were to vest(2) (3)	 	 	4,400,000	 

 

		1.	The outstanding shares of Series A Voting Preferred Stock (“Series A Stock”) of the Company are held by the
persons who were members of Crumbs Holdings LLC (“Holdings”) immediately prior to the Company’s 2011 merger transaction
(the “Merger”) and Julian Geiger, as a substituted member (collectively, the “Members”). The outstanding
shares of Series A Stock were issued contemporaneously with the issuance by Holdings of New Crumbs Class B Exchangeable Units (“Class
B Units”) to the Members. Each share of Series A Stock entitles its holder to cast 10 votes on any matter submitted to the
Company’s stockholders. The Class B Units are exchangeable for shares of Common Stock on a one-for-one basis. Upon the exchange
of a Class B Unit, the holder must also surrender 0.1 share of Series A Stock for redemption by the Company at its then par value.

 

		2.	Contingency Consideration includes 440,000 shares of Series A Stock of the Company and 4,400,000 Class B Units. Contingency
Consideration will vest upon satisfaction of certain stock price and/or EBIDTA targets as provided in that certain Business Combination
Agreement, dated as of January 9, 2011, as amended on each of February 18, 2011, March 17, 2011 and April 7, 2011 (the “Business
Combination Agreement”), by and among the Company, 57th Street Merger Sub LLC, Crumbs Holdings, LLC (“Crumbs”),
the members of Crumbs set forth on the signature pages thereto (the “Members”), and the representatives of Crumbs and
the Member.

 

		3.	In addition to vesting upon reaching the stock price and/or EBIDTA targets, all unvested Contingency Consideration will
immediately vest if there is a “Change of Control” of the Company or Holdings. A “Change of Control” will
occur if, among other things, a person or group (within the meaning of Rules 13d-3 and 13d-5 under the 1934 Act) (other than any
combination of the Permitted Holders or, in the case of Holdings, the Company) shall obtain beneficial ownership (as defined in
Rules 13d-3 and 13d-5 under the 1934 Act) or the voting stock of the Company or Holdings representing more than 35% of the voting
power of the capital stock of the Company or Holdings entitled to vote for the election of directors of the Company or Holdings
other than directly from a Permitted Holder in a transaction where the ultimate purchaser is known to the Permitted Holder. 

 

    	 

    	 

    

  

		4.	Includes 1,594,584 shares held in treasury.

Other Rights to Acquire Securities

 

Pursuant that certain
Exchange and Support Agreement, dated as of May 5, 2011, by and among the Company, Holdings, and the other parties thereto, as
modified by that certain Accession Agreement, dated as of November 14, 2011, by and among the Company, Holdings and Julian R. Geiger,
(a) the Company is entitled to receive New Crumbs Class A Voting Units upon the exchange of the New Crumbs Class B Units by the
holders thereof, (b) the holders of Common Stock will be entitled to certain adjustments in respect of the Common Stock in the
event of certain dilutive actions, issuances or fundamental transactions described therein by Holdings in respect of its New Crumbs
Class B Units, and (c) the holders of New Crumbs Class B Units of Holdings will be entitled to certain adjustments in respect of
the New Crumbs Class B Units in the event of certain dilutive actions, issuances or fundamental transactions described therein
by the Company in respect of the Common Stock.

 

Pursuant to the Amended
and Restated Certificate of Designation in respect of the Company’s Series A Stock, the holders of shares of Series A Stock
will be entitled to certain dividends and distributions in respect of the Series A Stock in the event the Company declares any
dividend or distribution on the Common Stock in shares of Common Stock, Preferred Stock or securities convertible, exercisable
or exchangeable for Common Stock or Preferred Stock, unless such dividend or distribution is approved by the written consent or
affirmative vote of the holders of at least two-thirds of the then outstanding shares of Series A Stock.

 

The Company’s warrants
provide that the number of shares covered thereby and the exercise prices thereof shall be subject to adjustment in the event of
certain changes in the Common Stock by way of stock dividends, split-ups, extraordinary dividends or other similar events.

 

The Company’s Equity
Incentive Plan, as amended (the “Amended Plan”) contemplates that, in the event
of any change in the Company’s corporate capitalization, then the Compensation Committee, in its sole discretion, may make
substitutions or adjustments to the number of shares reserved for issuance under the Amended Plan, the number of shares covered
by awards then outstanding under the Amended Plan, the limitations on awards under the Amended Plan, the exercise price of outstanding
options and such other equitable substitution or adjustments as it may determine appropriate the Compensation Committee may make
substitutions or adjustments to the number of shares of Common Stock reserved for issuance thereunder, the number of shares covered
by awards then outstanding thereunder, the limitations on awards thereunder, the exercise price of outstanding options and such
other equitable substitution or adjustments as it may determine appropriate. There are no options to acquire shares of Common
Stock issued under the Amended Plan; only shares of restricted stock have been granted.

 

Indebtedness

 

See disclosure in Schedule 3(s), which is
incorporated by reference herein.

  

    	 

    	 

    

  

Registration Rights Agreements

 

The Company is a party to a Registration
Rights Agreement, dated as of November 14, 2011, with Julian R. Geiger pursuant to which it has agreed to register for resale,
under specified conditions, the Registrable Securities (as defined therein) owned, or that may be acquired, by Mr. Geiger.

 

The Company is a party to a Registration
Rights Agreement, dated as of May 5, 2011, with 57th Street General Acquisition Corp., certain members of Holdings,
Morgan Joseph TriArtisan LLC, acting as representative for the initial public offering underwriter holders, and certain service
providers pursuant to which the Company agreed to register for resale, under specified conditions, the Registrable Securities (as
defined therein) that are owned, or may be acquired, by such Persons.

 

The Company is a party to a Registration
Rights Agreement, dated as of October 11, 2012, with Special Situations Fund III QP, L.P., Special Situations Cayman Fund, L.P.,
Special Situations Private Equity Fund, L.P. (collectively, the “Special Situations Funds”), Buckingham RAF Partners,
L.P., Buckingham RAF Partners II, L.P., Buckingham RAF International Partners Master Fund, LP, Whitney Capital Series Fund LLC
– Series LS1, Durban Capital LP, John Mills, P.A.W. Partners, L.P., P.A.W. Small Cap Partners, L.P., Prism Partners I, L.P.,
Prism Partners III Leveraged, L.P., Prism Partner IV Leveraged Offshore Fund, Arthur J. Samberg, Leonard Potter, Frederick Kraegel,
Jeffrey Roseman, Mark Klein, and Julian Geiger (collectively, the “Investors”), pursuant to which the Company agreed
to register for resale, under specified conditions, the Registrable Securities (as defined in the Registration Rights Agreement)
that are owned, or may be acquired, by such Investors pursuant to a Securities Purchase Agreement dated as of October 10, 2012
between the Company and the Investors (the “2012 SPA”).

 

    	 

    	 

    

 

SCHEDULE 3(s) –
INDEBTEDNESS

 

Pursuant to Section 4.4 of Holdings’
Third Amended and Restated Limited Liability Company Agreement (the “LLC Agreement”), Holdings is obligated under certain
circumstances to make pro rata quarterly Tax Distributions (as defined in the LLC Agreement) to its members in an amount equal
to the excess of (i) the Assumed Tax Liability (as defined in the LLC Agreement) for the applicable quarterly estimated tax period
over (ii) Tax Distributions (as defined in the LLC Agreement) made by the Company with respect to the calendar year of which such
quarterly estimated tax period is a part.

 

See the disclosure of
the Tax Receivable Agreement in Schedule 3(z), which is incorporated herein by reference.

 

In lieu of security deposits
required pursuant to the terms of several operating leases, Holdings has chosen to obtain letters of credit issued by Southeastern
Bank and JPMorganChase when such substitution is allowed by the landlords. See attached schedule of letters of credit issued by
Southeastern Bank. JPMorganChase has issued two letters of credit: (i) $68,000 (automatically renews each year through its expiration
date of February 29, 2016); and (ii) $30,000 (automatically renews each year through its expiration date of November 30, 2016).

 

On May 5, 2011, Holdings
entered into a Commercial Loan Agreement with Southeastern Bank in connection with the letters of credit issued by Southeastern
Bank in the form of a $575,000 revolving line of credit, with a variable rate based on the Wall Street Journal Prime Rate. Letters
of credit amounting to $539,425 were reserved under this line of credit as of March 31, 2013. The line of credit is secured by
a $575,000 certificate of deposit, and no amounts are outstanding on the line of credit.

 

    	 

    	 

    

 

Letters of Credit issued by Southeastern Bank

 

	Issue Date	 	Expires
 Date	 	Auto
 Renew	 	Days
 Notice	 	 	Date
 Financials
 and
 Memo
 Needed
 for
 Renewal
 Decision	 	Type	 	Amt	 	 	Most Recent Fee
 Collected	 	 	Date Most Recent Fee
 Collected
	5/20/2008	 	5/20/2013	 	Y	 	60	 	 	02/19/13	 	F	 	$	27,000.00	 	 	$	400.00	 	 	3/29/2013
	6/11/2008	 	6/11/2013	 	Y	 	60	 	 	03/13/13	 	F	 	$	17,500.00	 	 	$	400.00	 	 	3/29/2013
	6/11/2008	 	6/11/2013	 	Y	 	60	 	 	03/13/13	 	F	 	$	42,917.00	 	 	$	435.00	 	 	3/29/2013
	6/18/2008	 	4/30/2013	 	N	 	60	 	 	01/30/13	 	F	 	$	45,600.00	 	 	$	456.00	 	 	3/26/2012
	6/19/2008	 	6/19/2013	 	Y	 	60	 	 	03/21/13	 	F	 	$	15,000.00	 	 	$	400.00	 	 	3/29/2013
	6/1/2008	 	6/1/2013	 	Y	 	60	 	 	03/03/13	 	F	 	$	28,144.00	 	 	$	400.00	 	 	3/29/2013
	6/1/2008	 	6/1/2013	 	Y	 	60	 	 	03/03/13	 	F	 	$	9,440.00	 	 	$	400.00	 	 	3/29/2013
	7/1/2008	 	7/1/2013	 	Y	 	60	 	 	04/02/13	 	F	 	$	41,925.00	 	 	$	419.00	 	 	03/26/2012 and 5/22/2012*
	8/1/2008	 	8/1/2013	 	Y	 	30	 	 	06/02/13	 	F	 	$	62,500.00	 	 	$	625.00	 	 	5/22/2012
	8/1/2008	 	8/1/2013	 	Y	 	60	 	 	05/03/13	 	F	 	$	10,416.67	 	 	$	400.00	 	 	3/29/2013
	8/1/2008	 	8/1/2013	 	Y	 	60	 	 	05/03/13	 	F	 	$	24,300.00	 	 	$	400.00	 	 	3/29/2013
	8/20/2008	 	8/20/2013	 	Y	 	60	 	 	05/22/13	 	F	 	$	9,645.33	 	 	$	400.00	 	 	3/29/2013
	8/1/2008	 	8/1/2013	 	Y	 	60	 	 	05/03/13	 	F	 	$	50,000.00	 	 	$	500.00	 	 	3/29/2013
	9/1/2008	 	9/1/2013	 	Y	 	60	 	 	06/03/13	 	F	 	$	15,750.00	 	 	$	400.00	 	 	5/22/2012
	5/4/2009	 	5/4/2013	 	Y	 	60	 	 	02/03/13	 	F	 	$	7,500.00	 	 	$	400.00	 	 	3/29/2013
	5/7/2009	 	5/7/2013	 	Y	 	60	 	 	02/06/13	 	F	 	$	29,287.50	 	 	$	400.00	 	 	3/29/2013
	5/13/2009	 	5/13/2013	 	Y	 	60	 	 	02/12/13	 	F	 	$	43,749.99	 	 	$	450.00	 	 	3/29/2013
	7/28/2009	 	7/28/2013	 	Y	 	60	 	 	04/29/13	 	F	 	$	18,750.00	 	 	$	400.00	 	 	3/29/2013
	3/3/2011	 	3/3/2014	 	Y	 	60	 	 	12/03/13	 	F	 	$	40,000.00	 	 	$	400.00	 	 	3/29/2013
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	$	539,425.49	 	 	 	 	 	 	 

  

    	 

    	 

    

 

SCHEDULE 3(t) - LITIGATION

 

The following summary of litigation identifies
legal actions pending against the Company’s Chief Executive Officer, as disclosed in the Quarterly Report of Aéropostale,
Inc. (“Aéropostale”) on Form 10-Q for the quarter ended July 28, 2012, filed with the SEC on August 30, 2012.

 

In October 2011, Julian R. Geiger, in his
capacity as a director of Aéropostale, was named, along with the other directors and certain
officers of Aéropostale, as defendants in the case styled, Bell v. Geiger, et al.,
No. 652931/2011, a shareholder derivative lawsuit filed in New York state court seeking relief derivatively on behalf of Aéropostale.
The action alleges that the defendants breached their fiduciary duties to Aéropostale
between February 3, 2011 and August 3, 2011 by failing to establish and maintain internal controls that would have prevented Aéropostale
from disseminating allegedly false and misleading and inaccurate statements and other information to shareholders, and to manage
and oversee Aéropostale. As a result, the plaintiff alleges that the defendants exposed
Aéropostale to potential liability in the federal securities class action lawsuit styled,
City of Providence, v. Aéropostale, Inc., et al., No. 11-7132, described below.

 

In February 2012, Julian R. Geiger, in
his capacity as a former director of Aéropostale, was named, along with the other current
and former directors and certain officers of Aéropostale, as defendants in the case styled,
The Booth Family Trust v. Meads, et al., No. 650594/2012, a shareholder derivative lawsuit filed in New York state court
seeking relief derivatively on behalf of Aéropostale. As in Bell, this action alleges
that the defendants breached their fiduciary duties to Aéropostale by failing to establish
and maintain internal controls that would have prevented Aéropostale from disseminating
allegedly false and misleading and inaccurate statements and other information to shareholders, and to manage and oversee Aéropostale.
As a result, and as in Bell, the plaintiff alleges that the defendants have exposed Aéropostale
to losses and damages, including civil liability from City of Providence suit.

 

On April 24, 2012, the New York Supreme
Court, New York County, issued an order consolidating and staying the Bell and Booth actions pending a ruling on the motion to
dismiss filed in City of Providence, a class action lawsuit
filed in New York federal court in October 2011 alleging violations of the federal securities laws by certain officers of Aéropostale.

 

    	 

    	 

    

 

SCHEDULE 3(x) –
INTELLECTUAL PROPERTY RIGHTS

 

The Company has a pending Intent-to-Use
trademark application filed with the United States Patent and Trademark Office for the mark CRUMBS BAKE SHOP, and Design (Ser.
No. 77/603,879), for “Housewares, namely, baking molds, cake pans, cake tins and cake molds.”  The Company may
not use this mark for these goods in a sufficient manner and in sufficient time to prevent the application from becoming abandoned.

 

The Company has a pending Intent-to-Use
trademark application filed with the Canadian Intellectual Property Office for the mark CRUMBS BAKE SHOP, and Design (App. No.
1451649)  for  “Bakery products, namely, cupcakes, pastries, cookies, cakes, pies; and Retail bakery shops; take-out
bakery services.”  The Company may not use this mark in Canada for these goods and services in a sufficient manner and
in sufficient time to prevent the application from becoming abandoned.

 

    	 

    	 

    

 

SCHEDULE 3(z) –
SUBSIDIARY RIGHTS

 

Holdings has two classes
of membership interests outstanding: (i) New Crumbs Class A Voting Units (“Class A Units”), all of which are owned
by the Company, and (ii) the Class B Units, all of which are owned by the Members. The Class A Units constitute all of the voting
equity of Holdings and represent approximately 83.7% of all outstanding equity issued by Holdings. Holdings’ limited liability
company agreement generally requires distributions by Holdings to be pro rata to all its members, including the Company and the
holders of Class B Units, except in the case of distributions for public company expenses.

 

The Company entered into a Tax Receivable
Agreement, dated as of May 5, 2011, with Holdings and the Members (the “Tax Receivable Agreement) that provides for the payment
by the Company to the Members of up to 75% of the amount of the tax benefits, if any, that the Company is deemed to realize as
a result of (i) the existing tax basis in the assets of Holdings on the date of the Merger, (ii) any increases in such tax basis
and (iii) certain other tax benefits related to Holdings entering into the Tax Receivable Agreement, including tax benefits attributable
to payments under the Tax Receivable Agreement. These payment obligations are obligations of the Company and not of Holdings. For
purposes of the Tax Receivable Agreement, the benefit deemed realized by the Company will be computed by comparing the actual income
tax liability of Holdings (calculated with certain assumptions) to the amount of such taxes that the Company would have been required
to pay had there been no increase to the tax basis of the assets of Holdings as a result of the purchase or exchanges, had there
been no tax benefit from the tax basis in the intangible assets of Holdings on the date of the Merger and had the Company not entered
into the Tax Receivable Agreement. The term of the Tax Receivable Agreement will continue until all such tax benefits have been
utilized or expired, unless the Company exercises its right to terminate the Tax Receivable Agreement for an amount based on the
agreed payments remaining to be made under the Tax Receivable Agreement or the Company breaches any of its material obligations
under the Tax Receivable Agreement, in which case all obligations will generally be accelerated and due as if the Company had exercised
its right to terminate the Tax Receivable Agreement.

  

    	 

    	 

    

 

SCHEDULE 3(aa) –
TAX STATUS

  

None

 

    	 

    	 

    

 

SCHEDULE 3(mm)—MANAGEMENT

  

None

 

    	 

    	 

    

 

SCHEDULE 4(d)—USE
OF PROCEEDS

 

NoneConfidential Treatment Requested by LabStyle
Innovations Corp.

Confidential treatment requested with
respect to certain portions hereof denoted with “***”

 

	Exhibit 10.1
	 
	***CONFIDENTIAL
    TREATMENT REQUESTED***
	Note:  Confidential treatment requested with respect to certain portions hereof denoted with

 “***”

 

 

AGREEMENT

 

between

 

LABSTYLE INNOVATION LTD.

and 

FARLA MEDICAL LIMITED

 

    	1

    	 

    

 

Confidential Treatment Requested by LabStyle
Innovations Corp.

Confidential treatment requested with
respect to certain portions hereof denoted with “***”

 

This Distribution Agreement
(the “Agreement”) is entered into as of 25 April 2013 (the “Effective
Date”) by Labstyle Innovation Ltd. (and/or any other party related to the
company on a corporate basis) an Israeli company, with main offices at 7 Menachem Begin St., Ramat Gan 52681, Israel (the “Company")
and Farla Medical Limited and/or any other party
related to the company on a corporate basis) a company incorporated under the laws of England and Wales with registered offices
at 5 North End Road, London NW11 7RJ  the (“Distributor”).

 

Recitals

 

		WHEREAS	the Company is the developer and owner of the rights in and of "Dario", a product and its disposables/consumables,
which together are designed to measure levels of glucose in the blood and assist patients in the management of diabetes (the “Product”,
as further defined below and as specified in Exhibit A); and

 

		WHEREAS	the Distributor is engaged in the business of distributing products and assures the Company that it has the facilities, personnel,
and technical expertise necessary to promote, advertise, market, sell, distribute and support the Product in the Territory (as
defined in Exhibit B) under the Company’s Trademarks; and

 

		WHEREAS	the Distributor wishes to obtain, and the Company is willing to grant the Distributor, the right to distribute
the Product in the Territory, under the terms and conditions set forth in this Agreement.

 

NOW, THEREFORE, the parties hereto, intending to
be legally bound, hereby agree as follows:

 

		1.	DEFINITIONS

 

For the purpose of this Agreement, the following
terms shall have the respective meaning as stated below:

 

		1.1.	“Confidential Information" - any proprietary information relating to any of the
subject matter of this Agreement or the business of the Company, including but not limited to the Product and all Intellectual
Property Rights therein disclosed by or on behalf of the Company to the Distributor in any form or medium whatsoever including
in written, physical, digitized, oral or visual form.

 

		1.2.	“Term” – as defined in Section 4.

 

		1.3.	“Documentation” - all documentation related to the Product, including descriptive
materials, manuals and user-guides.

 

		1.4.	“End-User” – a customer who has purchased the Product from the Distributor
for their personal use and not for further distribution.

 

    	2

    	 

    

 

Confidential Treatment Requested by LabStyle
Innovations Corp.

Confidential treatment requested with
respect to certain portions hereof denoted with “***”

 

		1.5.	“Intellectual Property Rights” -  shall include, without limitation, copyrights,
trade-secrets, trademarks, trade-names, domain names, patents, know-how, formulation, data, technology, designs, inventions, discoveries,
processes, models or sales, financial, contractual and marketing information and all other intellectual or industrial property
and like rights whether or not registered.

 

		1.6.	“Dario Consumables” or “Consumables” - shall mean the consumables
and disposable materials for the Product as set forth in Exhibit A.

 

		1.7.	“Product” - shall mean a “Blood Glucose Meter”, specifications of which
are attached hereto as Exhibit A, and includes: (i) Dario Consumables, (ii) the Documentation; and, at the Company’s
sole discretion (as shall be evidenced by written conformation by the Company’s COO), also (iii) any improvement, new version
or new feature made thereto. The term "Product(s)" includes Product units.

 

		1.8.	“Specifications” - the specifications of the Product, attached hereto as Exhibit
A.

 

		1.9.	“Territory” – the territories identified in Exhibit B hereto.

 

		2.	APPOINTMENT

 

		2.1.	Appointment: During the Term and subject to the terms and conditions of this Agreement, the
Company hereby grants the Distributor, and the Distributor hereby accepts an exclusive, non-transferable, non-sublicenseable, revocable,
right and license limited only to distribute and resell the Product to End-Users in the Territory (the “License”).
The Distributor may not distribute and/or resell the Product to third parties located outside of the Territory without the prior
written consent of the Company, which may be granted or denied in the Company's sole and absolute discretion. Any failure to comply
shall be deemed a material breach of this Agreement by the Distributor.

 

		2.2.	Sub-Distributors: the Distributor represents and warrants that it does not currently have any
third party agents, representatives, or distributors for the promotion or sale of the Products in the Territory (“Sub-distributors”)
and that it will not appoint Sub-distributors without the Company’s prior written consent. For the avoidance of doubt, it
is hereby clarified, that in the event any Sub-distributors are appointed by the Distributor in accordance with this Section 2.2,
the Distributor shall remain fully responsible for the performance of all of its covenants and obligations hereunder. If this Agreement
is terminated, the Distributor shall have sole responsibility for termination of any of its Sub-distributors.

 

		2.3.	Restrictions: Other than the rights expressly licensed to the Distributor hereunder, no other
rights or interest whatsoever in the Product are transferred or granted to the Distributor. Without limiting the foregoing, the
Distributor shall not: (i) reverse engineer, disassemble, decompile, modify, or alter the Product, hardware, firmware, or software
included therewith or any part thereof, (ii) use the Product for any purpose other than the purposes of this Agreement; or (iii)
copy the Product, develop any derivative works thereof or include any portion of the Product in any other products.

 

    	3

    	 

    

 

Confidential Treatment Requested by LabStyle
Innovations Corp.

Confidential treatment requested with
respect to certain portions hereof denoted with “***”

 

		2.4.	Capabilities of Products: The Distributor shall not make any representations, claims or other
like statements regarding the characteristics or capabilities of the Products, other than those representations, claims or other
like statements contained in the Documentation or Product literature supplied to the Distributor by the Company.

 

		3.	REPRESENTATIONS AND WARRANTIES OF THE PARTIES:

 

		3.1.	Each party represents and warrants to the other party that:

 

		(i)	It has full corporate power and authority to execute this Agreement and to perform its obligations hereunder and all corporate
action on its part necessary for the authorization, execution, delivery and performance of this Agreement by it have been taken.

 

		(ii)	This Agreement, when executed and delivered by it, will constitute a valid and legally binding obligation on its part, enforceable
in accordance with its terms.

 

		(iii)	The execution, delivery and performance of this Agreement will not result in the breach or violation of any law or regulation
applicable to it or any contract or commitment by which it is bound.

 

		3.2.	Without derogating from the aforesaid, the Distributor hereby represents and warrants to the Company,
as follows:

 

		(i)	It has the required knowledge, experience and financial capacity to fulfill its obligations hereunder; that it has previous
experience and knowledge regarding the marketing of similar products to the Product in the Territory; that it has received and
reviewed all the information required by the Company; and that it has evlauated the merits of this Agreement before executing it.

 

		(ii)	It will comply with all applicable laws and regulations in the Territory pertaining to the performance of its obligations under
this Agreement, including the marketing and sale of the Product and receipt of all approvals and authorizations in connection thereto.
It shall promptly inform the Company of any formal or informal inquiry and/or inspection relating to any Product by any regulatory
agency of any state or national government or supranational authority.

 

		(iii)	It shall comply with all sales policies and operating regulations of the Company, as issued and modified from time to time
by the Company, provided however that in any event of contradiction between such sales policies and operating regulations of the
Company and the provisions of this Agreement, the provisions of this Agreement shall prevail.

 

    	4

    	 

    

 

Confidential Treatment Requested by LabStyle
Innovations Corp.

Confidential treatment requested with
respect to certain portions hereof denoted with “***”

 

		4.	DURATION OF THIS AGREEMENT

 

		4.1.	Term of the Agreement: This Agreement shall commence on the date of signature by both parties
hereto and shall terminate three (3) years from the commencement date (the “Initial Term”) unless it
is terminated sooner according to the provisions of this Agreement. .

 

		4.2.	Renewal: This Agreement will be automatically renewed upon the
expiration of the Initial Term for a subsequent twelve (12) months, unless not less than ***
prior to the end of the Initial Term or any renewal term, one party indicates in writing to the other party of its intention not
to renew this Agreement. The Initial Term together with any renewal term shall be collectively referred to herein as the “Term”.

 

		4.3.	Continuation or Survival of Certain Clauses upon Termination: Certain clauses, as specified
below, will survive and remain effective even after the termination or cessation of this Agreement. All other rights and obligations
of each party to the other shall terminate upon termination of this Agreement.

 

		5.	PARTIES’ OBLIGATIONS

 

		5.1.	Exclusivity: the Company hereby grants the Distributor the exclusive right to distribute
the Products in the Territory, subject to the limitations set forth below.

 

		5.2.	Territory: The Distributor may sell or distribute the Products to all End-Users in the Territory
covered under the terms of this Agreement. Territory is set out in Exhibit B.

 

		5.3.	Advertisement: The Distributor will be provided by the Company with marketing and promotion
materials of the Products (electronic files only) written and produced in the English language, as customary by the Company.

 

Such materials may
include without limitation, digital versions of: marketing and product presentations, video demonstrations (for advertising sales
and training purposes) data sheets, digital brochures, case studies, press releases and training materials and such other documentation
or product literature, all as shall be determined by the Company from time to time at its sole discretion in consultation with
the Distributor.

 

Any marketing and
promotion materials used by the Distributor and/or packaging label referring to the Product and/or to the Company shall be subject
to the Company’s prior written approval, at the Company’s sole discretion. Company shall solely own any and all rights
to any marketing materials created by the Company. Distributor shall solely own any and all rights to any marketing materials created
by the Distributor.

 

    	5

    	 

    

 

Confidential Treatment Requested by LabStyle
Innovations Corp.

Confidential treatment requested with
respect to certain portions hereof denoted with “***”

 

The
Distributor hereby commits that, during the Term, it will perform and execute, each year, advertising and marketing of the Product
in the Territory, all set forth in the Marketing Work Plan which is to be submitted to the Company once the Distributor completes
its market research (as per Letter of Intent attached hereto as Exhibit C). ***.

 

The
marketing work plan shall include, without limitation, minimum amount of funds that the Distributor commits to spend on said advertising
and marketing in the *** of the Term (the “Marketing Work Plan”.
The Marketing Work Plan may only be amended with the mutual written agreement of the parties hereto. 

 

		5.4.	Packaging: all packaging materials shall include the Distributor’s details as the Company’s
exclusive distributor in the Territory as well as the exclusive contact for any technical issues. Costs involved in ensuring such
information is on the packaging of the Product is to be covered by the Company.

 

		5.5.	Representations: the Distributor will not make any representations or give any warranties concerning
the Product or its capabilities which are false or misleading in any way whatsoever or go beyond those warranties and representations
made by the Company in this Agreement and in the Documentation.

 

		5.6.	Registration: *** register
the Product under the Company’s name for sale in the Territory, and shall be responsible for ensuring that any required registrations
and approvals *** remain valid at all times – ***
shall cooperate with *** to obtain such regulatory or other approvals and licenses.
The Company shall be responsible to procure applicable CE certification with respect to the Product as well as approval by The
Medicines and Healthcare Products Regulatory Agency. The Company shall also successfully register with the Drug Tariff. ***.

 

		5.7.	The Company does not expect any purchase orders or sales in the Territory until the necessary authorization,
certification and documentation for sales and distribution in the Territory of the Product is completed. Personnel: the
Distributor shall train, maintain and dedicate, for the performance of its obligations under this Agreement, a sufficient number
of highly qualified technical, professional, marketing and sales personnel to induce the selling of the Product in the Territory.
The Distributor and its staff shall maintain a high degree of knowledge of the Product and its use.

 

    	6

    	 

    

 

Confidential Treatment Requested by LabStyle
Innovations Corp.

Confidential treatment requested with
respect to certain portions hereof denoted with “***”

 

		5.8.	Training: The Company shall provide***
qualified personnel at the Distributor’s end with basic training in the use and operation of the Products. The Company shall
also provide supporting materials, such as reference books/booklets, software, and any other relevant items, in digital form only,
which might be required for technical support. Training will commence on a mutually agreeable date and will be based on the Company’s
standard training materials for its basic level training course. Such training will be conducted at a time and location agreed
between the Company and the Distributor.  

 

		5.9.	Discontinuation: Nothing herein shall be deemed to prevent the
Company from discontinuing the sale of a Product hereunder and terminate the Agreement with a ***
written notice to the Distributor, provided that all purchase orders submitted to the Company by the Distributor within such six
6 months’ period with respect to such Product shall be honored and fulfilled by the Company in accordance with the terms
hereof.

 

		5.10.	Insurance: During the Term ***,
the Company shall maintain, at its cost and expense, adequate insurance coverage (product liability and professional liability),
in an amount of not less than *** per occurrence
and per year. Upon written request and at reasonable times, the Company shall provide the Distributor with written evidence of
the existence and amount of such product liability insurance. The Company shall promptly inform the Distributor in writing in the
event that its insurance coverage is canceled or reduced in any manner during the Term. Such notice shall in no way be construed
to relieve the Company of its obligations to maintain insurance as provided herein.

 

		5.11.	Records: ***. For
the removal of doubt, any information (including without limitation, e-mail addresses, names and any other contact information)
obtained by Company via (a) the Product’s application and/or website operated and/or owned by the Company, and/or (b) any
other application and/or website operated and/or owned by the Company, shall be exlusively owned by the Company. ***.

 

Following
the expiration or termination of this Agreement, for any reason, *** shall retain full
ownership of the End-User Database and *** may, at its sole discretion, acquire the
exclusive ownership of such End-User Database. The fee payable for *** exclusive ownership
of End-User Database shall be ***. 

 

In
case the Company wishes to market other relevant products to the group of End-Users listed in the End-User Database, the Company
shall provide the Distributor with a notice to that effect, and, with respect to such relevant products, provide the Distributor
with a right of first refusal for for a period of *** as of said notice, such that
within said period of *** Distributor may provide an offer to the Company to serve
as the exclusive distributor of such other products.

 

    	7

    	 

    

 

Confidential Treatment Requested by LabStyle
Innovations Corp.

Confidential treatment requested with
respect to certain portions hereof denoted with “***”

 

Notwithstanding
anything herein to the contrary, other than as set forth above in this Section 5.11, the Company shall exclusivly own any and all
rights to all medical information and records as listed in Exhibit D attached hereto (the “Medical Information”).
All other data, including contact data, is limited to the restrictions set out in this Section 5.11.

 

		5.12.	Resale Outside the Territory: the Distributor shall refrain from seeking End-Users, from establishing
any branch, from maintaining any distribution depot and from any other action in relation to the Products, outside the Territory.

 

		5.13.	Potential Customers Outside the Territory: the Distributor shall refer potential End-Users
of the Products who are located outside of the Territory to the Company or such other distributor, as the Company may designate
in writing.

 

		5.14.	Non-Competition: During the Term ***,
the Distributor shall not market to any person, company or other entity any products which, directly or indirectly, compete with
the Product or with the Company, except with the prior written consent of the Company. .

 

		5.15.	Market Research: the Distributor shall cooperate with the Company in market research and furnish
the Company with all reasonable reports necessary to keep the Company informed of the market, competitive conditions and market
position, including market responses. The Distributor shall be responsible for any costs associated with the fulfilment of such
market research.

 

		5.16.	No Agent: The Distributor shall not: (i) enter into any agreement or arrangement with any third
party on behalf of the Company; (ii) sign Company's name to any commercial paper, contract or other instruments; or (iii) incur
any debt to a third party payable by the Company.

 

		6.	ORDERING PROCEDURE, MINIMUM COMMITMENTS, PAYMENT AND DELIVERY

 

		6.1.	Price and Terms: The Company will sell Products to the Distributor
according to the price schedule shown on Exhibit E hereto. ***. Payments
shall be made in US Dollars only, at the Company’s designated address by wire transfer, check or other means acceptable to
the Company. Terms of payment to Company shall be *** from the date of shipment of
the ordered Products. Such shipment shall be made by the Company within *** from the
receipt of a purchase order by the Company (a “Purchase Order”) ***.
These payment terms must be adhered to in order for the prices specified in Exhibit E hereto to remain in effect.
Any terms of sale not specified herein shall be governed by the Company’s standard sales order terms in effect at the time
of an applicable Purchase Order. Unless otherwise specified in an applicable Purchase Order and approved by the Company, the Distributor
shall bear all shipping costs and similar charges and all personal property taxes assessable on the Products after delivery to
the carrier from the Company’s designated site. In any case of contradiction between the provisons of any Purchase Order
and this Agreement, this Agreement shall prevail. 

 

    	8

    	 

    

 

Confidential Treatment Requested by LabStyle
Innovations Corp.

Confidential treatment requested with
respect to certain portions hereof denoted with “***”

 

		6.2.	Forecasts: Minimum Purchases: From ***,
the Distributor shall prepare and deliver to the Company an annual forecast of anticipated Product purchases for ***
(a “Forecast”). Within ***, the parties will agree
upon the minimum aggregate purchases of Products ***. 

 

The
Distributor's failure to (i) deliver a Forecast in a respective year as set forth above, or (ii) meet the Minimum Purchases or
a Forecast, shall enable the Company, at the Company's option and sole discretion, to either (a) notwithstanding any thing to the
contrary herein (including, without limitation, Section 2.1 above), to convert the License into a non-exclusive License,
mutatis mutandis, or (b) to terminate this Agreement by *** prior written notice
to the Distributor to that effect. Nothing herein shall derogate from the provisions of Section 13 below.

 

		6.3.	Resale Pricing: Distributor agrees that the price quoted or invoiced to End-Users with respect
to a Product shall not be less than as set forth in Exhibit E hereto. Notwithstanding, the Distributor reserves the
right to review its selling price to address market trends and respond to competiton. The Distributor will inform the Company of
any changes to the selling price should these arise.

 

		7.	TRADEMARKS AND DOMAIN NAMES

 

		7.1.	The Company hereby grants the Distributor a limited license to use and display the trademark DarioÔ
or any other mark used by the Company in connection with the Product (collectively the “Company’s Trademarks”)
only for marketing purposes in connection with the Product and only during the term of this Agreement. All advertising and other
materials in which the Company’s Trademarks are used shall be subject to the Company’s prior written consent.

 

		7.2.	Without limiting the above, all use by the Distributor of the Company’s Trademarks or domain
names shall be to the benefit of the Company, and the Distributor shall not obtain any rights with respect to the Company’s
Trademarks or domain names, other than the rights expressly set forth herein. The Distributor hereby irrevocably assigns to the
Company in perpetuity all worldwide right, title and interest, if any, that are owned or obtained by the Distributor in any of
the Company’s Trademarks or domain names.

 

		7.3.	The Distributor shall not remove, obscure or obliterate any patent, trademark or any other proprietary
notices incorporated in, marked on or affixed to the Product and owned by the Company.

 

		8.	OWNERSHIP OF RIGHTS

 

		8.1.	Title/Ownership: the Company owns and shall retain all Intellectual Property Rights, in and
to the Product, including any new version releases, updates, enhancements, modifications or improvements thereto made available
to the Distributor and in and to the Company’s Confidential Information and the Medical Information.

 

    	9

    	 

    

 

Confidential Treatment Requested by LabStyle
Innovations Corp.

Confidential
treatment requested with respect to certain portions hereof denoted with “***”

 

		8.2.	Infringement: the Distributor undertakes to promptly inform the Company of any possible infringement
by third parties of the Company's proprietary rights including any duplication of the Product, and to participate with the Company
regarding any legal action against such infringement which, in the Company's judgment, should be necessary.

 

		9.	INDEMNIFICATION

 

		9.1.	Indemnification by the Company: the Company agrees to defend, indemnify and hold Distributor
harmless from and against any claim or suit alleging that the Product directly infringes third parties' patents, and to pay all
costs, settlements, or judgments finally awarded; provided, however, that (1) the Distributor shall have given the Company a prompt
written notice of such claim, suit, demand, or action; (2) the Distributor shall reasonably cooperate with the Company in the defense
and settlement thereof at the Company’s expense; and (3) the Company shall have sole control of the defense of such claim,
suit, demand, or action and the settlement or compromise thereof.

 

		9.2.	Further Limitation: The foregoing shall not apply to the extent that the infringement arises:
(i) from the use of the Product in a manner for which it was not intended, or (ii) not in compliance with the Documentation
or Specifications thereof, or (iii) where the infringement results from the combination of the Product with third parties’
systems or components, where the Product standing alone, would not have infringed upon third party’s rights, or (iv) where
the Product was modified, serviced or maintained other than by the Company, or (v) from any action or omission of Distributor in
breach of this Agreement and/or due to Distributor’s negligence or wilful misconduct.

 

		9.3.	Distributor Remedy upon Prevention of Product Use: In the event that an injunction is obtained
against the Distributor's use of the Product arising from a suit, claim or proceeding, or if the Company anticipates that there
is a likelihood of a claim of infringement, the Company shall, at its option and expense, either (a) procure for the Distributor
the right to continue using the Product; or (b) replace or modify the same so that it no longer infringes upon such property rights,
so long as the Product continues to substantially conform with the Specifications; or (c) where (a) or (b) are not practicable,
to terminate this Agreement and any pending Purchase Orders, and call back the Products. Should the Company have to terminate this
Agreement on the grounds set out above the Company shall compensate the Distributor in relation to any losses occurred as a direct
result of such termination.

 

		9.4.	Exclusive Remedy: Without limiting the provisions set out in this Agreement, this Section 9
sets forth the exclusive and entire remedy of the Distributor against the Company with respect to any action or claim for an alleged
infringement of Intellectual Property Rights by the Product or any component thereof.

 

    	10

    	 

    

 

Confidential Treatment Requested by LabStyle
Innovations Corp.

Confidential
treatment requested with respect to certain portions hereof denoted with “***”

 

		9.5.	Company Indemnification: the Distributor shall indemnify, defend and hold the Company harmless
from and against all loss, damage, third party claims, and liability arising out of any culpable act or omission of the Distributor
with respect to the performance of this Agreement.

 

		9.6.	Distributor Indemnification: the Company shall indemnify, defend and hold the Distributor harmless
from and against all loss, damage, third party claims, and liability arising out of any culpable act or omission of the Company
with respect to the performance of this Agreement.

 

		10.	WARRANTY

 

		10.1.	Warranty: The Company warrants that for a period of ***
from the date of purchase by the End–User, except for the test strips which shall have a warranty period ending on the expiration
date appearing on the packaging of the respective test strips (“Warranty Period”), the Product and Consumables
shall conform substantially to the Specifications and shall be free from defects in material and workmanship. The Company’s
sole obligation and the Distributor’s exclusive remedy for any failure of the Product to perform as warranted, is the repair
or replacement, at the Company’s option, of the nonconforming Product, component thereof or Consumable, provided, however,
that the Distributor informs the Company in writing, within the Warranty Period of the defect, malfunction or nonconformity.

 

		10.2.	Without limiting the above, the foregoing warranty will not apply should such damages, malfunction
or failures, result from i) use of the Product in a manner for which it was not intended, or not in compliance with its Documentation;
(ii) the defects or malfunctions caused by alteration or modification to the Product without the Company’s prior written
approval; (iii) defects or malfunctions caused by improper installation, service or repair of the Product, by anyone other than
the Company; (iv) defects or malfunctions which do not adversely affect the ability of the Product to perform its usual designated
function; (v) the Product was subject to unusual electrical or physical stress; (vi) negligence by the Distributor or by the End-User;
(vii) use of the Product other than with the Company’s Consumables or consumables approved in advance by the Company; or
(viii) any other cause beyond the Company’s control.

 

		10.3.	Prior to shipping any defective Product to the Company, the Distributor
shall ensure that the Product is defective, and shall obtain a Return Material Authorization (“RMA”) number
from the Company, and in accordance with the Company's then-current RMA procedures. Any Product so replaced or repaired shall be
subject to the warranty for the remainder of the Warranty Period or *** after repair/replacement,
whichever is later.

 

    	11

    	 

    

 

Confidential Treatment Requested by LabStyle
Innovations Corp.

Confidential
treatment requested with respect to certain portions hereof denoted with “***”

 

		10.4.	The Distributor shall, in its promotional literature, provide information to End-Users to the effect
that warranty claims in the Territory should be referred solely to the Distributor for processing. Upon receipt of warranty claims
by End-Users, the Distributor shall be responsible for (i) verifying that the warranty claim is timely made, and (ii) communicating
such claims to the Company. For purposes of enabling the Distributor to verify the timeliness of a warranty claim, the Distributor
shall, in the case of Products which bear an individual serial number, record the serial number of each such Product sold on its
invoice to the End-User.

 

		10.5.	End-User Complaints and Inquiries: 

 

Distributor shall be responsible
as the first point of contact for providing Product technical support to End-Users.

 

Distributor shall establish
and operate a direct line of communication to Company in all matters relevant to vigilance and/or post-market surveillance concerning
the Products (including early warnings or signals) in accordance with all applicable laws.

 

Distributor
shall provide technical support to End-Users on the correct use of Products based on information supplied by Company. End-User
feedback relevant to safety and performance of the Products, the occurrence of Serious Incidents or Potentially Serious Complaints
will be reported by the Distributor immediately and in any event within ***
to Company 

 

"Serious Incident": shall
mean an incident involving the Products which is reportable to a Competent Authority as defined in the applicable Medical Devices
Directive and the European Commission’s Guidelines on a Medical Devices Vigilance System and shall include a Field Safety
Corrective Action.

 

"Potentially
Serious Complaints": shall mean any information coming to the notice of Company which might relate to a Serious
Incident, or to a significant lapse in the quality of the Product, or might lead to significant adverse public or media comment,
or otherwise significantly adversely affect Company's reputation or business. 

 

		10.6.	IN NO EVENT, EXCEPT FOR NEGLIGENCE, MISREPRESENTATION, ERROR OR OMISSION OR BREACH OF THIS AGREEMENT,
SHALL THE COMPANY BE LIABLE TO THE DISTRIBUTOR FOR ANY LOSS OF PROFITS, ANY INCIDENTAL, SPECIAL, EXEMPLARY, OR CONSEQUENTAL DAMAGES,
OR ANY CLAIMS OR DAMAGES BROUGHT AGAINST THE DISTRIBUTOR OR THE COMPANY BY ANY THIRD PARTY.

 

		11.	LIMITATION OF LIABILITY

 

		11.1.	Except for the express warranties and undertakings set forth in this Agreement, the Company disclaims
all warranties in respect to the Product and any service provided by the Company to Distributor under this Agreement.

 

    	12

    	 

    

 

Confidential Treatment Requested by LabStyle
Innovations Corp.

Confidential
treatment requested with respect to certain portions hereof denoted with “***”

 

		12.	CONFIDENTIALITY

 

		12.1.	All information furnished by a party hereto (the “Disclosing Party”) to the other
party (the “Recipient”), including but not limited to the business, marketing and sales plans of the Disclosing
Party, and designs, manufacturing process and other technical information pertaining to the Intellectual Property Rights
or to the Products (“Confidential Information”), shall be deemed to have been furnished in confidence and shall
not be used by the Recipient for any purpose whatsoever other than for Recipient’s performance hereunder, without the prior
written consent of the Disclosing Party. The parties hereto shall take all necessary precautions and maintain strict safeguards
to hold such Confidential Information in strict confidence and to prevent the disclosure thereof to any third party. Each party
shall exercise a degree of care to preserve and safeguard Confidential Information such as that which the Disclosing Party would
undertake to preserve and safeguard its own confidential information.

 

		12.2.	The Recipient, however, shall not be liable for the disclosure of the following Confidential Information
to third parties:

 

		(i)	information which is in, or becomes part of the public domain through no wrongful act;

 

		(ii)	information which is furnished to a third party by the Disclosing Party without restriction of the third party’s
rights to disseminate the information;

 

		(iii)	information already known to the Recipient prior to the receipt thereof from the Disclosing Party; and

 

		(iv)	information which is required to be disclosed by a government agency or other authority
with the legal power to require such disclosure.

 

		12.3.	In the event of expiration or termination of this Agreement, the Distributor shall promptly deliver
to the Company all documents, data and other information derived from or otherwise containing or pertaining to Confidential Information
and shall not retain any documents or other information containing or pertaining to any Confidential Information.

 

		12.4.	The obligations under this Section shall survive the expiration or termination of this Agreement.

 

		13.	TERMINATION

 

		13.1.	Termination for Cause: If either party hereto commits a material
breach of this Agreement or default in the performance of any material obligation hereof, and if such default or breach is not
cured within *** after the same has been called to the attention of the defaulting
party by a written notice from the other party, then the non-defaulting party, at its option, may thereupon terminate this Agreement
by submitting a written notice to the defaulting party.

 

    	13

    	 

    

 

Confidential Treatment Requested by LabStyle
Innovations Corp.

Confidential
treatment requested with respect to certain portions hereof denoted with “***”

 

		13.2.	Payment delay: Without derogating from the generality of the
foregoing provisions, a delay by the Distributor of more than *** in paying any amount
due shall be considered a material breach hereof.

 

		13.3.	Termination upon Liquidation: Either party may terminate this Agreement in case of: (a) insolvency,
dissolution or liquidation proceedings are instituted by or against the other party; (b) a receiver, trustee or similar officer
is appointed for the business or property of such party; (c) the other party files a petition seeking any reorganization, arrangement,
composition or similar relief under any law regarding insolvency or relief for debtors, or makes an assignment for the benefit
of creditors; (d) the other party adopts a resolution for discontinuance of its business or for dissolution.

 

		13.4.	The right of termination shall not be exclusive of any remedies or means of redress to which the party
terminating this Agreement may be lawfully entitled to or conversely liable to.

 

For the removal
of any doubt, upon the expiration or termination of this Agreement for any cause or reason whatsoever, the Company shall only be
free to directly contact and engage in business with any and all of the End-Users if it acquires the End-User Database from the
Distributor as set forth on Section 5.11 above.

 

		14.	EFFECTS OF TERMINATION

 

		14.1.	Cessation of Distributor Activities: Upon termination of this Agreement, the Company shall
buy back Distributor’s remaining stock of Products at the same price purchased from the Company by Didtributor hereunder
and Distributor will completely cease its activities in relation to the Product.

 

		14.2.	Materials and Confidential Information: the Distributor shall deliver to the Company all Documentation
and other materials related to the performance of this Agreement and/or to the Product, once the Distributor has cleared all its
stock of the Product or once the Company buys the stock back from the Distributor as set forth on Section 14.1 above.

 

		14.3.	Survival: Sections 5.10 (Insurance), 5.11 (Records), 5.12 (Resale outside the Territory) 5.14
(Non Competition), 5.16 (No Agent), 8.1 (Ownership of Rights), 9.1 to 9.6 inclusive (Indemnification), 10.1, 10.2 and 10.6 (Warranty),
11.1 (Limitation of Liability), 12.1 to 12.4 inclusive (Confidential Information), 17 (Governing Law; Dispute Resolution), and
18 (Miscellaneous) shall survive termination of this Agreement.

 

		14.4.	Other Rights and Remedies: Termination of this Agreement shall be without prejudice to any
other right or remedy of either party as stipulated in this Agreement.

 

    	14

    	 

    

 

Confidential Treatment Requested by LabStyle
Innovations Corp.

Confidential
treatment requested with respect to certain portions hereof denoted with “***”

 

		15.	RELATIONS OF THE PARTIES

 

		15.1.	The parties are independent contractors. Nothing in this Agreement shall be construed to constitute
the parties as principal and agent, employer and employee, franchiser and franchisee, partnership, joint venturers, corporate affiliates,
co-owners or otherwise as participants in a joint undertaking.

 

		16.	ASSIGNMENT

 

		16.1.	Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned
by either party without the prior written consent of the other party. Notwithstanding the foregoing, the Company may transfer or
assign, in whole or in part, any of its rights under this Agreement to any such person or entity controlled by or under common
control with the Company, to any successor to all or substantially all of the business or assets of the Company or in connection
with the sale or transfer of the operations of the Company related to this Agreement (whether by stock or assets).

 

Should such transfer,
assignment or sale, in whole or in part, take place and should it have a negative impact on the Distributor’s ability to
sell the product, then the Company shall compensate the Distributor and make good any losses, current and future, which might arise
as a result of such transfer, assignment or sale.

 

		17.	GOVERNING LAW; DISPUTE RESOLUTION

 

		17.1.	This Agreement shall be governed in all respects by, and interpreted in accordance with the laws of
Israel. All disputes and differences arising out of or relating to this Agreement or to its interpretation, shall be brought only
in a competent court in Tel-Aviv, Israel.

 

		18.	MISCELLANEOUS

 

		18.1.	Recitals and Exhibits: All Recitals and all Exhibits attached to this Agreement constitute
an integral part of this Agreement. The definitions of this Agreement shall apply to all Exhibits.

 

		18.2.	Headings: The headings of sections and subsections of this Agreement are inserted only for
the purposes of convenience and they shall not be construed as to affect the scope, meaning or intent of the provisions of this
Agreement or any part or portion thereof, nor shall they otherwise be given any legal effect.

 

		18.3.	Notices: Any notice given by either party in accordance with this Agreement shall be made in
writing and delivered by fax and by registered mail or by courier, addressed as first set forth above, or to other addresses as
the parties shall designate in prior written notice.

 

    	15

    	 

    

 

Confidential Treatment Requested by LabStyle
Innovations Corp.

Confidential
treatment requested with respect to certain portions hereof denoted with “***”

 

		18.4.	No Waiver: Failure by either party to enforce any provision of this Agreement will not be deemed
a waiver of future enforcement of that or any other provision.

 

		18.5.	Force Majeure: Neither party shall be responsible for any failure to perform due to unforeseen
circumstances or to causes beyond a party’s reasonable control, including but not limited to acts of God, war, riot, embargoes,
acts of civil or military authorities, fire, floods, strikes, or shortages of transportation, facilities, fuel, energy, labor,
or materials. In event of any such delay in delivery or payment, the party in delay may defer the performance date for a period
equal to the time of such delay, provided that the lack of liquidity by one party shall not constitute a Force Majeure.

 

		18.6.	Severability: If any provision of this Agreement is determined to be invalid or unenforceable,
the provision shall be deemed to be severable from the remainder of this Agreement and shall not cause the invalidity or unenforceability
of the remainder of this Agreement. The parties shall make their best efforts in order to render effective such provisions of this
Agreement not affected thereby and this Agreement will continue in full force and effect.

 

		18.7.	Entire Agreement: This Agreement, including all supplements and Exhibits constitutes the entire
Agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements, understanding or representations,
oral or written between the parties hereto regarding such matter.

 

		18.8.	Amendments: This Agreement may be modified or amended only in writing, signed by duly authorized
representatives of both parties.

 

		18.9.	Counterparts: This Agreement may be executed in one or more counterparts, each of which shall
be deemed an original, but all of which together shall constitute one and the same instrument.

 

		18.10.	Lawsuit costs: If a lawsuit is commenced to enforce the performance of any part of this Agreement,
including without limitation any order or release made hereunder, the prevailing party shall be paid by the other party reasonable
attorney’s fees and expenses.

 

[Signature
page follows]

 

    	16

    	 

    

 

Confidential Treatment Requested by LabStyle
Innovations Corp.

 

Confidential
treatment requested with respect to certain portions hereof denoted with “***”

 

IN WITNESS WHEREOF,
the parties hereto have executed this Agreement as of the date stated below.

 

	LABSTYLE
    INNOVATION LTD.	 
	Authorised
    signatoree’s name:	 
	 	 
	/s/
    Oren Fuerst	(signature)	 
	 	 
	25th
    of April of 2013	 
	 	 
	FARLA
    MEDICAL LIMITED	 
	Authorised
    signatoree’s name:	 
	 	 
	/s/
    Samuel Zalcberg	(signature)	 
	 	 
	25th
    of April of 2013	 

 

    	17

    	 

    

 

Confidential Treatment Requested by LabStyle
Innovations Corp.

Confidential
treatment requested with respect to certain portions hereof denoted with “***”

 

EXHIBIT A

 

Product Specification including Consumables

 

Blood glucose monitoring system

 

Blood glucose test strips

Confidential Treatment Requested by LabStyle
Innovations Corp.

Confidential
treatment requested with respect to certain portions hereof denoted with “***”

 

EXHIBIT B

 

Territory

 

England

 

Wales

 

Scotland

 

Northern Ireland

 

All British offshore and inshore islands

 

Belgium

 

    	18

    	 

    

 

Confidential Treatment Requested by LabStyle
Innovations Corp.

Confidential
treatment requested with respect to certain portions hereof denoted with “***”

 

EXHIBIT C

 

Letter of Intent 

 

***

 

    	19

    	 

    

 

Confidential Treatment Requested by LabStyle
Innovations Corp.

Confidential
treatment requested with respect to certain portions hereof denoted with “***”

 

EXHIBIT D

 

List of Medical Information

 

***

 

Confidential Treatment Requested by LabStyle
Innovations Corp.

Confidential
treatment requested with respect to certain portions hereof denoted with “***”

 

EXHIBIT E

 

Price Schedule

 

***

 

    	20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00216-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00216-of-00352.parquet"}]]